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Background: Articular cartilage repair is problematic due to its poor self-regenerative 
ability. Cell-based therapies and tissue engineering show great potential for cartilage 
repair. Human embryonic stem cells (hESCs) represent a promising cell source for 
regenerative medicine because of their unlimited self-renewal and ability to differentiate 
into various somatic cell lineages. However, major challenges impeding clinical 
application of hESCs include safety issues of tumorigenicity and functionality upon 
transplantation. To date, there is still limited understanding of the factors, signals, and 
even the environment necessary to induce hESCs to specifically differentiate into the 
chondrogenic lineage. Furthermore, few studies have explored the potential of hESCs and 
its derivatives for cartilage tissue engineering. The ability and fate of these hESC-derived 
cells in cartilage repair has not yet been addressed. 
 
Hypothesis: The main hypothesis is that hESC-derived cells under appropriate 
conditions can lead to improvement of cartilage repair.  
 
Methods: With the aim to verify the above hypothesis, a step-wise approach was 
designed. They are as follows:   
 Phase I: To establish hESCs as a model system to study chondrogenesis 
 Phase II: To understand the role of signaling growth factors in chondrogenesis 
 Phase III: To derive potentially clinically-compliant lineage-restricted hESC-derived 
chondrogenic cell lines 
 xii 
 Phase IV: To establish the safety and functionality of hESC-derived chondrogenic 
cells in ectopic and orthotopic sites in animal models in vivo. 
 
Results: In Phase I, a well-defined full-span chondrogenesis from chondrogenic 
induction to hypertrophic maturation was observed in hESC-derived embryoid bodies 
plated as a high-density micromass system. These findings verified the potential of 
hESCs as a model system for the study of chondrogenesis as well as its chondrogenic 
potential for cartilage repair. In Phase II, TGFβ1 was identified as the pivotal growth 
factor for chondrogenic differentiation of hESCs, resulting in the highest level of 
cartilage gene expression and matrix synthesis. In Phase III, lineage-restricted hESC-
derived chondrogenic cell lines were derived and demonstrated to be expandable, 
homogenous and unipotent in differentiation potential. These cells were functional with 
ability to form cartilaginous tissue in the pellet system, and stable with a normal 
karyotype and normal somatic cell cycle kinetics. In Phase IV, hESC-derived 
chondrogenic cells were used in cartilage tissue engineering with hyaluronic acid 
hydrogels to construct clinical-relevant size cartilage tissue constructs, which upon 
implantation, observed an orderly spatial-temporal remodeling into osteochondral tissue 
over 12 weeks, marked by development of characteristic architectural features including a 
hyaline-like neocartilage layer with complete integration with the adjacent host cartilage 
and a regenerated subchondral bone. The transplanted hESC-derived chondrogenic cells 
maintained long-term viability up to 12 weeks and no evidence of tumorigenicity was 
observed in both orthotopic and ectopic transplantations.       
 
 xiii 
Conclusion: This study demonstrates a progressive advancement from the basic science 
of establishing hESCs as a model system for chondrogenesis, understanding of the role of 
signaling growth factors during chondrogenesis to translational applications of deriving 
potentially clinically-compliant chondrogenic cell lines for cartilage tissue engineering 
and regeneration. Thus, our study demonstrates a safe, highly-efficient and practical 
strategy of applying hESCs for application in cartilage regenerative medicine. 
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Articular cartilage injuries, often caused by trauma, have a limited potential to heal, 
which over time, may lead to osteoarthritis (Buckwalter, 2002; Hunziker, 2002). Current 
surgical intervention by application of in vitro-expanded autologous chondrocyte 
transplantation procedure, also known as autologous chondrocyte implantation (ACI), has 
several disadvantages, including donor site morbidity, loss of chondrocyte phenotype 
upon ex vivo expansion and inferior fibrocartilage formation at the defect site (Brittberg 
et al., 1994; Roberts et al., 2009). Furthermore, there is also large donor variability in 
differentiation capability of chondrocytes from patients with osteoarthritis (Dozin et al., 
2002; Katopodi et al., 2009). As research in the field of cartilage tissue engineering and 
regeneration advances, new techniques, cell sources, and biomaterials to overcome these 
limitations and improve the quality of repair will need to be developed.  
 
Challenges related to the cellular component of tissue engineering include cell sourcing, 
as well as controlling expansion and differentiation so as to yield a safe, scalable and 
functional cell source for cartilage repair. Chondrocytes, fibroblasts, stem cells, and 
genetically modified cells have all been explored for their potential as viable cell sources 
for cartilage tissue engineering (Chung et al., 2008). 
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Human embryonic stem cells (hESCs) are stem cell lines of embryonic origin, isolated 
from the inner cell mass of the blastocyst-stage embryo (Thomson et al., 1998). Human 
ESCs have the capacity to proliferate in an undifferentiated state for a prolonged period 
in culture as well as to differentiate into several somatic cell types both in vitro and in 
vivo (Itskovitz-Eldor et al., 2000; Odorico et al., 2001). Nevertheless, such differentiation 
is often spontaneous and unregulated, as one would conceive that ESC differentiation in 
vitro mimics in a chaotic way the inductive events seen in a peri-implantation embryo in 
vivo. Therefore, to exploit the therapeutic potential of hESCs in cartilage repair, it will be 
essential to understand the developmental and molecular control of their growth and 
differentiation in a controlled context. Members of the TGFβ superfamily such as the 
BMPs and TGFβs, not only play a prominent role in driving embryonic patterning and 
cell commitment events, but are also involved in the regulation of limb development and 
cartilage formation (Kulyk et al., 1989; Duprez et al., 1996). A step-wise approach using 
growth factor induction was taken with the following objectives;   
 
1.1 Objectives 
 To establish hESCs as a model system to study chondrogenesis. 
 To understand the role of signaling growth factors in chondrogenesis. 
 To derive potentially clinically compliant hESC-derived chondrogenic cell lines. 
 To establish the safety and functionality of hESC-derived chondrogenic cells in 
animal ectopic and orthotopic models in vivo. 
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The ultimate goal for this study is to devise a safe, highly-efficient and practical strategy 
of applying hESCs for cartilage regeneration which may assist in future strategies to treat 
























2. LITERATURE REVIEW 
 
2.1 Articular cartilage and its associated clinical problems 
Articular cartilage is a unique avascular, aneural and alymphatic load-bearing tissue 
which is supported by the underlying subchondral bone plate. The extracellular matrix 
(ECM) is composed of a complex combination of collagen II fibrils which are 
specifically arranged and have bonded to them large water-retaining molecule called 
aggrecan together with its associated linked protein molecules. This combination of 
molecules gives the articular cartilage its unique ability to withstand the repetitive 
compressive loading in daily activities without undergoing premature repair (Poole et al., 
2001).  
 
Articular cartilage injuries, often caused by trauma, have a limited potential to heal, 
which over time, may lead to osteoarthritis (Buckwalter, 2002; Hunziker, 2002).  
Osteoarthritis (OA) is a chronic condition characterized by the breakdown of the joint’s 
cartilage. Cartilage is the part of the joint that cushions the ends of the bones and allows 
easy movement of joints. The breakdown of cartilage causes the bones to rub against 
each other, causing stiffness, pain and loss of movement in the joint (Buckwalter, 2002; 
Hunziker, 2002). Most cases of OA develop without a known cause of joint degeneration 
in what is referred to as primary or idiopathic OA. Genetic predisposition, age, obesity, 
greater bone density and excessive mechanical loading have been identified as risk 
 5 
factors for primary OA. Less frequently, OA develops as a result of joint degeneration 
caused by traumatic injury or a variety of inflammatory; or developmental, metabolic, 
and neurologic disorders, a group of conditions referred to as secondary OA (Ge et al., 
2006; Goldring et al., 2007). The World Health Organization estimates that several 
hundred million people already suffer from bone and joint diseases, with dramatic 
increases expected due to a doubling in the number of people over 50 years of age by 
2020 [From the Arthritis Foundation]. Despite the longevity and frequency of the disease, 
the cause is still not completely known and there is no cure [From the Arthritis 
Foundation]. 
 
Challenges faced in cartilage tissue engineering and regenerative medicine are 
attributable in large part to the intrinsic biology of cartilaginous tissue, which limits its 
capacity to self-regenerate. Because cartilage is nonvascularized and noninnervated, the 
normal mechanism of tissue repair involving humoral factors and recruitment of 
stem/progenitor cells to the site of damage does not apply (Hardingham et al., 2002). 
Moreover, the low cell density within cartilaginous tissue reduces the ability of local 
chondrocytes contributing to self-regeneration (Mitchell et al., 1976, Mankin et al., 1994, 
Frenkel et al., 1996).  
 
Current surgical intervention by application of in vitro-expanded autologous 
chondrocytes transplantation procedure, also known as autologous chondrocyte 
implantation (ACI) (Brittberg et al., 1994), is associated with several disadvantages, 
including donor site morbidity, loss of chondrocyte phenotype upon ex vivo expansion 
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and inferior fibrocartilage formation at the defect site (von der Mark et al., 1977; 
Schnabel et al., 2002). Other clinical procedures include arthroscopic lavage and 
debridement, microfracture techniques, and osteochondral transplantation (Clair et al., 
2009). While there are some promising results, most cartilage repair techniques lead to 
fibrocartilage formation, donor site morbidity and cartilage degeneration after a 
temporary relief of symptoms. Stem cells represent a promising cell source for cartilage 
repair and can be derived from two major sources: mesenchymal stem cells (MSCs) and 
embryonic stem cells (ESCs) (Lee et al., 2006). Adult MSCs isolated from various adult 
tissues including the bone marrow, synovium, muscle, adipose tissue have the potential to 
differentiate to various mesenchymal lineages, including adipocytes, chondrocytes, and 
osteoblasts (Pittenger et al., 1999; Liu et al., 2007; Segawa et al., 2009). Bone marrow 
(BM)-derived MSCs are currently undergoing clinical trials for several orthopedic 
applications including articular cartilage repair (Wakitani et al., 2002; Wakitani et al., 
2007; Nejadnik et al., 2010). However, there are still some limitations to the use of adult 
MSCs for applications in regenerative medicine. These include the limited capacity for 
self-renewal and with increasing donor age, proliferation and differentiation potentials 
are impaired (Quarto et al., 1995; Stenderup et al., 2003; Payne et al., 2010). Embryonic 
stem cells (ESCs) are pluripotent in nature with the capacity to differentiate into all cell 
types in the body, and representing an immortal cell source that could potentially provide 
an unlimited supply of cells for cell and tissue-based therapies and replacements 
(Thomson et al., 1998; Reubinoff et al., 2000). Recent advances in stem cell biology 
have also enabled the generation of ‘personalized’ pluripotent stem cell (PSC) sources 
from both fetal and adult fibroblasts through reprogramming by defined gene and protein 
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factors (Takahashi et al., 2007; Park et al., 2008). However, one of the greatest 
challenges in human PSC research is to understand, control and develop an efficient and 
stable culture milieu for directing differentiation to a particular lineage (Heng et al., 
2004).  
 
Furthermore, in order to transfer cell-based therapies to the clinic, several fundamental 
biological and engineering hurdles need to be overcome that include: controlling self-
renewal and lineage-specific differentiation, scalable expansion of the differentiated cells, 
phenotypic stability of differentiated cells and tissues, delivery systems and biomaterials 
for cartilage repair, and survivability and integration of the tissue graft to the host 
cartilage.  
 
This review aims to present an overview of emerging trends in cartilage tissue 
engineering and regenerative medicine. In particular, we will be focusing on ESCs as a 
promising cell source for cartilage regeneration, the recent advances in cell expansion, 
differentiation and tissue engineering, and the challenges that need to be overcome before 
clinical application which include issues of tumorigenicity and functionality of ESCs. 
 
2.2 Human Embryonic Stem Cells (hESCs) 
Embryonic stem cells (ESCs) are derived from the inner cell mass of the blastocyst-stage 
embryos and are characterized by their capacity to be proliferative in an undifferentiated 
state for a prolonged period in culture (Martin et al., 1981; Thomson et al., 1998) and to 
differentiate to several different somatic cell types (Odorico et al., 2001). Chondrogenic 
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potential of ESCs was first observed in teratomas, where islands of cartilage are clustered 
together with other tissue types in a disorganized manner. The application of ESCs is 
further advanced with the development of embryonic-like stem cells, also known as 
induced pluripotent stem cells (iPSCs), as a potential autologous pluripotent stem cell 
source that can be generated from a patient’s own skin or blood cells (Takahashi et al., 
2007; Park et al., 2008; Loh et al., 2009). To date, several approaches that include growth 
factor, biomaterial and biophysical stimulations have been employed to harness the 
chondrogenic potential of hESCs for cartilage regeneration and tissue engineering.  
 
2.2.1 Expansion of hESCs 
Human embryonic stem cells are conventionally co-cultured on mouse embryonic 
fibroblast (MEF) feeder cells for their self-renewal and propagation. However, culture on 
animal-derived serum replacers and mouse feeders poses the risk of hESCs taking up 
substantial amounts of potentially immunogenic non-human sialic acid Neu5Gc, making 
hESCs susceptible to immune attacks upon transplantation (Martin et al., 2005). 
However, this is reversible by subsequent culture under animal component-free 
conditions (Heiskanen et al., 2007).  
 
Nevertheless, these concerns about the exposure of hESCs to xenogenic contaminants 
have led to the developments of various human feeders, natural/synthetic ECM and 
conditioned medium systems. To date, there have been developments of several different 




Richards et al., 2002 reported the first establishment of human feeder supported culture 
of hESCs in xeno-free medium with human serum. In this study, human fetal and adult 
fibroblast feeders were able to support undifferentiated hESC growth, comparable to that 
of mouse embryonic fibroblast feeder. Subsequently, several other human feeders based 
on adult, fetal and neonatal human feeders (Richards et al., 2003), immortalized human 
cell lines (Choo et al., 2004), and adult BM-MSCs (Cheng et al., 2003) were reported. 
Based on FDA (Food and Drug Administration) approved clinical-grade human foreskin 
fibroblast feeder system, six clinical-grade hESC lines have been derived and banked 
under strict GMP clinically compliant standards (Crook et al., 2007). To further reduce 
the risk of contamination with infectious agents from the donor human feeders, 
autogeneic feeder systems based on hESC spontaneous differentiation to fibroblast-like 
cells or hESC directed differentiation to CD105+/CD24- hESC-derived MSCs were also 
reported (Stojkovic et al., 2005; Choo et al., 2008). More recently, fibroblast-like cells 
derived from hESCs with and without embryoid body (EB) formation exhibit differential 
supportive ability in maintaining undifferentiated hESC growth and pluripotency, with 
the hESCs cultured on EB-derived fibroblast cells sustaining a more stable 
undifferentiated state and differentiation potential (Fu et al., 2009).   
 
Xu et al., 2001 reported the first successful feeder-free culture of hESCs, with sustained 
undifferentiated growth of hESCs on Matrigel™ in MEF-conditioned medium 
supplemented with additional doses of FGF2. In this study, other tested ECM substrates, 
including collagen IV and fibronectin, were unable to support undifferentiated hESC 
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growth as well as Matrigel, suggesting the supportive role of ECM-biomaterials in 
addition to the conditioned medium and exogenous FGF2.       
 
2.3 Differentiation of hESCs into chondrogenic lineage 
Development of an efficient and stable culture milieu for directing expansion and 
differentiation of hESCs into a defined chondrogenic lineage prior to transplantation is 
critical, because undifferentiated hESCs are tumorigenic and pose high risks of teratoma 
formation in vivo (Heng et al., 2004). Although it is possible to enhance differentiation 
towards a certain cell type (Kawaguchi et al., 2005; zur Nieden et al., 2005), issues of 
obtaining a purified population of the desired cell type and ensuring the safety and 
functional competence of these differentiated ESC chondrogenic derivatives are 
challenging. Hence, understanding the factors, signals, and even the environment which 
induce the hESCs to specifically differentiate towards the chondrogenic lineage, and then 
characterizing the functionality of such hESC-differentiated cartilaginous tissue are 
crucial prior to any actual clinical application.  
 
Chondrogenic differentiation of hESCs can be broadly categorized into 1) Direct and 2) 
Indirect methods of differentiation.  
 
Directed differentiation enables isolation of chondrogenic cells at the earliest stage of 
development, which are likely to be chondroprogenitors that are more proliferative and 
therefore highly desirable for tissue engineering purposes. However, issues of 
differentiation efficiency, purity, tumorigenicity and functionality of the differentiated 
 11 
cell population are challenging. To date, direct differentiation protocols are mediated 
through hESCs with or without embryoid body (EB) formation, coupled with the use of 
growth factors and chondrogenic supplements including ITS (insulin, transferrin and 
selenium), dexamethasone, proline and ascorbic acid. A co-culture approach with the use 
of mature chondrocytes has also been reported to induce chondrogenic differentiation of 
ESCs by virtue of providing morphogenetic factors.  
 
In the indirect route of differentiation, instead of starting the differentiation process with 
undifferentiated ESCs or EBs, recent studies have generated populations of mesenchymal 
stem cells (MSCs) or mesenchymal cells from ESCs to initiate chondrogenic 
differentiation.  
 
Different strategies have been employed to induce chondrogenic differentiation of 
hESCs, most of which have been adopted from adult stem cells and mature chondrocytes. 
These include culturing in defined medium to which chondro-inductive cytokines, growth 
factors and chemicals have been added, co-culturing and the addition of conditioned 
medium (CM) , biophysical stimulation and genetic manipulation.  
 
2.3.1 Direct chondrogenic differentiation with EB formation 
Pioneering studies in mESCs involved differentiation via EB formation, a system which 
to a certain extent, mimics the early embryonic development with the formation of the 
three germ layers, namely mesoderm, ectoderm and endoderm, and their tissue 
derivatives. Therefore, EBs may be utilized in place of embryos or living animals to 
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study the effects of chemicals, small molecules and biological agents on early human 
development. However, there are several challenges in differentiation through EB 
formation. These include the identification of appropriate culture systems, growth factors 
and their concentrations.   
 
2.3.1.1 Growth factor induction 
Differentiation of ESCs towards the chondrogenic lineage can be enhanced by altering 
the culture conditions. An early study by Tanaka et al., 2004 compared the different 
culture systems and their effects on EB chondrogenesis. In the study, EBs were plated 
directly, encapsulated in alginate or dissociated into single cells and cultured as high-
density micromasses or pellets. In both micromass and pellet cultures, the expression of 
cartilage marker genes was significantly enhanced. By contrast, alginate encapsulation 
did not increase chondrogenic differentiation over EB direct plating. These findings 
suggested that high-density culture system creates the high-density three-dimensional 
(3D) microenvironment that facilitates overall cell-to-cell contact and mimics in vivo 
limb development where there is mesenchymal condensation prior to induction of 
chondrogenesis (Cancedda et al., 1995) 
 
Early studies in mouse ESCs (mESCs) indicated that growth factors added at different 
stages of EB development determine the extent of chondrogenesis, and it is likely that 
ESCs have to be differentiated to a precursor stage prior to chondrogenic induction. For 
example, addition of TGFβ1 was reported to reduce the number of cartilage nodules 
derived from mESCs (Kramer et al., 2000). Conversely, the addition of TGFβ3 under low 
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serum conditions after retinoic acid treatment of EBs favored chondrogenic 
differentiation (Kawaguchi et al., 2005). Defined mesodermal cell populations 
(PDGFRα+ and/or flk-1+) isolated from mouse EBs also responded to TGFβ3 for serum-
free chondrogenic differentiation and subsequent cartilage formation in the pellet system 
(Nakayama et al., 2003). In a similar context, BMP2 only led to an increase in number of 
collagen II-positive areas when applied during EB development from days 2 to 5, while 
addition at EB initiation (day 0 to 2) and after EB plating did not cause any significant 
chondrogenic induction (Kramer et al., 2000). In addition, combined effects of BMP2 
and TGFβ1 in chondrogenic differentiation of mouse EBs induced cartilage-specific gene 
expression in a timely coordinated fashion (zur Nieden et al., 2005).  
 
Collectively, these pioneering findings suggested that directed differentiation of ESCs to 
the chondrogenic lineage is largely dependent on the developmental stage and cell 
populations induced, together with the appropriate culture system, combination of growth 
factors, their concentration and time of application.       
 
2.3.1.2 Co-culture 
Vats et al., 2006 reported the first direct chondrogenic differentiation of hESCs. In the 
study, hESCs were induced to form EBs in serum-supplemented medium for 5 days prior 
to dissociation into single cells and co-culturing with human nasal chondrocytes in a 
transwell insert system for up to 4 weeks in vitro. At the end of 4-week differentiation, 
there were significant enhancements in cartilage gene expression and matrix synthesis.  
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2.3.1.3 Challenges in the EB differentiation system 
EBs are highly-heterogeneous with propensity for differentiation to multiple lineages due 
to the formation of all three germ layers. When EB-derived cells were subjected to 
chondrogenic differentiation in the pellet culture system, Safranin-O and collagen II-
positive cartilaginous nodules could be observed in the pellets. However, the 
cartilaginous tissues formed were not homogenous, indicating the presence of other cell 
types in the pellets (Jukes et al., 2008a). It has also been reported that size of EBs 
influence chondrogenesis, with EBs of <100 microns displaying a superior 
chondrogenesis compared to larger sized EBs, which showed a propensity to 
hematopoietic and endothelial differentiation (Messana et al., 2008). This might be due to 
poor perfusion of nutrients in larger sized EBs. Nonetheless, there is a need for 
standardization in order to have a better control of EB differentiation. Different systems 
have been innovated to overcome this problem of EB heterogeneity. Ng et al., 2008 
reported the a method (spin-EBs) that uses a recombinant protein-based, animal product-
free medium in which hESCs are aggregated in defined numbers, 3000 cells, by 
centrifugation to form EBs. In doing so, a reproducible and robust platform based on 
hESC differentiation through EB formation was set up for analysis of growth factor 
influence on differentiation.  
 
At this juncture, a model system set up to study the effect of growth factors on 
chondrogenic differentiation of hESCs would be useful for the dissection of the role of 
growth factors and their signaling in embryonic cartilage formation. 
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2.3.2 Direct chondrogenic differentiation without EB formation 
Direct differentiation of ESCs to chondrocytes, without the intermediate EB formation 
has also been explored. These are mediated by means of 1) growth factor induction, 2) 
genetic manipulation and 3) co-culture and conditioned medium (CM) approaches.  
 
2.3.2.1 Growth factor induction 
Yamashita et al., 2009 reported direct chondrogenic differentiation of mESCs, without 
the EB formation, using the high-density adherent micromass culture system. In the 
study, mESCs were directly trypsinized into single cells and plated at 1 x 10
5
 cells per 10 
μl droplet for 2 hr to form an adherent cell clump, prior to addition of differentiation 
medium. It was observed that chondrogenic induction and cartilage formation was best 
induced under minimal serum conditions manifested by ITS medium, supplemented with 
1% FBS and chondro-inductive growth factors (TGFβ1 and BMP2). By contrast, when 
mESCs were subjected to direct chondrogenic differentiation in the pellet system, without 
the EB formation, little to no cartilaginous tissue was observed (Jukes et al., 2008a). 
These findings suggested that there are differences between the high-density pellet 
system and the adherent micromass system, where the latter system is able to mediate a 
better loss of discordant cells through apoptosis and to induce a rapid onset of 
chondrogenic differentiation (Yamashita et al., 2009). 
 
2.3.2.2 Genetic manipulation 
By means of genetic manipulation, stable mESC lines that constitutively expressed 
exogenous human Sox9 were generated. Sox9 overexpressing mESC cell lines 
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demonstrated rapid chondrogenesis with appearance of adult collagen isoform, Col IIB, 
as early as day 3 of EB formation (Kim et al., 2005a). In contrast, normal wild type 5-day 
(5‘d’) EBs only displayed Col IIB after 14 days of chondrogenic differentiation in serum-
supplemented medium (Tanaka et al., 2004). Sox9 is the master regulator of 
chondrogenesis, regulating the expression of Type II, IX and XI collagens, as well as 
aggrecan (Bell et al., 1997; Lefebvre et al., 1997; Bridgewater et al., 1998; Sekiya et al., 
2000). In fact, loss of Sox9 function results in defective chondrocyte differentiation of 
mESCs in vitro (Hargus et al., 2008).     
 
2.3.2.3 Co-culture and conditioned medium 
In the co-culture approach, Sui et al., 2003 demonstrated that pluripotent ESCs can be 
programmed to differentiate into chondrocytes by direct co-culture with progenitor cells 
from limb buds of a developing embryo. In the study, mESCs were co-cultured with limb 
bud progenitor cells for 4 days, prior to antibiotic (G418) selection for 7 days to eliminate 
the limb buds cells. The co-cultured mESCs demonstrated temporal development of 
condensation and maturation to form Alcian blue-positive cartilage nodules.  
 
The co-culture systems, as described above, serves as a good in vitro model system to 
study cell fate determination, but may pose issues of contamination from the co-culture 
cell type affecting the yield and purity of the differentiated cells. In this instance, an 
indirect co-culture or CM approach may be more applicable. In an indirect co-culture 
system, hESCs were separated from bovine chondrocytes (Hwang et al., 2008a) in a 
transwell insert system. Morphogenetic and differentiation factors secreted by the mature 
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chondrocytes were able to induce chondrogenic differentiation of hESCs. Using the 
system, expandable chondrogenic cells could be generated from the co-cultured hESCs 
and demonstrated cartilaginous tissue formation in both pellet and polyethylene glycol 
(PEG)-based hydrogel systems.  
 
As well as co-culture with mature chondrocytes, mesodermal pre-induction has also been 
proposed to enhance chondrogenic differentiation of ESCs. Hwang et al., 2008d reported 
the treatment of mESCs with the human hepatocarcinoma cell line (HepG2)-CM, without 
EB formation, to induce rapid and enhanced mesoderm formation, which resulted in 
improved chondrogenic differentiation. In the study, mESCs were induced to mesoderm-
like cells in the presence of HepG2-CM for 3 days prior to chondrogenic differentiation 
in presence of TGFβ1 and chondrogenic supplements for up to 15 days. Using this 
approach, there was a reported 2-fold increase in cartilage matrix protein synthesis, 
compared to chondrogenic differentiation without the pre-conditioning phase in HepG2-
CM.  
 
Co-culture and CM approaches have been widely used in ESC differentiation to 
chondrogenic lineage and many other cell lineages (Barberi et al., 2005; Hwang et al., 
2008a). However, these approaches make use of primary explanted cells or immortalized 
cell lines for co-culture and CM, which often lack standardization and carry risks of 
pathogen transmission. Moreover, the components responsible for inducing 
differentiation are often poorly defined. These are important considerations to be made 
when trying to differentiate and derive clinically compliant cells from hESCs in a 
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reproducible and standardized manner for cell-based therapies. Thus, a defined 
differentiation protocol may still be preferred.   
 
2.3.3 Indirect differentiation 
Stepwise differentiation and generation of lineage-restricted cell lines from hESCs has 
been proposed for a number of lineage differentiations, as a means to avoid or reduce 
teratoma formation by hESCs (Lian et al., 2007; Daddi et al., 2008; Chen et al., 2009a). 
To date, several reports have described the derivation of MSCs and mesenchymal cells 
from hESCs for subsequent chondrogenic differentiation and cartilage tissue engineering. 
 
2.3.3.1 Chondrogenic differentiation of hESC-derived MSCs 
During embryonic development, MSCs that are capable of differentiation to bone, 
cartilage and fat are developmentally originated from mesoderm and neural crest. The 
first successful isolation of MSCs from hESCs was based on a co-culture system with 
murine OP9 stroma cells, followed by FACS sorting of CD73+ fraction as the putative 
MSCs (Barberi et al., 2005). To overcome the problems associated to the risks of animal 
cell and pathogen contamination due to co-culture with animal cells, Lian et al., 2007 
reported the derivation of potentially clinically compliant MSC lines from hESCs. In this 
study, hESCs were directly plated on gelatin-coated plates, without the EB formation, 
and cultured in medium supplemented with growth factors (FGF2 and PDGF-ab). After 1 
week, cells were sorted by fluorescence activated cell sorting (FACS) for the 
CD105+/CD24- cell population, as the putative mesenchymal precursors. In view of the 
fact that FACS sorting is technically demanding and carries risks of damaging the cells, 
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Chen et al., 2009a derived MSCs from hESCs by means of direct plating, without cell 
sorting, with monolayer expansion at very low densities (10 cells/cm
2
) to form colonies. 
The cells were initially cultured in presence of 5 ng/ml FGF2, before being transferred to 
serum-supplemented MSC growth medium and cultured at low density to form colonies 
of MSC-like cells. In a similar context, Lee et al., 2009a adopted an EB-based method of 
MSC derivation from hESCs. In the study, hESCs were cultured to form EBs in typical 
EB medium (hESC medium without FGF2) over a period of 14 days. Well-rounded EBs 
were selected for adherent growth in MSC growth medium and cultured for additional 16 
days. Subsequently, EB-derived cells were expanded in commercially available 
microvascular endothelial cell media-2 (EGM-2 MV) medium to yield hESC-derived 
MSCs. Using EGM-2 MV medium, hESC-derived MSCs were shown to be highly-
expandable (>150 days) and showed low cell senescence as compared to cell growth in 
MSC growth medium.   
 
In all the abovementioned studies, the hESC-derived MSCs were non-tumorigenic and 
showed similarities to the adult human MSCs including spindle-shaped fibroblast-like 
morphology, surface antigen profile (CD29+, CD44+, CD73+, CD90+, CD105+, 
CD166+, CD34-, and CD45-) and functional potential in differentiation to the 
mesenchymal tissues, such as cartilage, bone and fat.  
 
2.3.3.2 Chondrogenic differentiation of hESC-derived mesenchymal cells 
In a simplified approach by Hwang et al., 2006a, hESCs were cultured as EBs for 10 
days in hESC medium without FGF2, before plated as a monolayer and expanded for up 
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to 5 passages in serum-supplemented MSC growth medium to yield a population of 
mesenchymal-like cells which unlike typical MSCs, are CD73-. These mesenchymal-like 
cells showed limited chondrogenic differentiation in the pellet culture system, but 
demonstrated enhanced chondrogenic differentiation after encapsulation in arginine-
glycine-asparate (RGD)-modified polyethylene glycol diacrylate (PEGDA) hydrogels. In 
an attempt by Nakagawa et al., 2009 to bypass the stage of EB formation in chondrogenic 
differentiation, hESCs were first detached from the feeder layer by Type IV collagenase 
treatment for 2 hr, followed by trypsinization to get single cells. Human ESC-derived 
cells were then plated on gelatinized plates in serum-supplemented medium in the 
presence of 5 ng/ml FGF2, with medium change every 3-4 days. When confluent, cells 
were trypsinized and passaged in the same growth medium on normal plates. After 3 
weeks of expansion, spindle-shaped mesenchymal cells could be observed and harvested 
for chondrogenic differentiation. These mesenchymal-like cells demonstrated 
chondrogenesis in the pellet culture system with the highest pellet mass and sulfated 
glycosaminoglycan (s-GAG) deposition observed when pellet cultures were co-treated in 
presence of TGFβ1 (10 ng/ml) and BMP7 (300 ng/ml).    
 
In the abovementioned studies, chondrogenic differentiation was done using the 
conventional pellet culture and assessment of cartilage formation was mostly done by 
Alcian blue/Toluidine blue staining to demonstrate the deposition of s-GAG. Few studies 
demonstrated the deposition of collagen II. The types of the cartilage tissue produced 
using hESC-derived MSCs and mesenchymal cells are still unclear and require further 
characterization.   
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2.3.4 Biomaterial-assisted chondrogenic differentiation 
Biomaterials are a critical supporting technology for virtually every tissue engineering 
application. Biomaterials play a prominent role in the creation of three-dimensional (3D) 
scaffolds with initial biochemical and mechanical integrity to either provide structures for 
organization of cells into tissue structures or guide cell and tissue growth into the implant 
in vitro and/or in vivo (Spector, 2006). Recent efforts utilized biomaterials to provide 3D 
microenvironments for the culture and differentiation of ESCs in vitro. In this context, 
natural and synthetic biomaterials in the form of hydrogels, polymeric scaffolds and 
sponges have been widely used for the chondrogenic differentiation of ESCs and for 
cartilage tissue engineering. Some of the biomaterials and their associated outcomes in 
ESC-based cartilage tissue engineering and regenerative medicine are summarized in 
Table 1. 
 
Some of the natural biomaterials commonly used for chondrogenic differentiation and 
cartilage tissue engineering include alginate, agarose, hyaluronic acid, cellulose, gelatin, 
fibrin glue, collagen derivatives, and decellularized tissue matrices. Synthetic 
biomaterials such as poly(ethylene glycol) (PEG), poly(lactic-co-glycolic acid) (PLGA), 
poly(L-lactic acid) (PLLA) are also commonly used.      
 
2.3.4.1 Cartilage tissue engineering using hydrogels 
Cartilage tissue engineering using hydrogels enables the delivery of cells and bioactive 
agents, including growth factors, peptides and ligands. Hydrogels are 3D networks of 
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natural or synthetic hydrophilic polymers and have been widely used in cartilage tissue 
engineering due to their high water content, elasticity, biocompatibility, and ability to 
permit diffusion of nutrients and bioactive molecules. In addition, hydrogels afford the 
possibility of minimal invasive surgery where in situ tissue formation is desired. 
Hydrogels can also be injected transcutaneously into joints (Vinatier et al., 2009).  
 
Biomaterial choice is also likely to influence ESC differentiation. For example, when 
mouse EBs were encapsulated in alginate and cultured in expansion medium with 
dexamethasone, chondrogenic differentiation was not enhanced when compared to plated 
EBs (Tanaka et al., 2004). By contrast, when mouse EBs were encapsulated in PEG-
based hydrogels and cultured in chondrogenic medium in presence of TGFβ1, 
chondrogenesis was enhanced with increased levels of cartilage-related gene expression, 
compared to that of the conventional EB plating (Hwang et al., 2006b). Further 
chondrogenic augmentation within mouse EBs in PEG-based hydrogels, with improved 
cartilage matrix synthesis, was observed with the supplementation of glucosamine, an 
amino monosaccharide found in glycosaminoglycans such as hyaluronic acid, chondroitin 
sulfate and heparan sulfate (Hwang et al., 2006c).  
 
Studies with hESCs further demonstrated that dissociation of EBs into single cells 
promotes cell-to-cell contact and so better chondrogenesis. In a study by Koay et al., 
2007, dissociated EB-derived cells demonstrated better chondrogenic responses after self-
assembly in agarose molds to form functional cartilaginous tissue with better 
compressive and tensile properties than that generated from intact EBs. Different growth 
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factor regimes affect the biochemical and biomechanical properties of the cartilaginous 
tissue constructs. For example, EB-derived cells self-assembled in agarose and cultured 
as tissue constructs in chondrogenic medium, supplemented with TGFβ3, followed by 
BMP2, produced fibrocartilage-like constructs with high collagen I content and low 
collagen II content. In contrast, EB-derived cells treated with TGFβ3 followed by TGFβ1 
+ IGF-I particularly promoted cartilaginous tissue constructs with no collagen I (Koay et 
al., 2007).    
 
2.3.4.2 Cartilage tissue engineering using polymeric scaffolds 
In addition to hydrogels, porous biodegradable polymer scaffolds have also been used to 
support ESCs in order to induce better mechanical properties of the constructs.  
 
When intact EBs or EB-derived cells from mESCs were seeded onto poly(ethylene oxide 
terephthalate)-poly(butylene terephthalate) (PEOT/PBT) scaffolds, cartilage formation 
was observed, but the tissues formed were non-homogenous due to low differentiation 
and seeding efficiency. In the study, the seeding efficiency into PEOT/PBT scaffolds was 
improved by gel seeding and modification of the scaffold architecture. Agarose elicited 
better cell viability than matrigel for gel seeding. As regards to scaffold design, 3D fiber-
deposited scaffolds demonstrated a more homogenous seeding than compression-molded 
scaffolds (Jukes et al., 2008a).    
 
Levenberg et al., 2003 reported the use of PLGA/PLLA polymer scaffolds to direct 
differentiation of hESCs, where human EB cells were combined with Matrigel and 
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seeded into the scaffolds. Growth factors such as retinoic acid, TGFβ and activin-A or 
insulin-like growth factor (IGF) could direct hESC differentiation into 3D-tissue 
structures with the characteristics of neural tissues, cartilage, and liver respectively. 
Similarly, co-cultured hESC-derived chondrogenic cells seeded in PLLA scaffolds 
demonstrated cartilaginous tissue formation, with s-GAG and collagen II evident after 5 
weeks of subcutaneous implantation in SCID mice (Vat et al., 2006).   
 
Thus, current tissue engineering strategies as described in the above studies are hindered 
by insufficient and heterogeneous cartilaginous tissue formation, so posing difficulties for 
further applications. Heterogeneity and the low chondrogenic efficiency of the 
differentiation protocols lead to inferior cartilage formation and possible risk of teratoma 
formation from any remaining undifferentiated ESCs in the tissue. Clearly, there is a need 
for further improvement in such differentiation protocols and tissue engineering 
approaches. Optimal culture conditions, biomaterials, growth factor and mechanical 
stimulation regimes are key parameters that need to be determined for functional cartilage 
tissue engineering.  
 
2.4 Cartilage formation and regeneration using ESCs 
To date, there is only one study that has utilized hESC-derived cells for cartilage repair in 
an appropriate orthotropic model (Hwang et al., 2008b). In the study, co-cultured human 
EB-derived MSCs were pellet-cultured in chondrogenic medium for 3 days before being 
implanted into osteochondral defects in nude rats. Cartilage tissue formation could be 
observed, which remodeled over 8 weeks to repair the entire osteochondral defect. In 
 25 
contrast, control human EB-derived MSCs without co-culture stimulation from mature 
bovine chondrocytes failed to repair the osteochondral defect. Although there was no 
teratoma formation, it was not clear if the regenerated tissue was hyaline cartilage. 
Clearly, there is a need for improvement of such differentiation protocol and better 
characterization of the cell source for application in cartilage regeneration. A better 
understanding of the factors that influences cartilage formation in vivo would enable 
effective application of ESCs for eventual cartilage repair.     
 
In summary, the fate of ESC-derived cells in cartilage formation in vivo is likely to be 
influenced by the 1) Homogeneity and differentiation of ESCs 2) Delivery strategy and 
biomaterial choice 3) Site of transplantation and host cell interference.  
 
2.4.1 Homogeneity and differentiation of ESCs 
The differentiation state of ESCs is known to affect the occurrence of teratoma formation. 
Undifferentiated mESCs injected into immunodeficient mice in thighs and spinal 
processes yields teratomas in 100% of the implants. When mESCs were pre-
differentiated in chondrogenic medium, with splitting on a weekly basis, differentiated 
chondrogenic mESC derivatives only yield 50% teratoma formation. Furthermore, when 
these mESC derivatives, after 4 weeks of chondrogenic differentiation, were seeded into 
polycaprolactone scaffolds and implanted, none of the implants resulted in teratoma 
formation (Fecek et al., 2008). By contrast, mouse EBs pre-differentiated for 3 weeks in 
PEOT/PBT scaffolds resulted in teratoma formation upon subcutaneous implantation 
(Jukes et al., 2008a). In a study by Yamashita et al., 2009, micromass cultures of mESCs, 
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under ITS medium supplemented with TGFβ1 and BMP2, yielded chondrogenic cells 
that developed into cartilage formation in vivo. In contrast, cells derived under an ITS 
medium regime without growth factors or high serum conditions resulted in teratoma 
formation. It has been proposed that the longer the hESCs are differentiated in vitro, with 
extensive passaging during the process, the lower the risk of teratoma formation. Indeed, 
lineage-restricted cell lines generated from hESCs demonstrated absence of teratoma 
formation after intramuscular injection into immunodeficient mice (Lian et al., 2007). 
Co-cultured hESC-derived chondrogenic cells also gave rise to cartilaginous tissue 
formation, with good tissue growth and an absence of teratoma formation, after 
subcutaneous implantation for up to 24 weeks (Hwang et al., 2008a). Thus far, several 
strategies have been proposed to eliminate undifferentiated ESCs: 1) Cell sorting of 
undifferentiated ESCs from differentiated cell population; 2) Inducing further 
differentiation of the undifferentiated ESCs; 3) Expansion of the differentiated cell 
population 4) Eliminating the residual hESCs with specific antibodies (reviewed by 
Bongso et al., 2008). 
 
2.4.2 Delivery strategy and biomaterial choice 
Current cell-based therapies to repair cartilage defects involve injection of passaged 
chondrocytes under the periosteal flap and suturing onto the cartilage defect (Brittberg et 
al., 1994). An alternative would involve cell-seeded scaffolds, notwithstanding the choice 
of an appropriate biomaterial is critical.  
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Biomaterials are fast-emerging as an essential supporting technology for treatment of 
cartilage defects. Biomaterials serve as both a delivery vehicle for cells and growth 
factors, as well as a matrix framework to support cell growth and synthesis (Spector, 
2006). These properties are demonstrated in studies that have compared chondral defects 
in adult dogs implanted with cultured autologous chondrocytes (CACs) and CAC-seeded 
Type II collagen-GAG scaffolds cultured for 1 day and 4 weeks. The cell-seeded 
scaffolds induced more reparative tissue formation than in defects treated with cells 
alone, with longer culture periods (4 weeks) yielding a better hyaline cartilage 
composition (Breinan et al., 2000, Lee et al., 2003).  
 
In addition, biomaterials may also provide physical cues for cell orientation and 
spreading, which are critical for hESC differentiation and tissue formation. For example, 
co-cultured hESC-derived chondrogenic cells seeded in PLLA foams (Vat et al., 2006) 
and PEG-based hydrogels (Hwang et al., 2008a) displayed very different cartilaginous 
tissue morphology after subcutaneous implantation, with the latter showing typical 
rounded chondrocytes with lacunae.  
 
These findings indicate the importance and relevance of biomaterials in cartilage tissue 
engineering and regenerative medicine. An ideal scaffold for engineering a cartilage 
implant should be able to provide the 3D microenvironment necessary for 
chondrogenesis, to provide a sustained mechanical support to resist immediate load-
bearing at the time of implantation, and should ideally be degraded as the cells proliferate 
and deposit their own ECM (Spector, 2006; Hwang et al., 2008c; Vinatier et al., 2009).  
 28 
 
Besides the typical tissue engineering hurdles such as nutrient perfusion and homogenous 
cell seeding, the chondrogenic differentiation of ESCs for construction of clinical-
relevant size engineered cartilage implants is often hampered by low differentiation 
efficiency and inadequate homogenous cartilage tissue formation (Jukes et al., 2009)      
 
2.4.3 Site of transplantation and host cell interference 
Tumorigenesis of ESCs is influenced by the site of transplantation. A recent study by 
Prokhorova et al., 2008 demonstrated that the rate of teratoma formation with hESCs in 
immunodeficient mice was site-dependent (subcutaneous 25-100%; intratesticular 60%; 
intramuscular 12.5%; and under the kidney capsule 100%).  
 
When undifferentiated mESCs were injected into rat osteochondral defects to repair the 
defects, no teratoma formed. However, when mESCs were injected into the knee joint 
cavity, teratomas resulted and destroyed the entire knee joint (Wakitani et al., 2003; 
Wakitani et al., 2004). These studies were further substantiated by a follow-up study by 
Nakajima et al., 2008, that investigated the influence of knee movement and mechanical 
stimulation on cartilage and tumor formation by mESCs. It was observed that tumours 
formed in all the immobilized knee joints, whereas fibrocartilage was formed in the 
regenerated tissue when knee movements were allowed (Nakajima et al., 2008).    
 
Taken together, these studies performed in rats suggested that the specialized 
microenvironment of the osteochondral defect may be a tumor-privileged site, and that it 
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supports osteochondral differentiation, and that it reduces the occurrence of tumor 
formation by undifferentiated ESCs. However, there is still a serious risk of tumor 
formation when the knee movements are restricted, as might be the case in humans. 
Therefore, majority of the current approaches focus on pre-differentiating the ESCs into 
the desired lineage to avoid teratoma formation.  
 
Phenotypic stability of transplanted cartilaginous tissue is largely affected by host cell 
interference at the site of transplantation, where excessive vascularization might induce 
endochondral ossification and subsequent bone formation. In a study by Yamashita et al., 
2009, high-density micromass cultures of mESCs, in ITS medium supplemented with 
TGFβ1 and BMP2, yielded chondrogenic cells that developed into cartilage formation in 
vivo. This was coupled with endochondral ossification, vascularization and bone 
formation. In a similar context, Jukes et al., 2008b demonstrated that chondrogenically-
differentiated mESCs underwent hypertrophy, calcification and eventual replacement by 
bone tissue after subcutaneous implantation for 21 days in immunodeficient mice. In this 
study, mESCs that were differentiated under TGFβ3-chondrogenic conditions for either 3 
or 7 days fail to initiate bone formation, suggesting that the cartilaginous template that 
resulted from chondrogenic induction of mESCs for more than 14 days is critical for both 
endochondral ossification and subsequent bone formation in vivo. These studies 
suggested that ESC-derived cartilage tissue has the potential to mature and enter the 
process of endochondral ossification, as in embryonic cartilage development.  
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In a study by Vats et al., 2006, co-cultured hESCs were seeded into PLLA scaffolds and 
implanted subcutaneously into the backs of immunodeficient mice. After 5 weeks, 
implanted co-cultured hESCs developed to become cartilaginous tissues that were 
positive for s-GAG and collagen II. In addition, collagen I and calcification were 
detected, suggesting fibrocartilage and growth plate cartilage instead of a hyaline 
cartilage phenotype. In a similar way, co-cultured hESCs were expanded before 
encapsulation in PEG-based hydrogels to form cell-hydrogel implant (Hwang et al., 
2008a). Following subcutaneous implantation into athymic nude mice for up to 24 weeks, 
these cell-hydrogel implants developed to become homogenous cartilaginous tissue, with 
good tissue growth and an absence of teratoma formation. The cartilaginous tissue 
formed also displayed high levels of collagen type I and II, as well as some collagen X, 
indicating some extent of differentiation to fibrochondrocytes and growth plate 
chondrocytes. Collagen X is the marker for chondrocyte hypertrophy and cartilage 
maturation during the progression towards endochondral ossification. The potential of 
hESC-derived cartilage to complete endochondral ossification however remains to be 
elucidated.  
 
Although there are several studies on the differentiation of hESCs into cartilaginous 
tissues and derivation of hESC-derived cells for in vitro chondrogenic differentiation and 
cartilage tissue engineering, only one study to date has tested the reparative ability of 
hESC-derived cells for cartilage repair (Hwang et al., 2008b). Thus, more research needs 
to be done to fully assess the long-term reparative ability and donor fate of hESC-derived 
cells during cartilage regeneration.    
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2.5 Animal models 
The use of animal models is an essential component to functionally validate the efficacy 
of any treatment before its translation to clinical applications. Important factors in 
selecting an appropriate animal model include size of the animal, anatomic features, and 
the techniques available for analysis (Chu et al., 2010).  
 
Rats are commonly used as the xenogenic model. Immunodeficient or nude rats are 
available, or more commonly, normal rats are induced to become immunodeficient by 
treatment with immune suppressant drugs such as Cyclosporine A. By far, 
immunodeficient rat models are the larger animal model compared to mice, and most 
commonly used for the in vivo testing of hESC-derived xenografts (Daadi et al., 2008; 
Chen et al., 2009a). Experimentations in rats have determined the critical size of the 
osteochondral defect created on the patellar grove to be 1.5 mm width and 0.8 mm depth, 
after which no spontaneous repair was observed (Anraku et al., 2009). In addition, this 
animal model offers several advantages that include low costs, availability and ease of 
handling, and is useful for proof-of-concept studies. Limitations of this model include 
difficulties in creating a pure chondral defect, and in the mechanical testing of the tissue 













Table 1. Biomaterials that have been used in cartilage formation and repair 
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3. MATERIALS AND METHODS 
 
3.1 Reagents, chemicals, culture media and labware consumables 
Unless otherwise stated, all reagents and chemicals used in this study were obtained from 
Sigma Inc. (St. Louis, MO, USA). Dulbecco’s Modified Eagle’s Medium-F12 (DMEM-
F12) and cell culture components were obtained from Invitrogen (Grand Islands, NY, 
USA). All labware consumables were purchased from Corning Inc. (Lowell, MA, USA) 
and Becton Dickinson Inc. (Franklin Lakes, NJ, USA). Many of the protocols described 
here have been published (Toh et al., 2007b, Toh et al., 2010).  
 
3.2 Experimental design 
 
 
Fig. 1. Experimental flowchart 
 
As shown in the schematic representation in Fig. 1, this study is divided into phases from 
the basic science of establishing hESCs as the model system of chondrogenesis (Phase I), 
understanding the role of signaling growth factors in chondrogenesis (Phase II), to 
deriving potentially clinically compliant chondrogenic cell lines (Phase III), and to 
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translational applications for cartilage tissue engineering and cartilage repair in animal 
models (Phase IV). The ultimate goal for this study is to devise a safe, highly-efficient 
and practical strategy of applying hESCs for cartilage regeneration which may assist in 
future strategies to treat cartilage-related diseases such as osteoarthritis. 
 
3.3 Cell differentiation  
3.3.1 Culture of hESCs 
The National Institutes of Health (NIH)-registered H9 cell line, isolated and established 
at University of Wisconsin, was used in this study (Wicell™ agreement No. 04-W094) 
Human ESCs were cultured and passaged as previously described (Thomson et al., 
1998). Briefly, hESCs were grown on inactivated mouse embryonic fibroblasts (MEF) in 
hESC media [80% DMEM-F12, 20% Knockout Serum Replacement (KSR), 1 mM 
glutamine, 0.1 mM β-mercaptoethanol, 1% non-essential amino acids and 4 ng/ml 
fibroblast growth factor-2 (FGF2)]. FGF2 is critical in promoting the growth of the 
undifferentiated hESCs (Vallier et al., 2005; Xu et al., 2005).   
 
For splitting, medium was removed and hESCs were incubated with 1 ml per well of 1 
mg/ml of collagenase IV for 5 min. Using a 5 ml seropipette, the cells were scraped off 
into suspension and washed with hESC media. A cell scraper was used to scrape off the 
cells at the edge of the wells. After centrifugation, the cells were re-suspended in 
appropriate volume of medium, depending on the splitting ratio. For example, a 1:3 ratio 
will require 7.5 ml re-suspension for 2.5 ml per well. Medium change was done everyday 
for 6 days till the next passage. 
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3.3.2 Chondrogenic differentiation via embryoid body outgrowth culture   
To induce embryoid body (EB) formation, hESCs were subjected to collagenase as 
described earlier (3.3.1), and re-suspended in EB medium (hESC medium without FGF2) 
to induce development of EBs with distinct three germ layers - mesoderm, endoderm and 
ectoderm. One 6-well plate of hESCs was split to one 6-well plate of EBs, maintained at 
approximately 200 EBs per well. EB formation requires 5-day suspension culture in low-
attachment 6-well plates, with medium change every alternate day.  
 
5‘d’EBs were suspended in DMEM high-glucose supplemented with 10% FBS (Hyclone, 
Logan, UT, USA) and 10% KSR before being plated directly onto a 12-well plate pre-
coated with 0.1% gelatin. From the 6-well plate of EBs, 1 well was split to 10 wells of 
the 12-well plate, maintaining at approximately 30 EBs per well (1:10 splitting ratio). 
The EB cultures were incubated at 37
o
C for 24 hr to enable cell attachment, prior to 
induction of differentiation. This culture system will be abbreviated as ‘EB outgrowth’ 
for the rest of the thesis for clarity. For some experiments, the number of EBs seeded was 
increased accordingly from the initial seeding numbers of EBs  
   
3.3.3 Chondrogenic differentiation via high-density micromass culture 
For high-density micromass culture, 5‘d’EBs were dissociated into single cells by means 
of dissociation using a solution mixture containing 0.05% trypsin/EDTA and cell 
dissociation buffer at 7:3 ratio for 5 min at 37
o
C, followed by passing the cell suspension 
through the 22-G needle and a 40-µm pore size cell strainer to obtain single cells. The 
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dissociated single cells were then resuspended in DMEM high-glucose supplemented 
with 10% FBS and 10% KSR, and washed twice with the same medium before being 
cultured at a high density of 3 x 10
5
 cells per 15 μl spot onto a gelatin-coated 12-well 
plate. After incubation at 37
o
C for 2 hr, 1 ml of the same medium was carefully added to 
each well. Similarly, the high-density micromass cultures were incubated at 37
o
C for 24 
hr to enable cell attachment, prior to induction of differentiation.   
 
Chondrogenic differentiation of EBs under both EB outgrowth and EB high-density 
micromass culture systems was induced under serum-free conditions modified from the 
protocols previously described (Ahrens et al., 1977; Mello and Tuan et al., 1999). The 
basic serum-free chondrogenic medium consisted of DMEM high-glucose supplemented 
with ITS
+1
 (10 µg/ml insulin, 5.5 µg/ml transferrin, 5 ng/ml selenium, 0.5 mg/ml bovine 
serum albumin, 4.7 µg/ml linoleic acid (BD Bioscience Inc.), 1% KSR, 40 µg/ml L-
proline, 50 µg/ml  ascorbic acid 2-phosphate (AA2P), 1 % sodium pyruvate, 1% non-
essential amino acids (NEAA), 10
-7 
M dexamethasone and 100U/100μg 
penicillin/streptomycin (P/S), as listed in Table 2.    
 









DMEM-high glucose NA; 4
o
C ~92 ml NA 
L-glutamine 200 mM (100x); -20
o
C 1 ml 2 mM (1x) 
L-Proline 5 mg/ml; -20
o





C 1 ml 1% 
KSR 100x; -20
o
C 1 ml 1% 
NEAA 10 mM (100x); 4
o
C 1 ml 0.1 mM 
P/S 10,000U/10,000µg (100x); -20
o





C 100 μl 10-7 M 
AA2P 5 mg/ml (100x); -20
o
C 1 ml 50 μg/ml 
Sodium Pyruvate 100 mM (100x); 4
o
C 1 ml 1 mM (1x) 
NA: Not applicable 
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Following incubation for 24 hr to allow cell attachment, the medium was replaced with 
serum-free chondrogenic medium with or without growth factors (day 1 of 
differentiation) for a period of 21 days with medium change every alternate day. Growth 
factor-mediated chondrogenic differentiation was evaluated by adding to the basic 
chondrogenic medium either 10 ng/ml recombinant human TGFβ1 (R&D Systems, 
Minneapolis, MN, USA), 100 ng/ml recombinant human bone morphogenetic protein 2 
(BMP2) (R&D Systems), or a combination of both growth factors. Cultures in the basic 
chondrogenic medium alone without growth factor supplementation served as the control. 
1% KSR instead of the strictly serum-free medium was used in
 
this study, based on 
reports that mesodermal differentiation
 
of ESCs can be inhibited under serum-free 
conditions (Wiles et al., 1999). 
 
3.3.4 Isolation and expansion of hESC-derived chondrogenic cells 
Chondrogenic cells were isolated from the high-density micromass cultures by 0.15% 
collagenase P (Roche Diagnostics GmbH, Mannheim, Germany) treatment over an 
orbital rotator (Boeco, Hamburg, Germany) overnight at 37
o
C. The cultures were passed 
through the 40-μm mesh filter to obtain single cells. The isolated chondrogenic cells were 
then expanded as monolayer in DMEM-high glucose containing 10% FBS without 
(Control) or with the addition of TFP growth factors [1 ng/ml TGFβ1, 5 ng/ml FGF2 
(Invitrogen) and 10 ng/ml PDGFbb (Peprotech, Rocky Hill, NJ, USA). Reconstitution of 
the growth factors is described in Table 3. Expanded chondrogenic cells were assessed 
their post-expansion chondrogenic potential by means of pellet culture under control and 
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TGFβ1-induced chondrogenic differentiation conditions. The TFP growth factor 
combination has been used to propagate human primary chondrocytes in monolayers 
whilst maintaining their differentiation potential (Francioli et al., 2007). 
 
3.3.4.1 Culture of hESC-derived chondrogenic cells on various ECM substratum 
Isolated chondrogenic cells were plated on uncoated (UC), gelatin (GL) or Type II 




. After 6 hr of incubation, 
cells that did not adhere to the substrates were counted. Effects of ECM substratum on 
post-expansion differentiation were evaluated by means of 3D pellet culture (Mackay et 
al., 1998; Yoo et al., 1998; Toh et al., 2005).   
 
Preparation of 0.1% (w/v) gelatin-coated culture plates  
0.5 g porcine gelatin was weighed out in an autoclavable bottle and added 500 ml of 
distilled water (dH2O). The mixture was autoclaved to dissolve. After cooling to room 
temperature (RT), sufficient amount was added to cover the plates. The plates were 
coated overnight by incubating at 37
o
C until use.  
 
Preparation of 0.01% (w/v) COL II-coated culture plates  
COL II (Type II collagen from chicken sternal cartilage, Sigma) was dissolved in 0.3% 
(v/v) acetic acid in dH2O, with pH 3 to obtain a stock solution of 5 mg/ml. COL II 
solution (1 mg/ml) was diluted 10-fold with PBS to obtain a working concentration of 
0.01% (w/v), prior to coating of the plates at 10 μg/cm2 and incubated overnight at 37oC 
until use.  
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3.3.5 In vitro cartilage-like tissue formation  
To assess the quality of the expanded hESC-derived chondrogenic cells, conventional 3D 
pellet culture and hyaluronan (HA)-based hydrogel systems were used.  
 
Aliquots of 2 x 10
5
 cells/0.5 ml were spun down at 1,100 rpm for 5 min to form pellets 
and cultured in the serum-free chondrogenic medium without (Control) or with growth 
factor supplementation for up to 4 weeks. The anabolic growth factors tested included 
IGF1, BMP2, BMP7 and GDF5 applied at 100 ng/ml and/or TGFβ1 applied at 10 ng/ml 
in a singly or combined fashion (Table 3). 
 






Cat. No. Company 
TGFβ1 
10 μg/ml in 4 mM 
HCL/0.1%BSA 
1, 10 ng/ml 240-B R&D Systems 
BMP2 
100 μg/ml in 4 mM 
HCL/0.1%BSA 
100 ng/ml 355-BM R&D Systems 
BMP7 
100 μg/ml in 4 mM 
HCL/0.1%BSA 
100 ng/ml 354-BP R&D Systems 
GDF5 
100 μg/ml in 
PBS/0.1%BSA 
100 ng/ml 120-01 Peprotech 
IGF1 
100 μg/ml in 
PBS/0.1%BSA 
100 ng/ml 100-11 Peprotech 
PDGFbb 
100 μg/ml in 
PBS/0.1%BSA 
10 ng/ml 100-14B Peprotech 
FGF2 
2 μg/ml in 
PBS/0.1%BSA 
4, 5 ng/ml 13256029 Invitrogen 
 
HA-based hydrogels was prepared as per manufacturer’s protocol (Glycosan Biosystems, 
Salt Lake City, UT, USA). Human ESC-derived chondrogenic cells were mixed gently 
with 2:2:1 ratio of thiol-modified hyaluronic acid (Glycosil), thiol-modified gelatin 
(Gelin-S) and PEGDA (polyethylene glycol diacrylate, Extralink) to form constructs of 
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concentration 2 x 10
6
 cells/100 μl hydrogel. Both the cell pellets and cell-hydrogel 
constructs were cultured for up to 28 days in serum-free chondrogenic medium, with 
medium changes thrice a week. After 2 and 4 weeks, samples were harvested for 
histology, immunohistochemistry and biochemical analyses.  
 
3.3.6 Multi-lineage differentiation analysis 
To further assess the differentiation capacities of hESC-derived chondrogenic cells, 
differentiation to osteogenic and adipogenic lineages were performed as previously 
described (Liu et al., 2007). Human mesenchymal stem cells (MSCs) were isolated under 
the guidelines of the Institutional Review Board of National University Hospital of 
Singapore from bone marrow aspirates of donors who had given written consent.  
 





cultured in DMEM-high glucose supplemented with 10% FBS, 10 mM β-
glycerophosphate, 10
-8 
M dexamethasone, 50 µg/ml AA2P, and 100U/100μg P/S and 
cultured for 2 weeks. Differentiation to osteogenic lineage was assessed by RT-PCR of 
osteogenic genes and staining with Alizarin Red S.   
 





cultured in DMEM high-glucose supplemented with 10% FBS, 10 μM insulin, 10-7 M 
dexamethasone, 0.1 mM indomethacin, 0.5 mM 3-isobutyl-methyl xanthine and 
100U/100μg P/S and cultured for 2 weeks. Differentiation to adipogenic lineage was 
assessed by RT-PCR of adipogenic genes and staining with Oil red-O. 
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3.4 Cellular assays and cytogenetics 
3.4.1 Growth kinetics 
Population doubling level (PDL) was calculated following the formula PDL = 
log(N/No)/log2, where N is the number of cells in the culture flask at the end of a period 





Cumulative PDL is total PDL (tPDL) = ∑(PDL)n, where n is the passage number 
(Szczesny et al., 2003; Ko et al., 2007).  
 
3.4.2 Cell cycle analysis  
Cell cycle analysis was carried out as previously described (Fu et al., 2009). Cells were 
washed twice with PBS and harvested by trypsinization. Human ESCs were harvested 
using 0.1% collagenase IV, wash twice with PBS, and dissociated into single cells with 
cell dissociation buffer. Cells were then washed once with ice-cold PBS before spinning 
down at 200 g for 5 min and resuspending in 0.5 ml of ice-cold 0.1% BSA/PBS at 1 × 10
7
 
cells/ml concentration. Cells were then fixed by addition of 4.5 ml of ice-cold ethanol and 
keep for ≥2 hr on ice or at 4ºC overnight. Fixed cells were centrifuged at 200 g for 5 min 
and the supernatant ethanol was decanted. Cells were resuspended in PBS and 
centrifuged again. Cell pellet was resuspended in 1 ml of propidium iodide staining 
solution I [100μg/ml of propidium iodide, 100μg/ml RNase, 0.1% (v/v) Triton X-100]. 
Cells were incubated for 30 min at RT and protected from light.  Flow cytometer was set 
up for excitation at 488 nm and detection of PI emission at >620 nm. Cell fluorescence 
was measured by flow cytometry and data was analyzed using the DNA content 
histogram deconvolution software (Dako Cytomation, Glostrup, Denmark).  
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3.4.3 Surface marker analysis  
Fluorescence Activated Cell Sorting (FACS) is a technique for the analysis of cell surface 
markers. Cells were washed twice with PBS and harvested by trypsinization. Cells were 
collected in microcentrifuge tubes and spun down at 13000 rpm for 1 min, before 
resuspending the cells in 100 μl of FACS buffer (1% BSA/PBS). Primary antibodies were 
then added and incubated on ice for 30 min. Controls were isotype antibody or no 
primary antibodies. The list of antibodies and their dilutions for FACS are summarized in 
Table 4. The cells were spun down and wash once with the FACS buffer. 100 μl of 
diluted fluorescein isothiocyanate (FITC)-conjugated secondary antibody was then added 
to each tube and incubated in the dark on ice for 15 min. Cells were washed once in 
FACS buffer before resuspending in 200 μl of FACS buffer and transferred to the FACS 
tubes, ready for analysis on a FACScan (FACSCalibur, Becton Dickinson). Lastly, 
propidium iodide was added to distinguish dead cells from viable cells during the FACS 
analysis.  
 
Table 4. List of antibodies for FACS 
Antibodies(Abs) Host Dilution Application Company 
PrimaryAbs 
CD29 Mouse 1:60 FACS BD Bioscience 
CD34 Mouse 1:60 FACS BD Bioscience 
CD44 Mouse 1:60 FACS BD Bioscience 
CD45 Mouse 1:60 FACS BD Bioscience 
CD73 Mouse 1:60 FACS BD Bioscience 
CD90 Mouse 1:60 FACS BD Bioscience 
CD105 Mouse 1:60 FACS BD Bioscience 








3.4.4 Multi-color fluorescence in situ hybridization (mFISH) 
Metaphase spreads were prepared by standard techniques and hybridized with 24XCyte 
Human mFISH Painting Kit (MetaSystems GmbH, Altlussheim, Germany) as previously 
described (Vinoth et al., 2008). Microscopic analysis was performed by a Zeiss 
Axioplan-2 fluorescence microscope (Carl Zeiss GmbH, Oberkochen, Germany) 
equipped with an HBO-103 mercury lamp, using the following filter sets: FITC, Cy3.5, 
Texas Red, Cy5, Aqua, and DAPI. Images were captured, processed, and analyzed using 
Isis mFISH Multicolor Chromosome Analysis Module (MetaSystems GmbH, 
Altlussheim, Germany). A total of 50 metaphase spreads were analyzed for each sample 
to check the genome integrity of the cells.  
 
3.5 Molecular biology assays 
3.5.1 Total RNA extraction and cDNA synthesis 
Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Chatsworth, CA, USA), 
and passing through the Qiashredder following the manufacturer’s instructions. Total 
RNA extracted from human articular chondrocytes, human neuroblastoma cell line, SH-
SY5Y [ATCC CRL-2266, American Type Culture Collection (ATCC), Rockville, MD, 
USA], human umbilical vein endothelical cells, HUVEC (Cambrex, East Rutherford, NJ, 
USA) and human palate mesenchymal cell line, HPM (ATCC CRL-1486, ATCC) served 
as controls.  
 
Each sample was treated with RNase-Free DNase (Qiagen) to avoid genomic DNA 
contamination. The RNA quantity and quality were determined by measuring the 
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absorbance at 260 nm and 280 nm for each sample using the Nanodrop ND-1000 
spectrophotometer (NanoDrop Technologies, Wilmingon, DE). Based on the equation 
that 1 unit at 260 nm corresponds to 40 μg of RNA per ml, the RNA concentration was 
calculated. 
 
Reverse transcription reaction was performed using a PCR thermal cycler, Mycycler 
(Bio-Rad, Hercules, CA, USA). iScript cDNA synthesis kit (Bio-Rad) was used for 
cDNA synthesis, which was performed using 500 ng of total RNA per 20 µl reaction 
volume over a 30 min incubation time at 42
o
C, with the addition of 5X iScript reaction 
mix and iScript reverse transcriptase, followed by enzyme inactivation at 85
o
C for 5 min, 
following the manufacturer’s instructions.  
 
3.5.2 RT-PCR and real-time PCR quantitative analysis 
PCR of the cDNA samples were performed at 95
o
C for 5 min, followed by amplification 
cycles of 30-sec denaturation at 95
o
C, 45-sec annealing at 55 - 65
o
C, and 60-sec 
elongation at 72
o
C, and a final extension at 72
o
C for 5 min. The number of cycles varied 
between 23 and 38, depending on the abundance of a particular mRNA. β-actin 
amplification with no reverse transcriptase served as negative control to check for 
genomic contamination. In addition, all RNA samples were adjusted to yield equal 
amplification of β-actin as an internal control to normalize the PCR reactions. The 
amplified products were subjected to electrophoresis on 2% agarose gels and 
subsequently stained with ethidium bromide and photographed using the Light Imaging 
System (Bio-Rad). For semi-quantitative analysis, mean pixel intensity of each band was 
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measured using the NIH public domain imaging software-Imagej, and normalized to 
mean pixel intensity of the corresponding β-actin. Each sample was repeated at least 
twice for each gene of interest. PCR primers, annealing temperature, and their expected 
product sizes are described in Table 5.  
 
For quantitative analysis, Sox9, collagen I and II (Col 1 and Col 2) gene expression were 
analyzed by real-time RT-PCR reaction using the Power SYBR Green PCR Master Mix 
System (Applied Biosystems, Foster City, CA, USA) on PCR thermocycler Applied 
Biosystems 7500 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). 
cDNA samples (1 µl for a total volume of 20 µl per reaction) were analyzed for gene of 
interest normalized to reference gene glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH). The level of expression of each target gene was then calculated as 2
-∆∆Ct
, as 
previously described (Livak et al., 2001). Each sample was analyzed in duplicates for 
each gene of interest. Real-time RT-PCR was performed at 95
o
C for 10 min, followed by 
40 cycles of amplifications, consisted of a denaturation step at 95
o
C for 15 sec, and an 
extension step at 60
o
C for 1 min. All PCR reactions were carried out with negative 
control with no cDNA. Primers were obtained from published literature (Martin et al., 
2001). Specificity of the PCR products was confirmed by melting curve analysis and 
agarose gel electrophoresis. Real-time PCR primers are listed in Table 6. Since Col 2 is a 
typical marker of differentiated chondrocytes in hyaline cartilage, as opposed to Col 1, 
which is expressed by de-differentiated chondrocytes and other mesenchymal 
intermediate cells such as fibroblasts and osteoblasts, the ratio of mRNA expression 
levels of Col 2 to Col 1 (Col2/Col1) can be utilized as a differentiation index related to 
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the expression of collagens during chondrogenic differentiation, and in this context of 
hESC chondrogenic differentiation, to better assess the efficiency of chondrogenic 
differentiation (Martin et al., 2001; Marlovits et al., 2004; Toh et al., 2005).  
 
3.6 Biochemical assays 
All the colormetric and fluorometric measurements for the below biochemical assays 
(3.6.1-5) were performed using microplate reader (Infinite
®
 M1000, Tecan, Switzerland). 
 
3.6.1 Sulfated glycosaminoglycan quantification 
To measure the total sulfated glycosaminoglycans (s-GAG) deposited by hESC-derived 
chondrogenic cells during the course of differentiation, each sample was digested with 
300 μl papain digestion buffer (125 μg/ml in sterile PBS, pH 6.0 with 5 mM cysteine 
hydrochloride and 5 mM Na2EDTA) for 18 hr at 60
o
C. s-GAG content was assayed using 
the Blyscan Sulfated Glycosaminoglycan Assay kit (Biocolor Ltd, Newtownabbey, 
Ireland) (Brown et al., 2000). Briefly, 50 μl of the sample was mixed with 250 μl of 
dimethyl-methylene blue (DMMB) dye reagent (provided in the kit) and incubated at RT 
for 30 min. After incubation, the samples were spun down at 16,000g for 10 min. The 
dye-bound pellet was dissociated with 200 μl dissociation agent per sample to release the 
colour for spectrophotometric measurement at 630 nm. The s-GAG content was 
normalized to the DNA content, measured fluorometrically using the Hoechst 33258 
method (Kim et al., 1988). Standard curve of s-GAG was constructed using different 
concentrations of bovine trachea chondroitin sulfate (provided in the kit).  
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Table 5. Sequence of primers used for conventional RT-PCR 














































PDGFR- F: 5'-ATCAATCAGCCCAGATGGAC-3' 





NFH-F: 5’- TGAACACAGACGCTATGCGCTCAG-3’ 
































All primers except PDGFRα, NFH and β-actin (mouse/human) are human-specific. The PCR 






C/45 sec (except where specified 
otherwise), 72
o





Table 6. Sequence of primers used for real-time RT-PCR 
Gene Real-time primer sequence Product size (bp) 
Sox9 
Sox9F: 5’-CCTCCA CGA AGGGCCG-3’  















3.6.2 Collagen quantification 
The same sample lysates used for s-GAG quantification were used for total collagen 
quantification. Total collagen content was assayed using the Biocolor Sircol Collagen 
Assay Kit (Biocolor Ltd, Newtownabbey, Ireland). Briefly, 50 μl of the sample was 
mixed with 250 μl of Sirius red dye reagent (provided in the kit) and incubated at RT for 
30 min. After incubation, the samples were spun down at 16,000g for 10 min. The dye-
bound pellet was dissociated with 200 μl dissociation agent per sample to release the 
colour for spectrophotometric measurement at 540 nm. The total collagen content was 
normalized to the DNA content, measured fluorometrically using the Hoechst 33258 
method (Kim et al., 1988). Standard curve of collagen was constructed using different 
concentrations of bovine collagen (provided in the kit). 
 
3.6.3 Collagen II quantification 
ELISA (Enzyme Linked Immuno-Sorbent Assay) to quantify specifically the amount of 
collagen II was performed using the commercially available Type II Collagen Detection 
Kit, following the manufacturer’s instruction (Chondrex Inc., Redmond, WA, USA). 
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3.6.3.1 Sample preparation 
Each sample was treated with 200 μl of pepsin solution (0.1 mg/ml pepsin in 0.05 M 
acetic acid solution) for 1 week at 4
o
C over a rotator. Samples were then centrifuged at 
10,000 rpm for 3 min to collect the pepsin digested supernatant. 100 μl of elastase 
solution [(0.1 mg/ml elastase in TBS-CaCl2: 0.1 M Tris-base-0.15 M NaCl-5 mM CaCl2 
(pH 7.8)] was added to the pepsin insoluble fraction and incubated for another 2 days at 
4
o
C over a rotator. At the end of digestion, samples were centrifuged at 10,000 rpm for 3 
min to collect the elastase digested supernatant. The elastase digested supernatant was 
pooled together with the pepsin digested supernatant in the same collection tube. (This 
will amount to approximately 400 μl sample volume). 8 μl of 1 M Tris-base solution was 
added to neutralize the pH of the combined supernatant in the collection tube. 100 μl of 
Sample/Standard Dilution Buffer (supplied in the kit) was added to achieve a final 
sample volume of 500 μl. The samples were assayed immediately using the Type II 
Collagen Detection Kit or stored at -20 
o
C for subsequent assay.  
 
3.6.3.2 Collagen II ELISA 
Collagen II ELISA was performed using the Type II Collagen Detection Kit (Chondrex) 
following the manufacturer’s instructions. Briefly, 100 μl of capture antibody solution 
was added to each well of the 96-well microplate and incubated at 4
 o
C overnight. The 
antibody coated microplate was washed 3 times with the wash buffer, prior to addition of 
the 100 μl of pre-diluted standards and samples (section 3.6.3.1) to the respective wells 
for incubation at RT for 2 hr. Following incubation, the microplate was washed 3 times 
with wash buffer, before 100 μl of detection antibody solution was added to each well 
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and incubated at RT for 2 hr. After incubation, the plate was washed 3 times with wash 
buffer, before 100 μl of steptavidin peroxidase solution was added to each well and 
incubated at RT for 1 hr. Finally, the microplate was washed 3 times with the wash 
buffer, before addition of OPD (o-Phenylenediamine) solution (100 μl to each well) to 
visualise the antigen-antibody reactions. The colour reactions were stopped using 2N 
sulfuric acid solution, prior to absorbance reading at 490 nm on the microplate reader.  
 
3.6.4 DNA quantification 
To measure the DNA content, samples were diluted 10-fold in PBS to a final volume of 
100 μl before adding to the wells containing 100 μl of Hoechst 33258 dye solution (0.2 
μg/ml). The fluorescence measurement of Hoechst 33258 dye was performed at 360 nm 
excitation and 460 nm emission. Calf thymus DNA was used for construction of the 
standard curve for DNA quantification. Matrix syntheses (s-GAG, Total Collagen and 
Collagen II) were normalized against DNA content to determine the level of matrix 
synthesis per cell.  
 
3.6.5 Alkaline phosphatase (ALP) activity assay 
The total ALP activities of cells and matrix were measured according to the method as 
described (Yagami et al., 2000). Cells were harvested in an extraction buffer (1.5 M Tris 
buffer containing 1% Triton X-100). Cell suspension was then vortex every 10 min 
intervals for a total of 30 min to dissociate the ECM and liberate membraneous ALP for 
enzymatic assay. 50 µl of lysate was allowed to react with 150 μl ALP substrate and 
incubated for 30 min at 37
oC. 50 μl of 1N NaOH was then added to terminate the 
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reaction. Specific ALP activity was assayed as the release of ρ-nitrophenol from ρ-
nitrophenylphosphate and measured spectrophotometrically at 405 nm, with 1 A405 = 64 
nmol of product. Protein concentration was determined using the Pierce BCA protein 
assay kit (Pierce Chemicals, Rockford, USA), following the manufacturer’s instructions. 
The ALP activity was normalized against the protein concentration and expressed as 
nmol/min/mg protein.  
 
3.7 Histochemical and fluorescence staining techniques 
3.7.1 Staining of cell cultures 
3.7.1.1 Alcian blue staining 
Cell cultures were fixed with 10% (v/v) neutral buffered formalin for 30 min, followed 
by staining with 0.05% (w/v) alcian blue solution overnight. Excess stain was removed 
by washing in PBS, followed by a further wash in 5% (v/v) acetic acid to remove non-
specific staining. Digital images were then captured under IX70 inverted microscope with 
the Microimage
TM
 software (Olympus Inc., Tokyo, Japan). 
 
3.7.1.2 Alkaline phosphatase (ALP) staining   
Specimens were fixed with citrate buffer acetone for 30 sec, followed by washing with 
dH2O for 45 sec. The alkaline dye mixture, made up of naphthol AS-MX phosphate 
alkaline solution in diluted diazonium salt solution, was then added to the specimens and 
incubated in the dark for 30 min at RT. After incubation, the specimens were rinsed with 
dH2O for 2 min. The specimens were then counterstained with Mayer’s haematoxylin for 
10 min, before bluing in ammonium water for 2 min to develop a blue nuclear 
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3.7.1.3 Alizarin red S staining 
Samples were fixed with 10% neutral buffered formalin for at least 30 min, washed once 
with PBS, followed by staining for 5 min with 2% (w/v) Alizarin Red solution (pH 
adjusted to 4.1-4.3 using 0.5% ammonium hydroxide). Excess stain was removed by 
washing in dH2O to remove non-specific staining. Digital images were then captured 




3.7.1.4 Oil red-O staining 
The samples were washed once with PBS, and fixed with 4% paraformaldehye for 1 hr. 
The samples were washed with dH2O, followed by staining with 0.36% Oil red-O 
working solution for 1 hr. Excess stain was removed by washing twice in 60% 
isopropanol to remove non-specific staining, and washing thrice in dH2O to remove the 
background precipitates. Stained samples were stored at 4
o
C for subsequent viewing. 





For quantification, bound Oil-red-O dye was eluted using 100% isopropanol. 500 μl of 
100% isopropanol was added to each well of a 12-well plate and incubated for 15 min at 
RT to make sure all the dye was completely eluted. 200 μl of the eluate was taken for 
absorbance measurement at 500 nm using the Tecan microplate reader (section 3.6).  
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3.7.1.5 Immunofluorescence (IF) staining 
Cells were cultured in 24-well plates. The culture medium was removed completely and 
rinse once with PBS. Cells were fixed with 4% paraformaldehyde for at least 20 min at 
RT. Cells were then washed 3 times with PBS and permeabilized with 0.2% Triton-X-
100/PBS for 15 min at RT. To prevent non-specific staining, cells were then blocked with 
blocking buffer- PBS/2%BSA/10% goat serum for 45 min. Following blocking, cells 
were incubated with primary antibody diluted in PBS/2%BSA for 2 hr at RT. The 
antibodies and their dilutions used in immunofluorescence staining are described in Table 
7. Following primary antibody incubation, cells were washed thrice with PBS and 
incubated with the fluorochrome-tagged secondary antibody diluted in PBS/2%BSA for 1 
hr at RT in the dark. Finally, cells were washed thrice with PBS and rinsed with dH2O, 
before stained with Vectashield DAPI medium (Vector Laboratories, Burlingame, CA, 
USA) for nuclei-counterstaining. Antibody isotypes or no antibody sera served as the 
negative control. Images were taken using IX70 inverted microscope or FluoView
TM
 
















Table 7. List of antibodies for IHC and IF 
Antibodies(Abs) Host Dilution Antigen retrieval Application Company 
PrimaryAbs 






Collagen II Mouse 1:150 
0.2% Triton-X/PBS 
at RT for 15 min 
IF Chemicon 






Collagen I Rabbit 1:75 
0.2% Triton-X/PBS 
at RT for 15 min 
IF Chemicon 






Alpha-fetoprotein Mouse 1:500 
Sodium citrate buffer 
95
o
C for 20 min 
IHC Sigma 
Alpha-fetoprotein Mouse 1:100 
0.2% Triton-X/PBS 
at RT for 15 min 
IF Sigma 
Oct4 Rabbit 1:100 
0.2% Triton-X/PBS 
at RT for 15 min 




Sodium citrate buffer 
70
o
C for 30 min 
IHC Abcam 
Rat-specific CD68 Mouse 1:100 
Sodium citrate buffer 
70
o
C for 30 min 
IF Serotec 
Rat-specific CD8 Mouse 1:100 
Sodium citrate buffer 
70
o





Goat Neat NA IHC Lab Vision 
Biotinylated goat 
anti-rabbit IgG 
Goat 1:100 NA IHC Vector Lab 
Goat anti-mouse 
Alexa Fluor 488 




Alexa Fluor 594 
Goat 1:200 NA IF 
Molecular 
Probes 
IHC:  Immunohistochemistry; IF: Immunofluorescence; NA: Not applicable 
 
3.7.2 Staining of tissue specimens 
3.7.2.1 Processing of tissue specimens 
Cell pellet samples were harvested and washed once with PBS and then fixed in 10% 
neutral buffered formalin or 4% paraformaldehyde overnight at 4
o
C. Pellets were 
dehydrated in successive ethanol washes of 70%, 70%, 80%, 80%, 95% and 95% for 15 
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min each. Pellets were stained briefly with eosin, followed by two brief rinses in 100% 
ethanol. This stain serves to visualize the aggregates and aid in their handling. Pellet 
samples were finally dehydrated in two changes of 100% ethanol, 20 min each, before 
being transferred to two changes of xylene, 20 min each. Pellet samples were then 
transferred to 3 changes of paraffin, 20 min each. Pellet samples were then embedded in 
paraffin block as per standard embedding procedure. 5 μm sections of each sample were 
cut and 2-3 sections were transferred onto a microscope glass slide. Slides were dried 
overnight at 60
o
C before storing in slideboxes at RT for future staining.   
 
For cartilage explant samples, samples were harvested, rinsed once in PBS and then fixed 
in 10% neutral buffered formalin for a week. This was followed by decalcification using 
30% (v/v) formic acid for 2 weeks. Cartilage samples were then processed using tissue 
processor. Briefly, samples were dehydrated in successive ethanol washes of 50%, 70%, 
90%, 100% and 100% for 1 hr each. Samples were transferred to toluene/ethanol (50/50) 
for 1 hr and then to toluene for 7 hr. Finally, samples were transferred to 2 changes of 
paraffin, for 1 hr and 4 hr respectively. Samples were then embedded in paraffin blocks 
as per standard embedding procedure.    
 
3.7.2.2 Haematoxylin and eosin staining 
Tissue sections were deparaffinized in xylene before hydrated through descending order 
of alcohols, 2 min each, and then in water for 5 min. Specimens were first nuclear-stained 
with Mayer’s haematoxylin for 5 min before bluing in ammonium water and rinsing in 
the water. Specimens were then stained with eosin for about 30 sec for counterstaining of 
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the cytoplasm and other proteins. After staining, tissue sections were dehydrated and 
brought to xylene before mounting in the xylene-based DePex mounting medium (VWR 
International, Poole, Dorset, UK).   
 
3.7.2.3 Alcian blue staining  
Tissue sections were deparaffinized in xylene before hydrated through descending order 
of alcohols, 2 min each, and then in dH2O for 5 min. Specimens were stained with Alcian 
blue working solution [0.5% (w/v) in 0.1 M hydrochloric acid solution] for 30 min. After 
incubation, tissue sections were rinsed twice with water before counterstained with 
nuclear fast-red for 3 min. After staining, tissue sections were dehydrated and brought to 
xylene before mounting in the xylene-based DePex mounting medium.   
 
3.7.2.4 Safranin-O staining 
Tissue sections were deparaffinized in xylene before hydrated through descending order 
of alcohols, 2 min each, and then in dH2O for 5 min. Specimens were first nuclear-stained 
with Mayer’s haematoxylin for 3 min before bluing in ammonium water and rinsing in 
dH2O. Specimens were then stained in 0.02% aqueous fast green FCF for 5 min, then 
washed once with 1% acetic acid in dH2O for 15 sec. For proteoglycan detection, 
specimens were stained in 0.1% aqueous Safranin-O for 5 min. After staining, tissue 
sections were dehydrated and brought to xylene before mounting in the xylene-based 




3.7.2.5 Masson’s trichrome staining 
Tissue sections were deparaffinized in xylene before hydrated through descending order 
of alcohols, 2 min each, and then in dH2O for 5 min. Tissue sections were first immersed 
in Bouin’s solution for 2 min before rinsing the dH2O until the yellow colour disappears. 
For nuclear staining, the tissue sections were then stained in Weigert’s haematoxylin for 
1 min and then washed to remove excess stain. The tissue sections were then stained with 
Ponceau-fuchsin for 2 min, and then washed in 2% acetic acid wash for 30 sec to remove 
excess stain. The tissue sections were then immersed in 4% phosphotungstic acid for 1 
min, and washed in 2% acetic acid wash for 30 sec before staining the collagens with 2% 
light green solution for 5 min. Any excess stain was removed by washing in 2% acetic 
acid solution. Finally, the sections were dehydrated through graded alcohols, cleared in 2 
changes of xylene, 10 min each, before mounting in xylene-based DePex mounting 
medium.   
 
3.7.2.6 Immunohistochemical staining 
IHC (immunohistochemistry) was routinely performed using UltraVision HRP Detection 
System (Lab Vision Inc., Fremont, CA, USA).  
 
Tissue sections were deparaffinzed in two changes of xylene, 10 min each, before 
hydrated through descending order of alcohols, 2 min each, and then in PBS for 5 min. 
To facilitate antigen retrieval and antibody access, an appropriate antigen retrieval step 
was performed (Table 7).  
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Tissue sections were then rinsed once with PBS before blocked with hydrogen peroxide 
block for 15 min at RT to quench any endogenous peroxidase activity. Tissue sections 
were then washed 4 times with PBS and blocked with Ultra V Block for 5 min, prior to 1 
hr incubation at RT with primary antibody diluted in PBS. The list of antibodies and 
dilutions used in immunohistochemical staining are described in Table 7. At the end of 
primary antibody incubation, tissue sections were washed 4 times with PBS, before 
biotin-conjugated goat derived anti-mouse secondary antibody was added and incubated 
at RT for 30 min. At the end of secondary antibody incubation, tissue sections were 
washed 4 times with PBS, before incubating with streptavidin-conjugated horseradish 
peroxidase at RT for 45 min. Tissue sections were then washed 4 times with PBS before 
adding the DAB chromogen for approximately 3 to 5 min to visualize the antibody-
antigen reaction. Nuclear-counterstaining was performed using Harris’s hematoxylin for 
5 min, and then washed with water to remove excess stain. Finally, tissue sections were 
dehydrated in successive ethanol washes of 70%, 95%, and 100% ethanol, before 
clearing in 2 changes of xylene, 10 min each, and lastly mounting in xylene-based DePex 
mounting medium.  
 
For immunofluorescence staining of tissue sections, following the primary antibody 
incubation, tissue sections were washed 4 times with PBS, before incubating with 
fluorochrome-conjugated secondary antibody for 1 hr. Finally, tissue sections were 
washed 3 times with PBS and last wash with dH2O, before air-dried and stained with 
Vectashield DAPI medium (Vector Laboratories, Burlingame, CA, USA) for nuclei-
counterstaining. Antibody isotypes or no antibody sera served as the negative control.  
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All images were taken using IX70 inverted microscope or FluoView
TM
 FV1000 confocal 
microscope (Olympus, Tokyo, Japan). 
 
3.8 Animal studies  
3.8.1 In vivo implantation assay  
Severely Combined Immunodeficiency (SCID) mice (C.B-17-Igh-1b-Prkdcscid, Harlan 
UK.) were kept in AHU (Animal Holding Unit). Mice experiments were performed in 
accordance with Institutional Animal Care and Use Committee (IACUC) of 
National University of Singapore (043/08). 
 
Cells or tissue constructs were injected or implanted into SCID mice to assess its 
tumorigenicity by means of teratoma formation. For injection, approximately 5 x 10
6
 
cells were harvested and washed twice before suspended in 200 μl of PBS for injection. 
For implantation, tissue constructs were implanted subcutaneously into the SCID mice. 
 
Each mouse was first anaesthetized using the mouse anesthesia cocktail of Ketamine (75 
mg/kg) and Medetomidine (1 mg/kg) administered intraperitoneally at 0.1ml/10g body 
mass. Subsequently, cells in a 1 ml syringe were slowly injected into the thigh muscle of 
the SCID mouse. Alternatively, tissue constructs were implanted subcutaneously, into the 
dorsal pockets, at the back of the SCID mouse. Following operation, antisedan agent - 
Atipamezole hydrochloride (5 mg/ml) was administered intraperitoneally at 0.1 ml/10g 
body mass for reversal and recovery.  
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Tumors were harvested 6-9 weeks post-operatively and processed, following the standard 
histological procedures (section 3.7.2). Observation was extended to 12 weeks for non-
tumor forming mice and harvested for histological examination at the end of 12 weeks.  
 
3.8.2 Osteochondral defect model 
Sprague Dawley rats were first anaesthetized using the rat cocktail of Ketamine (75 
mg/kg) and Medetomidine (10 mg/kg) administered intraperitoneally at 0.2 ml/100 g 
body mass. Subsequently, the knees were shaved clean, and sterilized by iodine and 
alcohol swaps. To approach the femoropatellar joint, a lateral parapatellar incision was 
made and the patella was dislocated medially (Fig. 2A-B). 
  
  Fig. 2. Osteochondral defect model 
 
For articular cartilage defect transplantation, 2 delivery systems were analyzed. Human 
ESC-derived chondrogenic cells were either pre-differentiated as a cell pellet or cell-
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hydrogel construct for up to 28 days, before transplanted into osteochondral defects (≈1.5 
mm width and 1 mm depth; Fig. 2C-D) created using a drilling device on the patellar 
groove of the distal femur of Sprague Dawley rats. Cell-hydrogel constructs were cut out 
using a biopsy punch to the fitting size of the defects. After implantation, the articular 
capsule was sutured with 6-0 nylon sutures, while subcutaneous tissue and skin were 
sutured separately with polydioxanone (PDS) absorbable sutures (Fig. 2E-F). The rats 
were immediately given analgesia (Caprofen, 5 mg/kg) and antibiotics (Baytril, 5 mg/kg) 
administered subcutaneously at 0.1 ml/100 g body mass.  
 
Empty defects with no implant and defects implanted with HA hydrogel alone served as 
controls. Rat experiments were performed in accordance with IACUC of 
National University of Singapore (069/08). The histologic grading scale described by 
Wakitani et al., 1994 was used to evaluate the quality of the repaired tissue (Table 8). 
Scoring was performed by three blinded individuals.  
 
3.8.3 Post-operative procedures 
After surgery, the animals were housed in cages and were given free access to standard 
food and water, under ABSL2 (Animal Biosafety Level 2) facilities in AHU. For the 
following 3 days after surgery, the rats were given analgesia (Caprofen, 5 mg/kg) and 
antibiotics (Baytril, 5 mg/kg) administered subcutaneously at 0.1 ml/100g body mass. 
The rats were given daily administration of Cyclosporine, Sandimmune (Novartis, Basel, 
Switzerland) at 14 mg/kg body mass to prevent immune rejection of human cells 
A 
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implanted. At designated time-points, the rats were sacrificed and distal femora were 
resected en bloc and processed for micro-CT and histological analysis. 
 
3.8.4 Micro-computational tomography (micro-CT) 
The tissue specimens were analysed using the MicroCT scanner (SMX-100CT X-ray CT 
Sys, Shimadzu, Japan). The scan settings were: X-ray voltage=56kV, X-ray current = 
61uA, detector size = 9”, scaling coefficient = 50 and voxel resolution = 0.012mm. The 
scans were then reconstructed to create the 3D geometry using VGStudioMax (Version 
1.2, Volume Graphics, Germany). To estimate the bone and cartilage content of the repair 
site, we set a 1.9mm x 0.8mm rectangular region-of-interest (ROI) encompassing the 
desired region in the microCT slices for each specimen using CTAnalyser (v1.9, Skyscan, 
Belgium). The bone and cartilage portions were then segmented using the thresholding 
function, and thereafter their respective 3D volumes were computed from the segmented 
ROI in each micro-CT slice. At least 2 samples were analyzed at each time-point of 
harvest.  
 
3.8.5 Human cell chimerism 
Human-specific vimentin (hVIM) immunostaining to detect human cell chimerism was 
carried out following the IHC procedure as earlier described (section 3.7.2.6; Lee et al., 
2009b). Cell nuclei with cytoplasmic staining of hVIM were counted as human cells 
against cell nuclei without cytoplasmic stain as the rat cells. The number of human and 
rat cells within the regenerated cartilage layer was divided into centre and peripheral 
zones, and enumerated manually at 20X magnification to estimate the level of chimerism 
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of human cells (illustrated in Fig. 3). At least 2 sections from each sample were analyzed 
(n = 16). A median of 481 cells was counted for each sample (range 234 - 741).    
 
 
Fig. 3. Schematic model to illustrate the centre (C) and periphery (P) zones of the 
regenerated neocartilage layer. Cells in the dotted boxes were counted. 
 
 
3.9 Statistical analysis 
All quantitative data reported here were analyzed using one-way ANOVA and 
Scheffe/Turkey’s post-hoc test, with p < 0.05 being considered significantly different. At 









Articular cartilage  
Reparative tissue  
Subchondral bone  
P C P 
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Table 8. Histological grading scale (adapted from Wakitani et al.1994) 
 
Category                Points 
 
Cell morphology 
Hyaline cartilage        0 
Mostly hyaline cartilage       1 
Mostly fibrocartilage        2 
Mostly non-cartilage        3 
Non-cartilage only         4 
 
Matrix-staining (metachromasia)       
Normal (compared with host adjacent cartilage)    0 
Slightly reduced        1 
Markedly reduced        2 





Smooth (>3/4)         0 
Moderate (>1/2-3/4)        1 
Irregular (1/4-1/2)        2 





>2/3          0 
1/3-1/2          1 
<1/3          2 
 
Integration of donor with host adjacent cartilage 
Both edges integrated        0 
One edge integrated        1 
Neither edge integrated       2 
 
Total maximum                   14  
   
a. Total smooth area of the reparative cartilage compared with the entire area of the 
cartilage defect. 








4.1 PHASE I: MODEL SYSTEM 
4.1.1 Pluripotency of human embryonic stem cells 
ESCs are derived from the totipotent cells of early mammalian embryos and are capable 
of unlimited proliferation without differentiation under specific culture conditions in vitro 
(Evans et al., 1981; Martin et al., 1981) Undifferentiated hESCs are characterized by 
their distinct colony morphology as well as by their expression of a panel of molecular 
and surface markers. The molecular markers include Oct4, Sox2 and Nanog, which are 
involved in the maintenance of the undifferentiated state of the hESCs (Nichols et al., 
1998; Chambers et al., 2003; Avilion et al., 2003). Surface markers include alkaline 
phosphatase (ALP), stage-specific embryonic antigens 3 and 4 (SSEA-3 and SSEA-4), 
and TRA-1-60 (Thomson et al., 1998). Human ESCs were routinely screened for these 
markers to ensure their pluripotency (Fig. 4A-C). In addition, hESCs are tumorigenic. 
When injected into immunodeficient mice, these cells developed to become teratomas in 
vivo, of which several tissue types including neural rosettes (ectoderm), cartilage 
(mesoderm) and glandular structures (endoderm), representatives of the three germ layers 




Fig. 4. Pluripotent hESCs. H9 hESCs are characterized by their distinct colony 
morphology (A) and positive expression of ALP (B). Human ESCs also express 
pluripotency-associated genes which include Oct 4, Sox 2 and Nanog, which human fetal 
osteoblast cell line (FOB) showed absence of these pluripotency markers (C). H9 hESCs 
injected into SCID mice formed teratomas 8 weeks later (D), of which tissue types of 
three germ layers including neural rosettes (nr) of ectoderm, cartilage (c) of mesoderm 
and glandular structures (g) of endoderm could be observed (E). 
 
4.1.2 Effects of culture conditions in modulation of chondrogenesis   
Chondrogenic induction of hESCs occurred through EB formation. EBs were either 
plated directly at approximately 30 EBs per well and outgrowth of cells allowed (EB 
outgrowth), or dissociated into single cells and plated at a high density of 3 x 10
5
 cells per 




Cells expressed Col 2 in both EB outgrowth and micromass cultures under chondrogenic 
differentiation conditions, but the temporal gene expression profile differed dramatically 
in the two systems. In control EB outgrowth, the expression of Col 2 mRNA level 
increased from day 3 and plateaued by day 11, without significant changes thereafter. Col 
2 mRNA level in the BMP2-treated EB outgrowth was consistently higher than the 
control, with a slow and steady increase in the Col 2 mRNA level from day 3 onwards, 
before it peaked on day 14 with >2-fold increase compared to the control (p < 0.05), and 
declined thereafter (Fig. 5A). On the other hand, the micromass culture system resulted in 
an acute increase in Col 2 mRNA level that peaked on day 7 (6-fold increase compared to 
undifferentiated cells) and decreased to almost basal levels by day 14. This profile was 
similar in both the control and BMP2-treated micromass cultures, with BMP2 exerting a 
2-fold increase between day 7 and 14, compared to the control (p < 0.05, Fig. 5B). The 
high-density micromass system promoted an earlier onset of chondrogenic differentiation 
marked by the Col 2 expression level that peaked on day 7, as compared to the EB 
outgrowth system that peaked later, between day 11 and 14.   
 
Col 1 expression was also analyzed in both systems along the course of EB 
chondrogenesis. The expression of Col 1 mRNA level showed an upward trend in a time-
dependent manner in the EB outgrowth system, and was consistently higher in the 
presence of BMP2 (Fig. 5C). In contrast, the Col 1 gene expression profile differed 
significantly in the micromass system (Fig. 5D), where there was an increase in Col 1 
expression level up to day 7 before it plateaued. In the BMP2-treated micromass culture, 
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Col 1 expression level initially peaked at day 7 and day 11, with significantly higher 
levels than the control, before it declined to levels similar to the control by day 14.  
 
The gene expression profile of chondrogenic development in both systems was further 
substantiated by determination of the s-GAG synthesis (Fig. 6). Alcian blue staining at 
the end of 21-day differentiation showed no obvious difference between the control and 
BMP2-treated EB outgrowths (Fig. 6A). Under the EB outgrowth system, there was 
accumulation of s-GAG in both control and BMP2-treated groups along the course of 
differentiation with no significant additive effect from BMP2 (Fig. 6C). EBs plated in 
outgrowth fashion exhibited extensive proliferation, as shown by a 4-fold increase in 
DNA levels by day 7 of differentiation (Fig. 6E). Consequently, the s-GAG/DNA 
analysis showed continuous low levels in both control and BMP2-treated cultures when 
analyzing the s-GAG synthesis in a single cell level (Fig. 6G).  
 
Under high-density micromass culture conditions, BMP2 induced intensified 
mesenchymal condensation and cartilage nodule formation, as observed by alcian blue 
staining (Fig. 6B). The cells exhibited minimal proliferation, with less than 2-fold 
increase in DNA levels by day 7 of differentiation (Fig. 6F). There was no significant 
difference in the DNA levels between the control and the BMP2-treated groups. BMP2 
treatment increased s-GAG deposition from day 7 to day 14 (Fig. 6D), which after 
normalizing to the DNA content, resulted in a significant increase in s-GAG/DNA levels, 
compared to the control (p < 0.05, Fig. 6H). During the later stage of differentiation at 
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day 21, the s-GAG production plateaued (Fig. 6D), while there was still continuous 





Fig. 5. Chondrogenic differentiation in EB outgrowth and EB-derived micromass. 
5‘d’EBs were either plated directly or dissociated into single cells and plated as high-
density micromass under control and BMP2 supplemented chondrogenic conditions for 
21 days. High-density micromass culture system promotes a relatively earlier onset of 
chondrogenesis, as compared to the outgrowth system. Expression of Col 2 (A, B) and 
Col 1 (C, D) were analyzed along the course of chondrogenesis by quantitative real-time 
RT-PCR in both EB outgrowth (A, C) and micromass cultures (B, D). Mean magnitudes 
of mRNA levels were normalized to GAPDH, and expressed relative to the day 0 
expression level of 5‘d’EBs. Results are means ± SD from duplicate analysis of at least 
two experiments, with statistical significance set at *p < 0.05 compared to the control. 
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Fig. 6. Modulation of s-GAG synthesis in EB outgrowth and EB-derived micromass. 
5‘d’EBs were either plated directly or dissociated into single cells and cultured as high-
density micromass under control and BMP2 supplemented chondrogenic conditions for 
21 days. High-density micromass culture system promotes matrix synthesis of EBs in the 
presence of BMP2. No significant Alcian blue staining was observed in the cultures of 
EB outgrowth (A). Cartilage nodules with dark blue appearance were only observed in 
BMP2-treated micromass culture (B). For quantitative analysis, s-GAG content (C, D) 
and DNA content (E, F) were determined. The s-GAG content was normalized against 
the DNA content to determine the s-GAG synthesis per cell, s-GAG/DNA (G, H). 
Measurements reported were averaged from duplicate analysis of at least two 
independent experiments, and data are expressed as mean ± SD, with statistical 
significance set at *p < 0.05 compared to the control. Abbreviations: EB, embryoid body; 




4.1.3 Effects of culture conditions on hypertrophic development    
To investigate the hypertrophic maturation of EBs, Col 10 gene expression was analyzed 
during the course of differentiation (Fig. 7). No significant increase in Col 10 mRNA 
level was observed in the control EB outgrowth throughout the entire course of 
differentiation. Conversely in the BMP2-treated EB outgrowth, a significant increase in 
Col 10 mRNA level was observed from day 14 onwards, with an approximately 2-fold 
increase compared to the control on day 21 (p < 0.05, Fig. 7A).  
 
When compared to day 0 expression level, the high-density micromass system promoted 
a rapid increase in Col 10 mRNA level as early as day 7, and the upregulation 
progressively increased up to day 21 with a significant 700-fold and 1000-fold increase in 
the Col 10 expression levels observed in the control and BMP2-treated micromass 
cultures respectively (Fig. 7B). This progression appeared to be largely independent of 
BMP2 stimulation at the early stages of differentiation (day 7 to day 18), and a further 
increase in Col 10 expression level was only induced by BMP2 from day 18 onwards 
(Fig. 7B).  
 
Hypertrophic maturation was significantly enhanced in the high-density micromass 
system, marked by a striking 1000-fold upregulation in Col 10 expression levels, 
compared to the EB outgrowth counterparts by day 21 of differentiation (p < 0.001).  
 
Undifferentiated hESCs expressed high levels of ALP, which is an enzyme expressed by 
hESCs (Draper et al., 2002), hypertrophic chondrocytes (Goldring et al., 2006), as well 
 72 
as osteoblasts (Aubin et al., 1995). Hypertrophic maturation of EBs was further 
substantiated with analysis of ALP activity. ALP activity profiles differed dramatically 
between the two culture systems (Fig. 8). ALP activity of 5‘d’EBs at day 0 was high and 
upon further culture, there was an acute increase in ALP activity by day 7, which then 
decreased to almost basal levels by day 21 of culture in both control and BMP2 
supplemented medium. Furthermore, there was no significant induction in ALP activity 
by BMP2 in the EB outgrowth system (Fig. 8A). Conversely in the high-density 
micromass system, ALP activity dropped to almost basal levels by day 7, following cell 
dissociation and high density seeding as micromass (Fig. 8B). Subsequently, there was a 
sizeable and progressive increase in ALP activity from day 7 onwards, which eventually 
reached a plateau at day 21. The ALP activity was 30% higher under BMP2 treatment at 
day 21 of differentiation, in comparison to the control (p < 0.05). By day 21 of 
differentiation, the high-density micromass system demonstrated a 2.2-fold increase in 
ALP activity compared to the outgrowth system, which was further boosted to a 2.7-fold 
increase when BMP2 was added. This data correlated well with the Col 10 gene 
expression data, which showed that high-density micromass system promotes 
hypertrophic maturation and BMP2 played a moderate effect predominantly at the later 














Fig. 7. Hypertrophic development in EB outgrowth and EB-derived micromass. 5‘d’EBs 
were either plated directly or dissociated into single cells and plated as a high-density 
micromass. High-density micromass culture system promotes hypertrophic maturation of 
EBs, irrespective of BMP2 treatment. Expression of hypertophic marker gene Col 10 was 
analyzed along the course of chondrogenesis by quantitative real-time RT-PCR in the EB 
outgrowth (A) and micromass cultures (B). Mean magnitudes of mRNA levels were 
normalized to GAPDH, and expressed relative to the day 0 expression level of 5‘d’EBs. 
Results are means ± SD from duplicate analysis of at least two independent experiments, 
and statistical significance set at *p < 0.05 compared to the control. Abbreviations: EB, 









Fig. 8. Kinetics of ALP activity in EB outgrowth and EB-derived micromass. 5‘d’EBs 
were either plated directly or dissociated into single cells and plated as a high-density 
micromass. ALP activity was measured along the course of chondrogenesis. 
Measurements reported were averaged from duplicate analysis of two independent 
experiments, and data are expressed as mean ± SD, with statistical significance set at *p < 




4.1.4 Modulation of chondrogenesis in different EB seeding densities 
Next, the effects of increasing the seeding numbers of EBs on chondrogenic induction 
were investigated to answer the question of whether provision of a denser outgrowth of 
cells could facilitate cell condensation and henceforth chondrogenic differentiation. 
However, as observed by real-time PCR analysis (Fig. 9), Col 2 expression level 
decreased when higher number of EBs were seeded and BMP2 supplementation further 
reduced the Col 2 expression levels in a density-dependent manner. On the other hand, 
BMP2 induced increase in Col 1 and αFP expression levels at all densities tested. In fact, 
αFP expression was increased in a density-dependent manner even in the control and was 
further augmented in the presence of BMP2. Analysis of the Oct4 expression indicated 




4.1.5 Effects of culture conditions in lineage selection during chondrogenesis 
In the high-density micromass system, neuroectodermal differentiation (denoted by 
neuroD1) was inhibited, even in the absence of BMP2 (Fig. 10). On the other hand, 
BMP2 supplementation was required to completely inhibit the neuroectodermal lineage 
in the EB outgrowth system. The high-density micromass system was also able to 
partially inhibit differentiation of extra-embryonic endoderm lineage (indicated by αFP) 
and hematopoietic and endothelial lineages (indicated by VEGFR2). Adipogenesis 
(indicated by PPARγ) was promoted in the outgrowth system but was almost completely 
inhibited in the micromass system (Fig. 10). 
 
 
Fig. 9. Effects of increasing EB seeding numbers on chondrogenic differentiation in an 
EB outgrowth system. 5‘d’EBs were plated directly at seeding numbers 30, 60 and 120 
EBs. Expression of Oct4 (A), Col 2 (B), Col 1 (C) were analyzed at day 7 of 
chondrogenic differentiation by quantitative real-time RT-PCR. Higher seeding numbers 
of EBs promote differentiation to extra-embryonic endodermal lineage. Mean magnitudes 
of mRNA levels were normalized to GAPDH, and expressed relative to the day 0 
expression level of 5‘d’EBs. αFP (D), representative of the extra-embryonic endoderm, 
was analyzed by RT-PCR (insert) and quantified by ImageJ analysis. Mean pixel 
intensities of αFP expression were normalized against β-actin and expressed relative to 







Fig. 10. Lineage restriction analysis in EB outgrowth and EB-derived micromass. 
5‘d’EBs were either plated directly at 30 EBs per well or dissociated into single cells and 
plated as high-density micromass. High-density micromass culture system promotes a 
relatively restricted differentiation to chondrogenic lineage, as compared to the outgrowth 
system. RNA was extracted on day 7, 14 and 21 and RT-PCR analysis was performed to 
detect the expression of genes denoted. Expressions of pluripotency and differentiation 
gene markers of neuroectodermal, endodermal, as well as mesodermal-derived 
haematopoietic, endothelial and adipogenic lineages were analyzed. Appropriate positive 
and negative controls were included. Abbreviations: EB, embryoid body; C, control; B, 
BMP2; Cho, chondrocytes; Huv, human umbilical vein endothelial cells; Neu, 
neuroblastoma cell line; NTC, no transcript control. 
 
 
4.2 PHASE II: GROWTH FACTOR MODULATION 
4.2.1 Growth factor modulation of chondrogenesis   
Based on the established high-density micromass system, the effects of different growth 
factors (BMP2 and/or TGFβ1) were further evaluated. Micromass cultures were induced 
under growth factor treatment for 21 days and analyzed for their cartilage-related gene 
expression and matrix synthesis at the end of differentiation. Collagens and proteoglycans 
like Col 2, link protein (LP) and cartilage oligomeric protein (COMP) were not 
expressed in undifferentiated hESCs and 5‘d’EBs, but expressed specifically in 
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differentiated EB-derived micromass cultures under chondrogenic differentiation 
conditions (Fig. 11A). Col 2 was expressed in all micromass cultures, and was markedly 
elevated when treated with TGFβ1 alone. Other cartilage-related proteins such as Col 
9A1 and link protein (LP) also appeared to be upregulated upon treatment with TGFβ1 
(Fig. 11A). COMP was not present under control chondrogenic condition, but markedly 
elevated with treatments of BMP2 and/or TGFβ1. Co-treatment of BMP2 and TGFβ1 
was able to induce the highest expression of COMP. There were also upregulation of 
cartilage-related receptors CD44s and PDGFRα after micromass culture of the cells. 
CD44s was not expressed in undifferentiated hESCs and EBs, but expressed specifically 
by micromass cultures undergoing chondrogenic differentiation. PDGFRα was readily 
detected in undifferentiated hESCs and 5‘d’EBs, and was modestly enhanced in 
micromass cultures treated with growth factors (Fig. 11A). 
 
Quantitative real-time RT-PCR demonstrated that TGFβ1 induced the highest level of 
Col 2 expression by day 21 of differentiation, with a significant 3-fold increase when 
compared to the control (p < 0.01, Fig. 11B). There was no evidence of synergistic 
elevation in Col 2 expression observed with co-treatment of BMP2 and TGFβ1, as 
compared to TGFβ1 alone. Col 1 was expressed at low levels in undifferentiated hESCs 
and 5‘d’EBs, but was upregulated by micromass cultures under chondrogenic conditions. 
In the presence of TGFβ1, the level of Col 1 expression was comparable to that of the 
control. As a result, TGFβ1 was able to induce an overall highest differentiation index of 
Col 2/Col 1 ratio, with approximately 2.5-fold increase over the control (p < 0.01, Fig. 
11B). On the other hand, co-treatment of BMP2 and TGFβ1 induced highest expression 
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of Col 1, with approximately 2.5-fold increase over the control (p < 0.01, Fig. 11B). 
Consequently, co-treatment of BMP2 and TGFβ1 resulted in a lowest Col 2/Col 1 ratio.  
 
Consistent with the real-time PCR results, we observed that TGFβ1 treatment resulted in 
enhanced chondrogenic differentiation, with intense staining of collagen II-producing 
chondrogenic cells that formed a dense filamentous matrix network connecting the cells 
(Fig. 11C). Underlying the dense matrix, a small fraction of cells which co-expressed 
collagen II and collagen I could be observed. These cells may be mesenchymal 
intermediate cells as they possessed high collagen I and low collagen II contents. Under 
the co-treatment of both BMP2 and TGFβ1, these cells formed prominent cell clusters 
highly-enriched in collagen I.  
 
4.2.2 Growth factor modulation of matrix synthesis 
s-GAG synthesis was measured at end of 21-day differentiation to determine the 
influence of growth factors on matrix accumulation (Fig. 12). Analyzing the s-GAG 
synthesis in a single cell level, BMP2 treatment resulted in a ratio of s-GAG/DNA no 
higher than the control. On the other hand, TGFβ1 treatment resulted in a 2.5-fold 
increase in the ratio of s-GAG/DNA, when compared to control and BMP2-treated 
groups (p < 0.01). However, no evidence of synergistic elevation or inhibition exerted by 
BMP2 in the ratio of s-GAG/DNA was observed at day 21, when a combination of BMP2 









Fig. 11. Growth factor modulation of chondrogenesis in EB-derived micromass.  
5‘d’EBs were dissociated into single cells, plated as high-density micromass and cultured 
for up to 21 days in the absence or presence of BMP2, TGFβ1 or combination of both 
growth factors. (A) Expressions of cartilage-related genes including Col2A1, Col9A1, 
Link protein, COMP, Biglycan, Decorin, CD44s and PDGFRα were analyzed by semi-
quantitative RT-PCR after 21-day differentiation under stimulation by various growth 
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factors. β-actin amplification without reverse transcriptase and no template amplification 
served as the negative controls. (B) Quantitative analysis of Col 2, Col 1 and Col 2/Col 1 
ratio was done by quantitative real-time RT-PCR at the end of 21 days. Results showed 
the mean magnitudes of mRNA levels normalized to GAPDH, and expressed relative to 
the expression levels of undifferentiated hESCs. Data were analyzed by one-way 
ANOVA and expressed as means ± SD (n = 3). *p < 0.05 and **p < 0.01, compared to the 
control. (C) Representative interference contrast and immunofluorescence micrographs of 
micromass cultures after growth factor treatment for 21 days. Analysis of EB-derived 
chondrogenic cells with regard to collagen II (green) and collagen I (red). Co-localized 
expression of both collagen I and II results in a yellow colour. Abbreviations: ES, Human 
embryonic stem cells; EB, Embryoid body; HPM, Human palate mesenchymal cell line; 
BMP2, Bone morphogenetic protein 2; TGFβ1, Transforming growth factor-beta 1; 
CD44s, CD44 standard isoform; PDGFRα, Platelet-derived growth factor receptor-alpha; 









Fig. 12. Growth factor modulation of matrix synthesis. 5‘d’EBs were dissociated into 
single cells, plated as high-density micromass and cultured for up to 21 days in the 
absence or presence of BMP2, TGFβ1 or combination of both growth factors. The s-
GAG content was normalized against the DNA content to determine the s-GAG synthesis 
per cell (s-GAG/DNA). TGFβ1 induced the highest level in the ratio of s-GAG/DNA, 
among the various growth factor treatments. Data were expressed as mean ± SD, with 
statistical significance set at *p < 0.05 and **p < 0.01, compared to the control (n = 4). 







4.2.3 Growth factor modulation of chondrogenic commitment 
The effects of BMP2 and/or TGFβ1 on differentiation to other lineages were also 
investigated (Fig. 13). The EB-derived micromass system showed a considerable 
inhibition in development to other lineages, as compared to the EB outgrowth system 
under control chondrogenic condition. Under the micromass system, differentiation to the 
neuronal lineage (indicated by NFH) was greatly impeded. Differentiation to the 
epidermal lineage, marked by the expression of cK14, was only observed in BMP2-
supplemented conditions.  
 
In the presence of TGFβ1 alone, there was limited induction of extra-embryonic 
endoderm lineage (indicated by αFP), and suppression or limited induction of 
hematopoietic/endothelial lineages as indicated by VEGFR2 and PECAM1 respectively. 
Adipogenesis (indicated by PPARγ) was upregulated in the presence of BMP2 but was 
inhibited by TGFβ1 in the micromass system. Osteogenesis was limited, with only low 
level of osteocalcin (OC) detected in the EB outgrowth in chondrogenic condition 
without growth factor supplementation. Collectively, TGFβ1 induces a relatively 

















Fig. 13. Growth factor modulation of other lineage differentiation. TGFβ1 induces a 
relatively restricted chondrogenic differentiation, as compared to the other growth factor 
conditions. (A) RT-PCR analysis was performed to detect the expression of the genes 
denoted. Expressions of differentiation gene markers of neuroectodermal, endodermal, 
mesodermal lineages were analyzed. β-actin amplification without reverse transcriptase (-
RT) served as the negative control. Results are representative of three independent 
experiments. (B) Magnitude of mRNA levels was normalized to β-actin and expressed as 
mean ± SD (n = 3). #p < 0.05 compared to undifferentiated ES cells; *p < 0.05 compared 
to control micromass. Abbreviations: UD, Uninduced; ES, Embryonic stem cells; EB, 
Embryoid body; C, Control; B, BMP2; T, TGFβ1; BT, BMP2/TGFβ1; HPM, Human 
palate mesenchymal cell line; EB
OG
, EB outgrowth. 
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4.2.4 TGFβ1 induction of chondrogenic cells  
Using Col 2 as a specific marker for chondrogenesis, as the most prominent collagen 
specific to hyaline cartilage, a time course analysis of Col 2 expression in TGFβ1-treated 
micromass was further carried out (Fig. 14A). Under high-density micromass culture 
conditions, induction of Col 2 expression by TGFβ1 began after day 7, but was more 
intensified and prolonged thereafter, with approximately 1.5-fold increase by day 14 and 
a 3-fold increase by day 21 when compared to the control (p < 0.05). Furthermore, the 
expression of Sox9, a transcription factor involved in regulation of Col 2, showed a 
similar expression pattern as Col 2, with an average 1.3-fold increase by day 14 and 1.5-
fold increase by day 21 when compared to the control. On the other hand, TGFβ1 
induced comparable levels of Col 1 to the control throughout the course of differentiation. 
In both control and TGFβ1 supplemented conditions, Col 1 expression increased up to 
day 14 before it declined by day 21. At the end of 21-day differentiation, substantial 
number of cells was collagen II positive and co-localization of collagen I and II further 
showed that majority of the chondrogenic cells were highly-enriched in collagen II, and 
formed dense filamentous collagen II network interconnecting the cells within the 
micromass cultures (Fig. 14B). By means of immunofluorescence staining, remnants of 
undifferentiated Oct4-positive cells could still be observed in these differentiated 
micromass cultures, but were distinctly exclusive from the collagen II-positive 
chondrogenic cells (Fig. 15).  
 
In summary, these results suggest that TGFβ1, among the different growth factor 
treatment regimes, induced a relatively restricted chondrogenic differentiation, 
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substantiated with highest differentiation index of Col 2/Col 1 ratio and highest number 






Fig. 14. TGFβ1-induced chondrogenesis. (A) Temporal expression profile of 
chondrogenic genes Col 1, Col 2 and Sox9 in TGFβ1-induced chondrogenic 
differentiation of EB-derived micromass cultures. Results showed the mean magnitudes 
of mRNA levels normalized to GAPDH, and expressed relative to the expression levels 
of undifferentiated hESCs. Results are means ± SD with statistical significance at *p < 
0.05, compared to the control (n = 3). (B) Chondrogenic cells derived from micromass 
cultures at day 21 of TGFβ1-induced chondrogenic differentiation were double-stained 
with anti-collagen II (green) and anti-collagen I (red) specific antibodies and nuclear-
counterstained with DAPI (blue) (a). Higher magnification images for phase-contrast (b), 
collagen I (red) (c), collagen II (green) (d), nuclear staining with DAPI (blue) (e), and 
merged images of collagen II and DAPI (f), and collagen I/II and DAPI (g). Single 
collagen II-positive cells are highly-enriched in the presence of TGFβ1 (arrow). 







Fig. 15. TGFβ1-induced chondrogenesis vs. pluripotency. EB-derived micromass 
cultures at day 21 of TGFβ1-induced chondrogenic differentiation were double-stained 
with anti-Col II (green) and anti-Oct4 (red) specific antibodies and nuclear-
counterstained with DAPI (blue). When compared to the (A) undifferentiated hESCs, (B) 
micromass cultures of EB-derived cells were highly-enriched with Col II-positive 
chondrogenic cells. Remnants of Oct4-positive undifferentiated cells could be observed 
but were mutually exclusive from the Col II-positively stained areas in the cultures.  
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4.3 PHASE III: ISOLATION OF CHONDROGENIC CELLS  
4.3.1 Derivation of hESC-derived chondrogenic cells   
As chondrogenic cells were organized not only in nodules but also in the filamentous 
collagen network in the periphery within the micromass cultures, we attempted to enrich 
them by collagenase treatment and passing the cells through a 40-μm mesh. Single cell 
suspensions derived from collagenase digestion were plated onto UC, GL or COL II-
coated plates to test whether different substrates could influence the differentiation 
characteristics and marker gene expression of the isolated chondrogenic cells.  
 
Upon plating, the percentage of cells adhering to UC, GL and COL II surfaces were 35%, 
65% and 51% respectively (Fig. 16A). De-differentiation of hESC-derived chondrogenic 
cells, marked by a time-dependent decrease in Col 2 and concomitant increase in Col 1, 
was observed within a week after isolation, irrespective of the ECM substratum used for 
attachment. Cells cultured on COL II substratum showed the highest expression of Col 2 
in the first 3 days of culture, but declined in expression by day 5 of culture (Fig. 16B). 
Col 1 expression increased after day 3 of culture, with cells cultured on COL II substrata 
having the highest Col 1 expression levels (p < 0.01 compared to uncoated control, Fig. 
16B). Consistently, homogenous populations of collagen I-positive cells were observed 
by day 5 after isolation (Fig. 16C). In summary, there was rapid de-differentiation of the 
chondrogenic cells upon monolayer attachment and expansion, yielding a homogenous 
population of collagen I-positive cells, regardless of the ECM substratum that was used 







Fig. 16. Isolation and monolayer plating of hESC-derived chondrogenic cells. (A) Cell 
seeding efficiency on various ECM surfaces. (B) Rapid de-differentiation of isolated 
chondrogenic cells occurred upon monolayer plating, as observed from the gene 
expression analysis of Col 2 and Col 1. Mean magnitudes of mRNA levels were 
normalized to GAPDH, and expressed relative to the expression levels of isolated 
chondrogenic cells at day 0. Results are mean ± SD with statistical significance at *p < 
0.05, relative to the uncoated control (n = 3). (C) Immunofluorescence staining of 
collagen I and collagen II further confirmed the real-time PCR analysis. Isolated 
chondrogenic cells were double-stained with anti-collagen I (red) and anti-collagen II 
(green; arrowhead) specific antibodies and nuclear-counterstained with DAPI (blue). 
Eventual de-differentiation of the hESC-derived chondrogenic cells occurred regardless 
of the ECM substratum used for attachment and expansion. Abbreviations: UC: uncoated; 





4.3.2 Expansion of hESC-derived chondrogenic cells 
Isolated hESC-derived chondrogenic cells maintained high proliferative ability and 
chondrogenic differentiation potential when cultured in the presence of TFP (TGFβ1, 
FGF2, PDGFbb) growth factors. When these chondrogenic cells were cultured in TFP 
supplemented medium, a homogenous and expandable population of spindle-shaped, 
fibroblast-like cells was generated within 2 weeks (Fig. 17A). Chondrogenic cells 
initially displayed a slow proliferation rate, but proliferation increased significantly after 
passage 1. Chondrogenic cells were continuously expanded in the presence of TFP 
growth factor combination for 27 days (a total of 8 passages), with the total PDL being 
13.47 (10
4
-fold increase in total cell number; doubling time, td=38.5 hr; Fig. 17B). In 
addition, hESC-derived chondrogenic cells cultured in TFP supplemented medium were 
able to retain a higher Sox9 expression with a 1.5-fold difference compared to culture in 
the control (DMEM/10% FBS) medium (p < 0.05; Fig. 17C).  
 
4.3.3 Differentiation capability of hESC-derived chondrogenic cells 
Pellet cultures of expanded hESC-derived chondrogenic cells demonstrated significant 
deposition of s-GAG only when differentiated in the presence of TGFβ1 (Fig. 17D). In 
the presence of TGFβ1, chondrogenic cells expanded in TFP growth factor combination 
were able to generate homogenous cartilaginous tissues, which stained for s-GAG by day 
14 of differentiation. In contrast, chondrogenic cells expanded in control (DMEM/10% 
FBS) medium formed pellets faintly stained for s-GAG, observed only at the periphery of 
the pellets. Sulfated GAG deposition observed from the histological staining was further 
substantiated with quantitative analysis. Chondrogenic cells expanded in control and TFP 
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growth factor combination produced pellets with comparable, low amounts of s-GAG 
when differentiated in the absence of TGFβ1. The s-GAG/DNA content was significantly 
higher when pellets were cultured in presence of TGFβ1, and were the highest if pellets 
were based on TFP-expanded chondrogenic cells (p < 0.05, Fig. 17D). For this reason, 





Fig. 17. Chondrogenic differentiation capability of hESC-derived chondrogenic cells.     
(A) Cellular morphology and (B) growth characteristics and (C) Sox9 expression of 
chondrogenic cells cultured in presence of TFP growth factors. (D) Chondrogenic cells 
were expanded in DMEM/10% FBS (control) and TFP medium for 5 passages (≈10 
population doublings) before induced to differentiate in pellet cultures for 14 days under 
control and TGFβ1 induced chondrogenic conditions and assessed by histological and 
biochemical analysis. *p < 0.05 vs. control differentiated pellets; #p < 0.05 vs. control 
expanded, TGFβ1 differentiated pellets. Abbreviations: C, control; T, TGFβ1. 
 90 
4.3.4 Characterization of hESC-derived chondrogenic cell line (TC1)  
Human ESC-derived chondrogenic cell line, derived and maintained in the presence of 
TFP growth factors, is named TC1. These cells demonstrate loss of pluripotency with no 
detectable ALP activity and loss in expression of pluripotency-associated genes including 
Oct4 and Rex1 (Fig. 18A). In addition, analysis by means of specific immunostaining 
further confirmed that these cells are lineage-restricted and depleted of other cell types, 
particularly the undifferentiated and the endodermal cells (Fig. 18B). These cells are 
highly-proliferative with approximately 60% of cells being positive for Ki67. Upon 
differentiation in pellet culture in the presence of TGFβ1, these chondrogenic cells 
formed highly homogenous cartilaginous tissue with morphological similarities to 
neocartilage, such as round cells embedded in lacunae (Fig. 18B). Absence of 
endodermal cells was further confirmed by AFP immunostaining (Fig. 18B).  
 
To further investigate the lineage restriction of hESC-derived chondrogenic cells, 
osteogenic and adipogenic differentiations were performed using the established methods 
for primary adult MSCs (Liu et al., 2007). In contrast to multipotent MSCs, hESC-
derived chondrogenic cells are unipotential, being restricted to differentiation along the 
chondrogenic pathway and are not responsive to osteogenic and adipogenic 
differentiation conditions (Fig. 19). In addition, FACS analysis of surface markers 
revealed further differences in surface marker expression (Table 9). While both hESC-
derived chondrogenic cells and hMSCs were negative for the pluripotency-associated 
surface marker (TRA-1-60) and haemopoietic surface markers (CD34 and CD45), the 
former display a lower expression of CD90 and CD105. Of note, FACS analysis 
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confirmed the homogeneity of hESC-derived chondrogenic cells with a high CD44 







Fig. 18. Analysis of pluripotency and lineage-restriction of hESC-derived chondrogenic 
cells. (A) ALP activity and RT-PCR analysis of pluripotency-associated genes in H9, 
TC1 and HPM. (B) Morphological and lineage analysis of TC1 and derived cartilaginous 
pellet. Human ESC-derived chondrogenic cell line (TC1) is lineage-restricted with loss of 
pluripotency and demonstrates capability for homogenous cartilaginous tissue formation. 
Abbreviations: HPM, Human palate mesenchymal cell line; H&E, Haematoxylin and 









Fig. 19. Multi-lineage differentiation analysis of hESC-derived chondrogenic cells. 
Comparative multi-lineage differentiation of TC1 and hMSCs was analyzed. Unlike 
hMSCs, TC1 did not differentiate to osteogenic and adipogenic lineages under inducing 
conditions, but only differentiate to the chondrogenic lineage. Differentiation was 
assayed by (A) specific staining, (B) gene expression analysis and (C) quantitative assays. 
The mRNA expression of genes specific for adipogenesis (PPARγ), osteogenesis (Cbfa1 
and OC), and chondrogenesis (Col2a1 and COMP) are determined by RT-PCR. Lane 1 
shows uninduced cells; Lane 2 shows induced cells. *p < 0.05; **p < 0.01 compared to 
the corresponding controls. 
 
 
Table 9. Surface marker analysis of hESC-derived chondrogenic cells. Comparative 
surface marker analysis of TC1 and hMSCs was analyzed.   
 
 Cell types 
Surface markers TC1 hMSC 
TRA-1-60 Neg. Neg. 
CD34 Neg. Neg. 
CD45 Neg. Neg. 
CD44 99.4% 90.6% 
CD73 90.4% 84.8% 
CD90 54.1% 83.7% 





In addition, hESC-derived chondrogenic cells display normal somatic cell cycle kinetics 
(Fig. 20) and a normal karyotype (Fig. 21). As expected from the loss of pluripotency and 
the normal cell cycle profile, intramuscular injection of hESC-derived chondrogenic cells
 
in SCID mice, unlike undifferentiated hESCs which developed palpable teratomas after 6 
weeks, did not
 
produce teratomas even after more than 9 weeks post-injection (Fig. 22). 
 
 
Fig. 20. Cell cycle kinetics of hESC-derived chondrogenic cells. Comparative cell cycle 
analysis of undifferentiated H9, TC1 and HPM cells. Human ESC-derived chondrogenic 
cells (TC1) demonstrate a somatic cell cycle kinetics. Abbreviation: HPM, Human palate 





Fig. 21. Genome integrity of hESC-derived chondrogenic cells. Chromosomal analysis of 
TC1 at passage 7. A total of 50 metaphase spreads were analyzed and showed a normal 
karyotype of 46,XX for TC1. Metaphase spread (top panel) and karyotype (bottom panel) 
as observed under M-FISH. Human ESC-derived chondrogenic cells (TC1) demonstrate 





Fig. 22. Tumorigenicity of hESC-derived chondrogenic cells. Teratoma observation and 
histological analysis at week 9 after injection with either TC1 (left) or parental 
undifferentiated H9 hESCs (right). Teratomas in SCID mice injected with H9 hESCs 
showed neural rosettes (nr), cartilage (c), tubular (tb) and glandular (g) structures. There 
was no observable teratoma formation in SCID mice injected with TC1. Human ESC-
derived chondrogenic cells (TC1) are non-tumorigenic. The boxed area in the top panel is 






4.3.5 ECM modulation of hESC-derived chondrogenic cells  
Despite the inability of ECM substratum to maintain the chondrocyte phenotype, the 
differentiation capacity of hESC-derived chondrogenic cells was largely modulated by 
the ECM during expansion (Fig. 23).  
 
After 4 weeks of pellet culture in chondrogenic medium in the presence of TGFβ1, 
human ESC-derived chondrogenic cells cultured on COL II substratum were able to 
generate homogenous cartilaginous tissues which stained intensely for s-GAG and 
collagens. The staining intensity for s-GAG, collagen I and collagen II appeared to be 
most intense in pellets generated by hESC-derived chondrogenic cells cultured on COL II 
substratum (Fig. 23A). In contrast, hESC-derived chondrogenic cells cultured on UC and 
GL surfaces generated pellets that displayed heterogeneous or weak deposition of s-GAG 
and collagens respectively. There was an absence of collagen X in all pellets generated 
by hESC-derived chondrogenic cells. Histological data was further confirmed using 
quantitative analyses (Fig. 23B). COL II-expanded hESC-derived chondrogenic cells 
produced pellets with the highest levels of matrix synthesis, with a 6-fold increase in s-









Fig. 23. ECM modulation of post-expansion differentiation capability of hESC-derived 
chondrogenic cells. Cells were expanded on UC, GL and COL II-coated surfaces for up 
to five passages (≈10 population doublings) before induce to differentiate in pellet 
cultures in the presence of TGFβ1 for 28 days. At the end of differentiation, the pellets 
were harvested for (A) histological examination and (B) biochemical analysis of s-GAG 
and total collagen. COL II-expanded chondrogenic cells formed cartilaginous tissue with 
significant highest levels of s-GAG and total collagen deposition, notably collagen I and 
II as observed histologically. Data were expressed as mean ± SD and statistical 
significance at *p < 0.05, compared to the uncoated control (n = 3). Abbreviations: UC: 











4.4 PHASE IV: FUNCTIONALITY  
4.4.1 Cartilage tissue engineering using hESC-derived chondrogenic cells 
Pellet culture is a useful screening system to evaluate chondrogenic potential of the 
hESC-derived chondrogenic cells. However, it does not generate the large tissue volumes 
that are needed in clinical settings of cartilage tissue loss. As hESC-derived chondrogenic 
cells yield predominantly fibrocartilage tissue formation in the pellet system, we 
examined the growth factor requirements and biomaterial effects on hESC-derived 
chondrogenic cells for hyaline cartilage tissue formation in vitro. 
 
4.4.1.1 Optimal growth factor induction for cartilage tissue engineering  
Human ESC-derived chondrogenic cells responded to anabolic growth factors such as 
BMP2 and BMP7, and to a lesser extent IGF1 and GDF5, for matrix synthesis in the 
pellet culture system. Synergistic effects on matrix synthesis were observed when these 
factors were applied in conjunction with TGFβ1. Combination of BMP7/TGFβ1 was 
identified as the most potent inducer, marked by highest level of s-GAG synthesis by day 
14 of differentiation (Fig. 24). 
 
4.4.1.2 Effects of 3D HA hydrogel encapsulation in cartilaginous tissue development 
To create a cartilaginous tissue of clinical-relevant size, a tissue engineering approach of 
hydrogel-encapsulation of hESC-derived chondrogenic cells, coupled with the optimized 
growth factor induction (BMP7/TGFβ1), was further investigated. When compared to the 
conventional pellet system under parallel BMP/TGFβ1 treatment, the hydrogel system 
demonstrated superior chondrogenesis, with a striking 4.4-fold increase in s-GAG/DNA 
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(p < 0.05) and a 5.9-fold increase in collagen II/DNA (p < 0.05) by day 14 of 






Fig. 24. Response of hESC-derived chondrogenic cells to anabolic growth factors of 
matrix synthesis. Human ESC-derived chondrogenic cells were subjected to pellet culture 
for 2 weeks in the presence of growth factors which included IGF1, BMP2, BMP7 and 
GDF5 applied in a singly or combined fashion with TGFβ1. s-GAG/DNA was 
determined and normalized against level of the untreated control, which was set as 1.  
Combination of BMP7/TGFβ1 was identified as the most potent inducer, marked by 












Fig. 25. Comparison of 3D HA hydrogel system with the pellet system. Superior 
chondrogenesis indicated by significant higher levels of s-GAG and collagen II was 
observed in the hydrogel system. Results are means ± SD with statistical significance at 
*p < 0.05, compared to the pellet system (n = 3).  
 
 
4.4.1.3 Human ESC-derived chondrogenic cell-engineered cartilage (HCCEC) 
To further evaluate BMP7/TGFβ1-induced chondrogenic differentiation of hESC-derived 
chondrogenic cells in the 3D HA hydrogel system, quantitative assessments of matrix 
synthesis (s-GAG and collagen II) were carried out at day 14 and 28 of differentiation. 
The resultant hESC-derived chondrogenic cell-engineered cartilage (HCCEC) constructs 
at the end of 28-day differentiation under BMP7/TGFβ1 treatment were also evaluated by 
the end-point histological assessment (Fig. 26). 
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Quantitative assessment of matrix synthesis indicated significant increase in s-GAG and 
collagen II in the presence of BMP7/TGFβ1 treatment, as compared to the untreated 
control. By day 28 of differentiation, BMP7/TGFβ1 induction resulted in a striking 33.5-
fold increase in s-GAG/DNA (p < 0.001, Fig. 26A) and a 5.8-fold increase in collagen 
II/DNA (p < 0.001, Fig. 26B) over the control.     
 
During the course of BMP7/TGFβ1 treatment, HCCEC demonstrated characteristic time-
dependent patterns of matrix synthesis. There was robust increase in s-GAG content 
between day 0 and 14 (2.2 ± 0.1 to 41.7 ± 10.9 μg/μg s-GAG/DNA, p < 0.01), before 
plateauing between day 14 and 28 (Fig. 26A). On the other hand, there was a relatively 
slower onset in collagen II synthesis, with low levels at day 14, but showed a significant 
increase between day 14 and 28 (30.3 ± 16.5 to 78.9 ± 25.7 ng/μg collagen II/DNA, p < 
0.05, Fig. 26B).  
 
Consistent with the quantitative assessment of matrix synthesis, HCCEC exhibited 
morphological similarities to neocartilage with round cells embedded in lacunae, and 
appeared hyaline-like, with high amounts of s-GAG and collagen II, low amount of 
collagen I and almost no collagen X at the end of 4-week differentiation (Fig. 26C). 
Collectively, synergistic involvements of BMP7/TGFβ1 and 3D hydrogel system 







Fig. 26. Cartilage tissue engineering using hESC-derived chondrogenic cells. Synergistic 
involvements of BMP7/TGFβ1 and HA hydrogel system promote hyaline-like cartilage 
tissue formation of hESC-derived chondrogenic cells. Quantitative analysis of (A) s-
GAG and (B) Collagen II indicated significant increase in cartilage matrix protein 
synthesis in the presence of BMP7/TGFβ1 treatment (*p < 0.05; ***p < 0.001 compared 
to control, n = 3) (C) Histological assessment of hESC-derived chondrogenic cell-
engineered cartilage (HCCEC) using H&E, Alcian Blue, and immunohistochemical 
staining specific for collagen I, II and X. Human origin of HCCEC was further verified 
by immunohistochemical staining of human-specific vimentin. Abbreviations: H&E, 









4.4.2 Cartilage regeneration in osteochondral defect 
4.4.2.1 Comparison of hESC-derived chondrogenic cells and HCCEC in cartilage 
repair 
Initial investigation compared the reparative tissues in osteochondral defects in adult 
Sprague Dawley rats implanted with hESC-derived chondrogenic cells in the form of cell 
pellets (CP) and cell-hydrogel constructs (i.e. HCCEC) that have been pre-conditioned 
under BMP7/TGFβ1 co-treatment for 4 weeks prior to implantation.  
 
In the CP-treated group, there was complete filling of the defect and the repaired tissue 
consisted of a mixed composition of both hyaline-like cartilage and fibrous tissues. The 
hyaline-like cartilage tissue displayed moderate amounts of s-GAG and collagen II, while 
the fibrous tissue found mainly at periphery of the defect and at the surface, displayed 
high amount of collagen I and low cellularity. In contrast, defects left empty resulted in 
fibrous tissue repair, marked by high amount of collagen I, and negligible amounts of s-
GAG and collagen II (Fig. 27A).  
 
In the HCCEC-treated group, HCCEC-repaired tissue demonstrated a smooth cartilage 
surface and a uniform and comparable matrix staining of s-GAG and collagen II to the 
adjacent host cartilage. In addition, HCCEC yielded a greater amount of reparative tissue 
than implantation of cells alone in the form of cell pellets. The HCCEC-repaired tissue 
comprised predominantly hyaline-like cartilage tissue, with high amounts of s-GAG and 
collagen II, and low amount of collagen I. There was also observation of fibrocartilage 
that co-expressed collagen I and II at the surface (Fig. 27A).  
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By 6 weeks post-implantation, the overall histological scores for group I (Empty), group 
II (CP) and group III (HCCEC) were 13.0, 7.5 and 2.8 respectively (Fig. 27B). Human 
ESC-derived chondrogenic cells, implanted as cell pellets, demonstrated significant 
improvement in cartilage repair when compared to the empty defect control (p < 0.01). 
Reparative ability of hESC-derived chondrogenic cells was further augmented when 
implanted as engineered cartilage constructs. HCCEC resulted in significant 
improvement in cartilage repair [p < 0.001 compared to group I (Empty) and p < 0.05 
compared to group II (CP)]. The scoring results were summarized in Table 10.  
 
These results indicated that implantation of hESC-derived chondrogenic cells as 
engineered cartilage constructs (i.e. HCCEC) confer a better repair than implantation of 
cells alone as cell pellets and the in vitro pre-differentiation conditions affects the in vivo 







Fig. 27. Comparison of hESC-derived chondrogenic cells and HCCEC in cartilage repair 
(A) In vivo cartilage repair at 6 weeks post-implantation. Osteochondral defects (1.5 mm 
in diameter and 1 mm depth) were created at the patellar grooves at both knees of 
Sprague Dawley rats. Human ESC-derived chondrogenic cells were pre-conditioned 
under BMP7/TGFβ1 co-treatment for 28 days to form cell pellets (CP) and cell-hydrogel 
constructs (i.e. HCCEC) prior to implantation. In vitro culture of HCCEC increased the 
total amount of fill and the amount of the reparative tissue that was hyaline-like, while 
decreasing the amount of fibrous tissue. Dotted lines indicate the boundaries between the 
adjacent host cartilage (left) and the regenerated neo-tissue (right). (B) Overall 
histological scoring of reparative tissues. The repair is inversely correlated with the score. 
When implanted as cells alone in the form of cell pellets, hESC-derived chondrogenic 
cells demonstrated significant reparative ability compared to the defects left untreated. 
The reparative ability of hESC-derived chondrogenic cells was further augmented when 
implanted as cell-hydrogel constructs. (ns: not significant; *p < 0.05; **p < 0.01; ***p < 
0.001) Abbreviations: H&E, Haematoxylin and Eosin; Saf-O, Safranin-O; Col, collagen; 
CP, cell pellet; HCCEC, hESC-derived chondrogenic cell-engineered cartilage. 
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Table 10. Results of histological scoring of reparative tissues. The reparative tissues were 
evaluated for cell morphology, matrix-staining, surface regularity, thickness of cartilage 
and integration of donor with host adjacent cartilage. The repair is inversely correlated 
with the score.  
 
Grading 6 weeks 6 weeks 6 weeks 
  Empty (n = 5) CP (n = 4) HCCEC (n = 4) 
Cell morphology 3.67 (3 - 4) 2.00 (0 - 3) 0.67 (0 - 2) 
Matrix-staining 2.67 (2 - 3) 1.75 (1 - 2) 0.50 (0 - 2) 
Surface regularity 2.67 (2 - 3) 1.25 (1 - 2) 0.33 (0 - 1) 
Thickness of cartilage 2.00 (2) 1.50 (1 - 2) 0.25 (0 - 1) 
Integration with host adjacent cartilage 2.00 (2) 1.00 (0 - 2) 1.08 (0 - 2) 
Total score 13.00 (12 - 14)  7.50 (4 - 11) 2.83 (1 - 5) 
Note: Each data represents mean and range (parentheses) of the scales. Abbreviations: CP, cell 
pellet; HCCEC, hESC-derived chondrogenic cell-engineered cartilage. 
 
 
4.4.2.2 HCCEC in cartilage regeneration 
The initial promising results of HCCEC in cartilage repair prompted further investigation. 
The full span cartilage regenerative capability of HCCEC was evaluated by means of 
gross morphology examination, histological and immunohistochemical examination, 
semi-quantitative histological scoring analysis, as well as quantitative micro-CT 
evaluation of cartilage and bone volume.  
 
Macroscopically, all defects appeared depressed and irregular with poor integration to the 
host cartilage at 2 weeks post-operatively (Fig. 28). By 6 weeks, the entire HCCEC-
treated defect appeared with neo-tissue graft of moderately flat surface regularity. In 
contrast, the control group with empty defect displayed incomplete neo-tissue coverage 
with depressed and irregular articular surface, while the HA-treated group displayed 
moderate neo-tissue coverage and surface regularity (Fig. 29). At 12 weeks, the HCCEC-
treated defect displayed good surface regularity and appeared close morphological 
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similarities to the age-matched native unoperated control. In contrast, the control groups 
left empty or treated with HA displayed complete neo-tissue coverage, but with irregular 
articular surfaces (Fig. 30).   
 
Histologically, 2 weeks after transplantation of HCCEC, the compact engineered 
cartilage implant occupied the entire osteochondral defect, and expressed high amounts 
of s-GAG and collagens including high amounts of collagen I and II, but no collagen X. 2 
out of 6 implants demonstrated partial integration, while the remaining 4 implants 
demonstrated poor integration. In contrast, defects left empty or transplanted with HA 
alone resulted in limited repair, with negligible amount of s-GAG and collagen II. At 2 
weeks, the overall histological scores for group I (Empty), II (HA alone) and III (HCCEC) 
were 13.6, 13.7 and 5.4 respectively [p < 0.001 compared to group I (Empty) and II (HA), 
Fig. 28 and Fig. 31].  
 
By 6 weeks, there was mostly fibrous tissue repair in both control groups, with severe 
surface irregularity and noticeable bone in-growth in the empty defects. Some 
chondrocytic cells could be observed in the HA-treated defects as observed by Safranin-
O staining. In the HCCEC-treated group, HCCEC implant regenerated a smooth cartilage 
surface and a hyaline-like reparative tissue with comparable matrix staining to the 
adjacent cartilage. These HCCEC-repaired tissues exhibited uniform staining for s-GAG 
but with relatively lower intensity of collagen II, when compared to the results at 2 weeks. 
There was limited amount of collagen I present in chondrocytic cells, distributed 
primarily at the periphery surrounding the implant. Hypertrophic chondrocytes that 
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exhibited pericellular staining for collagen X were mainly observed at the lower half of 
the implant in the deep zone of the subchondral bone. 2 out of 4 implants demonstrated 
partial integration to one end of host cartilage, while the remaining 2 implants 
demonstrated poor integration. At 6 weeks, the overall histological scores for group I 
(Empty), II (HA alone) and III (HCCEC) were 13.0, 9.1 and 2.8 respectively [p < 0.001; 
p < 0.01 compared to Group I (Empty) and II (HA alone) respectively, Fig. 29 and Fig. 
31].   
 
At 12 weeks post-operation, there were only fibrous tissue repair found in the control 
groups, with little observable matrix staining. The subchondral bone in both control 
groups was completely regenerated. In the HCCEC-treated group, a new cartilage layer 
bridging both ends of the host cartilage could be observed. The regenerated cartilage 
layer appeared hyaline-like with comparable matrix staining to the native cartilage and 
exhibited good structural integration to the adjacent host cartilage. Under high 
magnification view, the cells in the reparative tissue appeared spherical and clustered 
within lacuna. In addition, there was almost complete subchondral bone regeneration, 
marked by new bone formation sequestered within the matrix network of hypertrophic 
cartilage. At 12 weeks, the overall histological scores for group I (Empty), II (HA alone) 
and III (HCCEC) were 11.5, 8.0 and 2.6 respectively (p < 0.001 and p < 0.05 compared 
to Group I (Empty) and II (HA) respectively, Fig. 30 and Fig. 31). 4 out of 6 implants 
demonstrated complete integration to both ends of the host cartilage, while the remaining 
2 demonstrated partial integration. Furthermore, there was significant improvement in 
overall histological scores of HCCEC at 6 weeks (p < 0.05) and 12 weeks (p < 0.01) 
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when compared to 2 weeks post-transplantation, indicating that the engineered cartilage 
underwent a dynamic remodeling process with post-transplantation time to enhance its 
reparative effect (Fig. 31). The scoring results were summarized in Table 11.   
 
These findings were consistent with the quantitative CT results, where we observed 
characteristic remodeling processes marked by changes in the ratio of cartilage to bone 
volume of the repaired tissue (Fig. 32). The percentage of cartilage and bone volume of 
the HCCEC-treated defect progressed from 86.2 ± 5.7% cartilage and 13.8 ± 5.7% bone 
at 6 weeks post-implantation to 30.5 ± 9.1% cartilage and 69.5 ± 9.1% bone at 12 weeks 
post-implantation. The HCCEC-regenerated osteochondral tissue resembled closely to 
the age-matched un-operated native control of 40.2 ± 6.6% cartilage and 59.8 ± 6.6% 






Fig. 28. In vivo cartilage repair at 2 weeks post-implantation. Osteochondral defects (1.5 
mm in diameter and 1 mm depth) were created at the patellar grooves at both knees of 
Sprague Dawley rats. Experimental group (HCCEC) was compared against the control 
groups either with defects left empty or implanted with the scaffold alone (HA hydrogel). 
The rats were euthanized at 2 weeks post-implantation and observed by macroscopic 
examination of the gross appearance, as well as histological analysis using H&E and 
Safranin-O, and immunohistochemical staining specific for collagen I, II and X. At 2 
weeks, experimental group implanted with HCCEC showed complete filling of the defect, 
with partial integration with the adjacent host cartilage. Control groups either implanted 
with HA hydrogel or left empty were filled with fibrous tissue. Grafted sites are indicated 
by the concave open boxes. Abbreviations: GA, gross appearance; H&E, Haematoxylin 
and Eosin; Saf-O, Safranin-O; Col, collagen; HA, hyaluronic acid; HCCEC, hESC-





Fig. 29. In vivo cartilage repair at 6 weeks post-implantation. The rats were euthanized at 
6 weeks post-implantation and observed by macroscopic examination of the gross 
appearance (GA), as well as histological analysis using H&E and Safranin-O, and 
immunohistochemical staining specific for collagen I, II and X. At 6 weeks, there were 
mostly fibrous repair in the control groups. In the HCCEC-treated group, HCCEC 
implant regenerated a moderately flat cartilage surface with comparable matrix staining 
and good structural integration to the adjacent host cartilage, but no obvious tidemark 
was observed. There was limited amount of collagen I distributed at the periphery 
surrounding the implant. Collagen X indicative of hypertrophy was mainly observed at 
the lower half of the implant in the deep zone of the subchondral bone. Abbreviations: 
GA, gross appearance; H&E, Haematoxylin and Eosin; Saf-O, Safranin-O; Col, collagen; 







Fig. 30. In vivo cartilage repair at 12 weeks post-implantation. The rats were euthanized 
at 12 weeks post-implantation and observed by macroscopic examination of the gross 
appearance (GA), as well as histological analysis using H&E and Safranin-O, and 
immunohistochemical staining specific for collagen I, II and X. At 12 weeks, there were 
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only fibrous tissue repair in the control groups (Empty and HA-treated), with little 
observable matrix staining. In the HCCEC-treated group, a new cartilage layer bridging 
both ends of the host cartilage, with good structural integration, could be observed. The 
regenerated neocartilage appeared hyaline-like with comparable matrix staining to the 
native cartilage and under high magnification view (200X), cells in the regenerated 
neocartilage appeared spherical and clustered with lacunae. There was also subchondral 
bone regeneration, marked by new bone formation sequestered within the matrix network 
of hypertrophic cartilage. Dotted lines indicate the boundaries between the regenerated 
neocartilage (left) and the adjacent host cartilage (right), while the arrow indicates the 
tidemark. Abbreviations: GA, gross appearance; H&E, Haematoxylin and Eosin; Saf-O, 










Fig. 31. Overall histological scoring. The repair is inversely correlated with the score. 
HCCEC demonstrated significant improvement in cartilage repair, when compared to the 
control groups at all time-points. (ns: not significant; *p < 0.05; **p < 0.01; ***p < 0.001) 
There was also significant improvement in scores of HCCEC at 6 weeks (
#
p < 0.05) and 
12 weeks (
##
p < 0.01) when compared to 2 weeks post-transplantation. Abbreviations: 











Table 11. Histological scoring results of HCCEC in cartilage repair. The reparative 
tissues were evaluated for cell morphology, matrix-staining, surface regularity, thickness 
of cartilage and integration of donor with host adjacent cartilage. The repair is inversely 
correlated with the score. 
        
Grading 2 weeks 2 weeks 2 weeks 
  Empty (n = 4) HA (n = 2) HCCEC (n = 6) 
Cell morphology 3.75 (3 - 4) 4.00 (4) 0.72 (0 - 1) 
Matrix-staining 2.83 (2 - 3) 3.00 (3) 1.28 (0 - 2) 
Surface regularity 3.00 (3) 2.67 (1 - 3) 1.28 (1 - 2) 
Thickness of cartilage 2.00 (2) 2.00 (2) 0.39 (0 - 1) 
Integration with host adjacent cartilage 2.00 (2) 2.00 (2) 1.78 (1 - 2) 
Total score 13.58 (12 - 14) 13.67 (12 - 14) 5.44 ( 3 - 8) 
    
        
Grading 6 weeks 6 weeks 6 weeks 
  Empty (n = 5) HA (n = 4) HCCEC (n = 4) 
Cell morphology 3.67 (3 - 4) 2.67 (2 - 4) 0.67 (0 - 2) 
Matrix-staining 2.67 (2 - 3) 2.25 (2 - 3) 0.50 (0 - 2) 
Surface regularity 2.67 (2 - 3) 1.50 (0 - 3) 0.33 (0 - 1) 
Thickness of cartilage 2.00 (2) 1.42 (0 - 2) 0.25 (0 - 1) 
Integration with host adjacent cartilage 2.00 (2) 1.25 (0 - 2) 1.08 (0 - 2) 
Total score 13.00 (12 - 14)  9.08 (5 - 14) 2.83 (1 - 5) 
    
        
Grading 12 weeks 12 weeks 12 weeks 
  Empty (n = 5) HA (n = 4) HCCEC (n = 6) 
Cell morphology 3.46 (3 - 4) 2.67 (2 - 4) 0.78 (0 - 1) 
Matrix-staining 2.54 (2 - 3) 2.33 (2 - 3) 0.83 (0 - 2) 
Surface regularity 2.08 (1 - 3) 1.33 (0 - 3) 0.22 (0 - 1) 
Thickness of cartilage 2.00 (2) 1.17 (0 - 2) 0.44 (0 - 2) 
Integration with host adjacent cartilage 1.46 (1 - 2) 0.50 (0 - 2) 0.33 (0 - 1) 
Total score 11.54 (9 - 14) 8.00 (4 - 14) 2.56 (0 - 5) 
Note: Each data represents mean and range (parentheses) of the scales. Abbreviations: HA, 














Fig. 32. Micro-CT model of HCCEC remodeling process in cartilage regeneration (A) 3D 
geometry of the implant site. Cross-sectional view of the implant site and its surrounding 
native tissue is obtained along the line AA. (B) Cartilage (yellow) and bone growth (grey) 
within the HCCEC implant were isolated out in micro-CT models, and compared to the 
native unoperated control. The host cartilage and bone are denoted pink and blue 
respectively. (C) The cartilage and bone portions of the reparative tissues were 
segmented using the thresholding function, and their respective 3D volumes were 
computed from the segmented ROI. Quantitative CT results observed characteristic time-
dependent remodeling process marked by significant changes in ratio of cartilage to bone 
volume in the repaired tissue (ns: not significant; *p < 0.05). Abbreviations: HA, 







4.4.2.3 Human cell chimerism 
Immunostaining with human-specific vimentin (hVIM) antibody in this xenogeneic 
model revealed high level of human cell chimerism in the regenerated cartilage layer at 2 
weeks (centre: 74.3 ± 14.4% vs. periphery: 72.3 ± 13.3%, no significant difference), but 
reduced significantly at 6 weeks (centre: 26.6 ± 11.4% vs. periphery: 37.2 ± 6.2%, p < 
0.05), and was only detectable at very low levels by 12 weeks post-transplantation (centre: 
1.3 ± 0.9% vs. periphery: 6.7 ± 5.9%, p < 0.05, Fig. 33A-B).  
 
Double immunostaining with rat-specific CD68 and human-specific hVIM antibodies 
demonstrated presence of CD68-positive rat macrophages at the periphery of the HCCEC 
implant in the deep zone of the subchondral bone at 2 weeks, which later infiltrated into 
the implant in close occurrence with hVIM positive human cells at 6 weeks post-surgery. 
At 12 weeks, only low number of host macrophages could be observed in the tidemark 
region underneath the regenerated cartilage layer. Similar degree of host macrophage 
infiltration was found in rats transplanted with acellular HA controls across all time-
points (Fig. 34). Only very low numbers of CD8-positive T cells could be detected in 









Fig. 33. Human cell chimerism and survivability of hESC-derived chondrogenic cells in 
vivo. (A) Survival of hESC-derived chondrogenic cells was observed by human-specific 
hVIM immunostaining. Arrowheads indicate the boundaries of the neocartilage tissue 
and the adjacent host cartilage. Human cells were counted in the centre (C) and periphery 
(P) zones of the regenerated neocartilage layer to estimate the percentage of human cell 
chimerism. (B) Human ESC-derived chondrogenic cells demonstrated high degree of 
human cell chimerism in the regenerated cartilage layer at 2 weeks, but reduced 
drastically at 6 weeks, and only detectable at very low levels at 12 weeks post-
transplantation. The periphery zones of the neocartilage displayed a relatively higher 










Fig. 34. Macrophage infiltration following transplantation of HCCEC. CD68-positive rat 
macrophages (green) were observed in the subchondral bone (SB) at the periphery of the 
HCCEC implant at 2 weeks, which later infiltrated into the implant at 6 weeks, and only 
detected at low numbers in the tidemark region underlying the regenerated neocartilage 
layer (NCL) at 12 weeks post-transplantation. Similar degree of infiltration was observed 
in the HA-treated controls. White arrows indicate regions of close occurrence of CD68-
positive rat macrophages (green) and hVIM positive human cells (red). Abbreviations: 
HA, hyaluronic acid; HCCEC, hESC-derived chondrogenic cell-engineered cartilage; 















Fig. 35. CD8 T cell response following HCCEC transplantation. Under the immune 
suppressive effects of cyclosporine, only very low numbers of CD8-positive T cells 
(green) could be detected in both control (HA) and HCCEC-implanted defects at all time-
points. Human-specific VIM positive human cells (red) could be observed at the defect 
site at 2 weeks, but reduced drastically at 6 weeks, and only detectable at very low levels 
at 12 weeks post-transplantation. Abbreviations: HA, hyaluronic acid; HCCEC, hESC-
derived chondrogenic cell-engineered cartilage; hVIM, human-specific vimentin, SB, 
subchondral bone; neocartilage layer, NCL.  
 
 
4.4.3 Phenotypic stability of hESC-derived chondrogenic cells 
The phenotypic stability of HCCEC implants was further evaluated in an ectopic model. 
After 12 weeks of subcutaneous implantation, HCCEC displayed vascular invasion and 
signs of phenotypic instability with maturation, calcification, and subsequent replacement 
by bone tissue, where hallmarks of hypertrophic cartilage, bone-aligned cartilage and 
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new bone formation could be observed in the histological analysis. Quantitative micro-
CT analysis further demonstrated that 48.9 ± 4.1% of the HCCEC developed further to 
become bone tissue at the end of 12 weeks, with the rest of the tissue being cartilaginous 
and fibrous tissues (Fig. 36). Consistently, there was no sign of teratoma formation in all 





Fig. 36. Endochondral ossification of hESC-derived chondrogenic cells. HCCEC 
implants were harvested after 12 weeks of subcutaneous ectopic implantation and 
observed by macroscopic examination of the gross appearance (A), histological analysis 
using H&E (B, D, E, F) and Masson’s Trichrome (G, H, I), and immunohistochemical 
staining specific for collagen II (G1) and collagen X (H1). Micro-CT analysis (C) 
indicated approximately 49% bone volume. Hallmarks of endochondral ossification 







5.1 PHASE I: MODEL SYSTEM 
5.1.1 Human ESCs as a model system to study chondrogenesis 
Human embryonic stem cells (hESCs) are stem cell lines of embryonic origin, isolated 
from the inner cell mass of the blastocyst-stage embryo (Thomson et al., 1998). Human 
ESCs have the capacity to proliferate in an undifferentiated state for a prolonged period 
in culture as well as to differentiate into several somatic cell types both in vitro and in 
vivo (Itskovitz-Eldor et al., 2000; Odorico et al., 2001). Therefore, hESCs serve as an 
excellent system for the study of human embryonic cartilage development through in 
vitro differentiation, a process that recapitulates many aspects of chondrocyte 
differentiation and cartilage regeneration.  
 
5.1.1.1 Chondrogenic differentiation in EB outgrowth  
BMPs, as members of the TGFβ superfamily of growth and differentiation factors, were 
originally identified as potent inducers of cartilage and bone formation at ectopic sites 
(Reddi et al., 1992). Of note, BMP2 is expressed in the condensing mesenchyme of the 
developing limb (Lyons et al., 1990), regulates chondrogenic differentiation and 
maturation of mesenchymal progenitors (Duprez et al., 1996; Carlberg et al., 2001), as 
well as stimulates the synthesis of chondrocyte matrix components by articular 
chondrocytes in vitro (Luyten et al., 1992; Sailor et al., 1996).  
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From our published findings (Toh et al., 2007a), it was established that BMP2 induced 
hESC chondrogenesis through direct plating of EBs, with an initiation of mesenchymal 
condensation in regions of the EB outgrowth, forming collagen II-positive cartilage 
nodules. Single chondrogenic cells were also observed at the peripheral outgrowth of the 
chondrogenic nodules and EBs. Presumably, these chondrogenic cells migrated out of the 
EBs to the periphery where they proliferated to form centers of mesenchymal 
condensation, in which cells synthesize ECMs that were abundant in collagen II. There 
was also significant induction of Col 1, Col 2a1, Link protein and Sox9 under control 
chondrogenic condition which was further enhanced by BMP2 treatment. As BMP2 gene 
expression was up-regulated under control chondrogenic conditions, it was likely that 
endogenous BMP2 signaling could be triggering chondrogenic differentiation in the 
control cultures. Our findings correlate with the murine ESC studies which showed that 
BMP2 is capable of inducing chondrogenic differentiation in vitro (Kramer et al., 2000; 
zur Nieden et al., 2005). 
 
However, further analysis suggested that chondrogenesis in the EB outgrowth appeared 
to be limited due to the uncontrolled outgrowth of EB-derived mesenchymal cells, as 
indicated by the continuous high levels of Col 1, and it was likely that only a small 
proportion of committed chondrogenic cells were responsive to the exogenous BMP2 
stimuli. Other cell types, presumably the extra-embryonic endodermal cells and the 
mesenchymal intermediate cells, fibroblastic or osteoblastic, might also be induced by 
BMP2 in a 2D outgrowth culture system, as previously reported (Pera et al., 2004, 
Tanaka et al., 2004; zur Nieden et al., 2005). Consequently, the chondrogenic effect of 
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BMP2 was limited in the EB outgrowth system, and as indicated by our s-GAG analysis, 
BMP2 was unable to induce significant increase in matrix synthesis over the control in 
the outgrowth system.    
 
The conventional EB direct-plating system, strictly speaking, represented a mixture of 3D 
environment within the EBs as well as monolayer in the EB outgrowth. Previous studies 
demonstrated differentiation of mouse EBs into the chondrogenic lineage in the EB 
outgrowth system (Kramer et al., 2000; Hegert et al., 2002). Our findings suggested that 
direct-plating of EBs could not provide for controlled seeding density and is insufficient 
to create an effective and uniform 3D microenvironment necessary for chondrogenic 
induction. One might envisage that in such a system, an array of cellular differentiation 
events and lineages coexist and behave in a rather chaotic way, depending on the 
biochemical cues and microenvironment within the culture. Moreover, direct-plating of 
EBs could not provide for controlled seeding density which created difficulty for 
consistent controlled differentiation. Earlier observations by Hwang et al., 2006b 
suggested that EBs cultured as outgrowths or encapsulated in hydrogels did not 
consistently undergo chondrogenesis. Consistent with our study, heterogenous and 
uneven matrix staining in the EB outgrowths was also observed. 
 
5.1.1.2 Effects of high-density microenvironment on chondrogenic differentiation  
In an attempt to enhance chondrogenic differentiation, we further explored the possibility 
of disrupting the 5‘d’EBs and culture the single cells obtained in a 3D high-density 
micromass configuration. In the micromass cultures, under both control and BMP2 
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supplemented conditions, morphological mesenchymal condensations were apparent by 
day 7 of differentiation and distinct cartilaginous nodules could be observed by day 14 
which further increased in number and size up to day 21. Gene expression analysis 
further showed that chondrogenic differentiation occurred much earlier and with 
enhancement in the micromass system when compared to the EB outgrowth system. 
Comparatively, there was a slower and weaker induction of chondrogenesis in the EB 
outgrowth system that only become efficient when the cells reached post-confluence at a 
later stage of differentiation (between day 11 and 14 of culture).  
 
The derivation of single cells from the EBs, controlled cell seeding and provision of 3D 
high-density micromass system at the beginning of differentiation allowed immediate cell 
condensation to form chondrogenic nodules, and in combination with BMP2, resulted in 
enhanced chondrogenic differentiation. These findings are consistent with other studies 
that have shown that chondrogenic differentiation could be enhanced by dissociation of 
ESCs or EBs and culturing the cells at high densities as micromasses or pellets (Tanaka 
et al., 2004; Yamashita et al., 2009). Our findings indicated that the high-density culture 
system creates the high-density 3D microenvironment that facilitates overall cell-to-cell 
contact and mimics in vivo limb development, in that there is condensing mesenchyme 
prior to induction of chondrogenesis (Cancedda et al., 1995) 
 
The effects of BMP2 on chondrogenesis are also likely to be modulated by the culture 
system, where chondrogenic effects of BMP2 on cartilage matrix s-GAG synthesis are 
markedly demonstrated in the high-density micromass system but not in the outgrowth 
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system. These findings suggest that the effects of growth factors, in this instance BMP2, 
are likely to be modulated by the culture conditions, as previously described (Pera et al., 
2004). This has also been reported in the case of mesenchymal progenitor cells, where 
chondrogenic induction by BMP2 depends greatly on cell-to-cell interactions (Denker et 
al., 1999; Lengner et al., 2004), and that in monolayer culture conditions, BMP2 leads to 
mesenchymal multi-lineage development of these cells, ending up predominantly with 
osteoblasts, and low levels of chondrocytes and adipocytes (Ahrens et al., 1993; Shea et 
al., 2003; Date et al., 2004).  
   
5.1.1.3 Effects of high-density microenvironment on hypertrophic maturation  
The differences in temporal order and magnitude of early chondrogenesis in both the EB 
outgrowth and micromass culture systems were further demonstrated in the subsequent 
hypertrophic maturation. The high-density micromass system induced rapid onset of 
hypertrophic maturation from day 7, following the decline in Col 2 expression. 
Concomitantly, matrix synthesis of s-GAG decreased after day 14, which correlated with 
the increase in ALP activity thereafter. 
 
Based on these results, it is evident that chondrogenesis of hESCs follows a temporal 
orderly development from chondrogenic differentiation to hypertrophic maturation, 
which is recapitulated in the high-density micromass system established in this study.   
 
Hypertrophic maturation appeared to be independent of BMP2 stimulation, with effects 
of BMP2 on Col 10 expression level and ALP activity only being observed at the later 
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time-points (after 18 days of differentiation) of differentiation. Results from Hwang et al., 
2006b suggested a possible inhibitory role of BMP2 in hypertrophic differentiation. In 
contrast, our observations suggest that hypertrophic maturation can be induced by cell-to-
cell contact and BMP2 treatment, while in combination, these conditions further resulted 
in much elevated Col 10 expression and ALP activity. It is evident that high-density 
micromass system facilitated by cell-to-cell contact not only promotes earlier 
chondrogenic activation but also an earlier and more robust activation of hypertrophic 
development than the EB outgrowth system.   
 
5.1.1.4 Effects of higher EB seeding numbers on chondrogenic differentiation 
This study which examined the effects of increasing seeding density of EBs in the 
outgrowth system further demonstrated that a 3D high-density microenvironment at the 
beginning of differentiation was critical for directing a chondrogenic cell fate. A high-
density environment created by increasing the seeding numbers of EBs is not exactly the 
same as the high-density 3D microenvironment created by the dissociated EBs, and is 
insufficient to drive the cells to a chondrogenic cell fate. 
 
In fact, at higher EB seeding numbers, the cells lost their stem cell properties marked by 
decreased Oct4 expression, indicating differentiation. The chondrogenic potential of 
these cells also dropped drastically, marked by decreasing levels of Col 2 expression, 
along with increasing numbers of EBs plated. Addition of BMP2 resulted in even lower 
Col 2 expression levels. In contrary, the levels of Col 1 and αFP expression were 
augmented by BMP2 in all densities of EBs tested. One possible explanation could be 
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that pleiotropic effects of BMP2 are driving differentiation to other lineages especially 
extra-embryonic endodermal (Pera et al., 2004), instead of solely chondrogenic lineage in 
an EB outgrowth system.  
 
5.1.1.5 Effects of high-density microenvironment on other lineage differentiation  
The effects of high-density micromass culture on EB chondrogenesis may be correlated 
with rapid loss of pluripotency and inhibition of other lineage differentiation. In the 
micromass system where cells were dissociated and cultured in a high-density 3D 
microenvironment, earlier onset of chondrogenic differentiation was accompanied by a 
rapid loss of pluripotency, as indicated by disappearance of Oct4 and a decline in ALP 
activity. Yamashita et al., 2009 showed that micromass culture of mouse ESCs was able 
to induce a rapid differentiation to a chondrogenic lineage by mediating loss of 
discordant cells through apoptosis. Further analysis of other lineage gene markers 
indicated a much more restricted chondrogenic lineage differentiation in the micromass 
system, as compared to the outgrowth system which showed presence of differentiation 
to derivatives of neuroectoderm, endoderm and mesoderm. Interestingly, high-density 
micromass culture system was able to inhibit neuronal differentiation from the start, with 
little expression of neuroD1, even in the absence of BMP2. On the other hand, inhibition 
of neuroectoderm differentiation in the outgrowth system required the presence of BMP2. 
This is consistent with several reports that showed suppression of BMP signaling by 
noggin resulted in enrichment of neural precursors (Pera et al., 2004; Itsykson et al., 
2005). In addition, time-dependent increase was observed in the expression of αFP in the 
outgrowth system under both control and BMP2 conditions, which further supported the 
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earlier findings that the default differentiation pathway by EB-derived cells in the 
outgrowth conditions may be more inclined towards the extra-embryonic endodermal 
lineage differentiation. By dissociation of EBs and plating as a micromass, this default 
pathway adopted by the EBs was disrupted and partially inhibited, as observed by lower 
expression levels of αFP, rendering the differentiation more permissive and directed 
towards the chondrogenic lineage. It is likely that in the EB outgrowth 
cultures, intercellular contact and gap junctional coupling that play a crucial role in extra-
embryonic endoderm development within the EBs remain intact (Hogan et al., 1981; 
Casanova et al., 1988; Conley et al., 2004). By contrast, in the micromass system, the 
EBs were first dissociated enzymatically into a single cell suspension, which breaks 
down the intercellular contact and gap junctional coupling involved in endodermal 
differentiation. There was also an overall reduction in differentiation to haemopoietic and 
adipogenic lineages, denoted by VEGFR2 and PPARγ respectively.  
 
Taken together, the high-density micromass culture condition potentially inhibits other 
lineage differentiation while selecting for the growth of a subpopulation of EB-derived 
progenitors or stem cells with the capability of chondrogenic differentiation. Furthermore, 
the micromass system also modulates the effects of BMP2 on chondrogenesis and other 
lineage differentiation. BMP2 influenced EB differentiation to multiple cell fates, 
including that of extra-embryonic endodermal and other mesenchymal lineages in the EB 
outgrowth system, but was more committed to driving a chondrogenic cell fate in the EB 
high-density micromass system. In combination with BMP2, the micromass culture 
system resulted in both enhancement and enrichment of chondrogenic differentiation. 
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5.2 PHASE II: GROWTH FACTOR MODULATION 
5.2.1 Growth factor modulation of chondrogenesis  
In the second phase of this study, based on our published findings (Toh et al., 2009), we 
sought to understand the involvement of different growth factors (BMP2 and/or TGFβ1) 
in directing chondrogenic commitment of EBs using the established high-density 
micromass culture system. 
 
Gene expression of cartilage-related matrix collagens and proteoglycans such as LP, Col 
9A1, COMP, Col 1 and Col 2  and cartilage-related receptors such as CD44s and 
PDGFRα were profiled for the EB micromass cultures undergoing chondrogenic 
differentiation for a period of 21 days. However, some of these markers such as Col 9A1, 
and PDGFRα were also expressed in undifferentiated hESCs and 5‘d’EBs. On the other 
hand, Col 2 and COMP seemed to be the most cartilage-specific with expression only in 
the differentiating EB-derived cells. Based on these findings, it is likely that BMP2 and 
TGFβ1 modulate the expression of various protein components of cartilage differently 
(Roark et al., 1994; Shintani et al., 2007). Whilst BMP2 or TGFβ1 alone was able to 
enhance expression of COMP, the combination of both factors was able to induce highest 
expression of COMP by day 21. This did not correlate to the Col 2 expression whereby 
highest expression was only observed in the presence of TGFβ1 alone. This could be due 
to spatiotemporal differences in growth factor requirements and it was possible that 
sequential addition of growth factors would be necessary so as to cater to the differential 
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requirement of each growth factor at different stages of chondrogenic development 
(Roark et al., 1994; Hanada et al., 2001; Indrawattana et al., 2004; Shintani et al., 2007).  
 
Co-treatment with TGFβ1 and BMP2 induced the formation of clusters of cells that were 
highly-enriched in collagen I, and low in collagen II. This was consistent with the gene 
expression data with the highest level of Col 1 relative to low level of Col 2, 
characteristic of chondrocytes of a fibrocartilage phenotype. This finding is somewhat 
similar to the observation by Koay et al., 2007 whereby sequential induction by TGFβ3 
followed by BMP2 induced fibrocartilage-like formation of EB-derived cells. This was 
unlikely due to bone formation since gene expression of the bone marker, osteocalcin, 
was not observed in the cultures. However, under this growth factor combination, there 
was still presence of differentiation to the ectodermal and endodermal lineages.  
 
On the other hand, TGFβ1 induced low levels of Col 1 and yielded an overall highest 
differentiation index denoted by Col 2/Col 1 ratio. Consistently, highest number of 
collagen II-positive chondrogenic cells forming dense filamentous matrix network was 
observed in the presence of TGFβ1. These findings are consistent with findings reported 
for chondrogenic induction of human embryonic germ cells (Kim et al., 2005b; Varghese 
et al., 2006) and murine embryonic stem cells (Hwang et al., 2006b), of which TGFβ1 





5.2.2 Effects of TGFβ1 on other lineage differentiation  
The effect of TGFβ1 on chondrogenesis may be correlated with enhanced chondrogenic 
commitment and the loss of propensity to ectodermal, hematopoietic and adipogenic 
lineages. In line with our Phase I findings (Toh et al., 2007a), the default differentiation 
by EBs towards the extra-embryonic endoderm differentiation, marked by the presence of 
cystic structures and expression of αFP, was moderately inhibited under high density 
culture conditions and further reduced in the presence of TGFβ1. In addition, there was a 
substantial inhibition in differentiation to other mesodermal-derived lineages including 
hematopoietic, osteogenic and adipogenic lineages, suggesting indeed that the 
mesodermal progenitors derived in the presence of TGFβ1 were likely to be 
chondroprogenitors committed to the chondrogenic lineage differentiation. However, as 
TGFβ1 signaling is also implicated in ESC pluripotency, an understanding of the role of 
TGFβ1 in regulating pluripotency and differentiation is imperative for derivation of 
chondrogenic cells that are devoid of tumor-forming ability (James et al., 2005).  
 
5.2.3 Pluripotency vs. chondrogenesis - Role of TGFβ1 
Following the time course of differentiation, it was observed that TGFβ1 had an early 
inhibitory effect on chondrogenesis of EB-derived cells, with a lower Col 2 expression 
level at day 7 of differentiation and only significantly enhanced chondrogenic 
differentiation from day 14 onwards, with much intensified and prolonged expression of 
Col 2 up to day 21. This transient inhibitory effect of TGFβ1 could be attributed partly to 
the involvement of TGFβ/activin/nodal signaling in maintenance of pluripotency in 
hESCs (James et al., 2005). This was examined in our separate study reported by Yang et 
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al., 2009, where a comparative study of chondrogenesis between undifferentiated hESCs 
and 5‘d’EBs was carried out. Under low attachment conditions, hESCs aggregate to form 
EBs that mimic the structure of developing embryos and recapitulate the developmental 
stages of three germ layers and their derivatives. It was observed that undifferentiated 
hESCs and hESCs that differentiated to become cells of a later developmental stage 
(5‘d’EB-derived cells) responded differently to TGFβ1. It is noteworthy that TGFβ1 
played a stage-dependent effect on both pluripotency and differentiation, where addition 
of exogenous source of TGFβ1 exerts an early inhibitory effect on chondrogenesis, with a 
more profound effect on undifferentiated hESCs compared to 5‘d’EB-derived cells. 
Studies using TGFβ/activin/nodal signaling inhibitor (SB431542) further confirmed that 
TGFβ1 inhibited early chondrogenic induction but was required at the later stage of 
differentiation. Remnants of undifferentiated Oct4-positive cells could still be observed 
in these differentiated hESCs or EB-derived micromass cultures at the end of 21-day 
differentiation, but were mutually exclusive from the collagen II-positive chondrogenic 
cells. These findings suggested a ‘bipolarized’ role of TGFβ1 in both pluripotency and 
differentiation. It is proposed that hESCs or its subpopulations at different stages of 
differentiation responded differently to TGFβ1 in making cell-fate decisions in 
pluripotency and differentiation, and EB-derived cells represent an enriched population 
of mesodermal progenitors that are able to pursue a chondrogenic lineage differentiation 
in the presence of TGFβ1 (Nakayama et al., 2003). Thus, an intermediate step of 
differentiation via EB formation is favorable for hESCs to pursue a chondrogenic lineage 
differentiation (Yang et al., 2009).   
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5.3 PHASE III: ISOLATION OF CHONDROGENIC CELLS  
5.3.1 Human ESC-derived chondrogenic cells  
Direct chondrogenic differentiation ESCs was greatly hampered by cellular heterogeneity 
of the resulting cell population which impaired the generation of sufficient numbers of 
differentiated cells for further testing and applications (Toh et al., 2007a; Toh et al., 2009; 
Jukes et al., 2009). Hegert et al., 2002 reported isolation of chondrocytes from nodules 
after 16 days of EB differentiation in the mESC system. However, in his approach, 
isolated chondrogenic cells exhibited rapid de-differentiation in phenotype as well as 
plasticity in differentiation to other lineages including adipocytes, epithelial cells and 
skeletal muscle cells. Clearly, there were issues of transdifferentiation as well as purity 
with the presence of contaminating mesenchymal progenitor cells. These findings also 
strengthen the view that standardized and reproducible selection strategies will be 
necessary to obtain defined cell populations for therapeutic applications.  
 
5.3.1.1 Effects of growth factors and ECM on hESC-derived chondrogenic cells 
As reported in our published findings (Toh et al., 2009), we envisaged that a combination 
of selective ECM plating and growth factor conditions as the standardized protocol for 
isolating chondrogenic cells from differentiating EB micromass cultures. So, we 
attempted to enrich these chondrogenic cells by means of collagenase treatment and 
selective plating on different ECM substratum. Isolated chondrogenic cells derived from 
the EB micromass cultures behave like primary chondrocytes in which they rapidly de-
differentiate upon monolayer expansion (Benya et al., 1978). This occurs regardless of 
the ECM substratum used for attachment. Similarly, these chondrogenic cells also tend to 
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de-differentiate to a fibrochondrogenic lineage upon extensive monolayer expansion, and 
thus were unable to participate in cartilage formation.   
 
Similar to human primary chondrocytes, a combination of TFP (TGFβ1, FGF2 and 
PDGFbb) growth factors was sufficient to propagate these hESC-derived chondrogenic 
cells while retaining their chondrogenic potential to form homogenous cartilaginous 
tissue in the presence of TGFβ1 (Francioli et al., 2007). This hESC-derived chondrogenic 
cell population (named TC1) is lineage-restricted with loss of pluripotency, highly-
expandable, and displays a normal karotype and normal somatic cell cycle kinetics 
(White et al., 2005). In addition, the risk of teratoma formation is minimal as lineage-
restricted hESC-derived chondrogenic cells did not induce tumor formation in a SCID 
mouse model in vivo. These findings support hESC-derived chondrogenic cells (TC1) as 
a viable cell source for applications in cartilage tissue engineering and repair.  
 
Despite the inability of ECM substratum to retain the chondrocyte phenotype, the 
differentiation capacity of hESC-derived chondrogenic cells was largely modulated by 
the ECM during expansion. When expanded on COL II substratum, hESC-derived 
chondrogenic cells formed a more homogenous cartilaginous tissue in the pellet culture 
system with increased collagen II deposition. There was also an overall enhancement in 
s-GAG and collagen I deposition. However, the cartilaginous tissue produced in the pellet 
culture system was still of a fibrocartilage phenotype. The mechanisms by which growth 
factors and ECM modulate the post-expansion differentiation capability of chondrogenic 
cells are not well-understood. It is likely that provision of a cartilage-related ECM, Type 
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II collagen, in the initial plating and later in expansion in selective growth factor 
condition helps in continuous selection of ECM-responsive subpopulations of cells with 
enhanced pre-existing commitment towards the chondrogenic lineage (Barbero et al., 
2006; Deng et al., 2007). Indeed, chondrocytes were found to respond to ECM 
components, including Type I collagen (Kino-Oka et al., 2005), Type II collagen 
(Barbero et al., 2006) and hyaluronic acid (Miralles et al., 2001), resulting in the 
regulation of various chondrocyte behaviors and processes such as cell shape changes, 
chondrocytic phenotype maintenance, chondrogenic differentiation and re-differentiation.  
 
In summary, using high-density EB micromass cultures in the presence of specific 
growth factors, we have developed a method to induce chondrogenic commitment of the 
hESCs with generation of putative chondrogenic cells. We have also established a 
method to isolate and enrich the chondrogenic cells for expansion while still retaining the 
chondrogenic differentiation potential for differentiation to form cartilage-like tissue in 
the conventional pellet system in vitro. This protocol enables the derivation of 
homogenous and potentially clinically compliant chondrogenic cells from hESCs in a 
defined manner that circumvents the need for transfection of any genetic material (Kim et 
al., 2005a) and co-culture with chondrocytes [Vats et al., 2006, Hwang et al., 2008a). It 
also efficiently compensates for the lack of known surface markers specific for the 
chondrogenic lineage. This defined protocol offers a simple and robust design that is 




5.4 PHASE IV: FUNCTIONALITY  
5.4.1 Human ESC-derived chondrogenic cells in cartilage tissue engineering 
Obtaining the appropriate cell source for cartilage repair is important, but identifying the 
optimal delivery strategy and appropriate biomaterial are equally critical, as part of 
cartilage tissue engineering principles (Chung et al., 2008). Human ESC-derived 
chondrogenic cells offer advantages of easy isolation, expandability to large numbers and 
potential for chondrocyte differentiation and cartilage formation, which make them an 
ideal cell source for cartilage tissue engineering.    
 
5.4.1.1 Human ESC-derived chondrogenic cell-engineered cartilage (HCCEC) 
In the last phase of this study, we have engineered a cartilaginous tissue construct using 
hESC-derived chondrogenic cells and assessed the long-term reparative ability in 
repairing critical-sized osteochondral defects in the adult rat model.  
 
Previous in vitro studies have demonstrated that growth factors can influence anabolic 
and catabolic processes in chondrocytes. BMPs (Duprez et al., 1996), TGFβ (Seyedin et 
al., 1986), and IGF-I (Hunziker et al., 1994) each can stimulate mitotic activity, 
proteoglycan synthesis, and chondrocyte differentiation. In our study, hESC-derived 
chondrogenic cells responded to anabolic factors such as BMP2 and BMP7, and to a 
lower extent IGF-I and GDF5. Synergistic effects on matrix synthesis were observed 
when these factors were applied in conjunction with TGFβ1. Combination of 
BMP7/TGFβ1 was identified as the most potent inducer. A recent report also documented 
synergistic effects of BMP7 and TGFβ1 in inducing chondrogenic differentiation of 
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hESC-derived mesenchymal cells in the pellet culture system (Nakagawa et al., 2009). 
There has also been use of this growth factor combination (BMP7/TGFβ1) for 
chondrogenic induction of adult MSCs (Miyamoto et al., 2007).  
  
Therefore, the combination of BMP7 and TGFβ1 was applied in this study for application 
in cartilage tissue engineering using hESC-derived chondrogenic cells. HA-based 
hydrogel was selected as the cell carrier in this study due to the widespread application of 
HA-based biomaterials in cartilage tissue engineering and regeneration (Liu et al., 2006; 
Chang et al., 2006; Lee et al., 2007). Compared with the conventional pellet system, the 
hydrogel system demonstrated better efficiency in supporting chondrogenic 
differentiation of hESC-derived chondrogenic cells, possibly through improved cell 
seeding homogeneity, nutrient perfusion and tissue growth (Hwang et al., 2008c; Chung 
et al., 2009; Jukes et al., 2009). By contrast, the pellet system has limitations of tissue 
growth, nutrient penetration and perfusion to the centre of the tissue, and therefore 
impeding efficient cartilage formation. Using the hydrogel system, hESC-derived 
chondrogenic cell-engineered cartilage (HCCEC) exhibited a dynamic temporal profile of 
matrix synthesis similar to that of MSC chondrogenesis, marked by early secretion of s-
GAG followed by collagen II (Barry et al., 2001). At the end of 4 weeks, chondrogenic 
differentiation of the HCCEC constructs in the presence of BMP7/TGFβ1 growth factor 
conditions resulted in formation of homogenous ECM-enriched cartilaginous construct 
that exhibited morphological similarities to an neocartilage with round chondrocyte-like 
cells embedded in lacunae, and appeared hyaline-like, with high amounts of s-GAG and 
collagen II, low amount of collagen I and almost no collagen X. Previous studies showed 
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either heterogenous or insufficient cartilage formation from hESCs (Vats et al., 2006; 
Koay et al., 2007; Hwang et al., 2008a). These may be attributed to the differentiation 
protocol, growth factors and choice of biomaterial.  
 
In this study, we report a high-efficiency chondrogenic system employing the 
differentiation of hESC-derived chondrogenic cells in the HA hydrogel to yield a 
homogenous hyaline-like cartilaginous tissue for tissue engineering applications. This 
protocol of utilizing lineage-restricted chondrogenic cells for cartilage tissue engineering 
also enables up-scalability for producing clinically relevant amounts of cartilage for 
tissue engineering and regenerative medicine applications.   
 
5.4.2 Human ESC-derived chondrogenic cells in cartilage regeneration  
Human ESC-derived chondrogenic cells may serve as a potential alternative cell source 
for cartilage repair where the current cell-based therapies involving MSCs and 
chondrocytes (ACI) may have issues of limited availability of donor tissue and limited 
proliferative and regenerative capacity that decreases with age (Quarto et al., 1995; 
Stenderup et al., 2003; Payne et al., 2010).  
 
5.4.2.1 Osteochondral defect model 
A xenograft osteochondral defect model was used in this study for assessment of 
reparative ability of hESC-derived chondrogenic cells in cartilage regeneration. Critical-
sized osteochondral defects of diameter 1.5 mm were created in adult Sprague Dawley 
rats, prior to transplantation of hESC-derived chondrogenic cells. Consistent with other 
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studies (Anraku et al., 2008; Anraku et al. 2009), we did not observe any spontaneous 
repair in empty defects of diameter 1.5 mm created in this study. The size of defect is 
important, as empty defects of size less than diameter 1 mm (0.7 mm) in rats has reported 
spontaneous repair (Anraku et al., 2009). 
 
5.4.2.2 Role of HCCEC in cartilage repair 
Hwang et al., 2008b reported cartilage regeneration following implantation of co-cultured 
hESC-derived MSCs in the form of cell pellets into the osteochondral defects in rats, but 
the study was limited by the lack of histological evidence and grading of the reparative 
tissues. Preliminary findings implanting hESC-derived chondrogenic cells in the form of 
cell pellets into the osteochondral defects demonstrated increased amount of reparative 
tissue filling the defects, with increased amount of hyaline-like cartilage when compared 
to the defects left untreated. However, there was also fibrous tissue surrounding the pellet 
grafts in the defects, resulting in sub-optimal cartilage repair (Toh et al., 2009). This 
inadequate repair can be attributed to unsecure fixation of pellet graft which allowed 
infiltration of host cells and surrounding tissue resulting in a fibrous tissue repair.  
 
It was later hypothesized that a press-fit biomaterial-assisted strategy might be able to 
circumvent this problem. Human ESC-derived chondrogenic cells, encapsulated in HA 
hydrogel and in vitro cultured for 4 weeks in the presence of BMP7/TGFβ1, yielded 
ECM-enriched cartilage constructs (HCCEC), which by 6 weeks post-implantation, 
induced more hyaline-like reparative tissue formation than the implantation of cells alone. 
Similarly in the canine model, chondrocyte-seeded type II collagen-GAG scaffolds 
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cultured for 1 day and 4 weeks demonstrated more reparative tissue formation than in 
defects treated with cells alone, with longer culture period (4 weeks) having a better 
hyaline cartilage composition (Breinan et al., 2000, Lee et al., 2003).  
 
5.4.2.3 Role of HCCEC in cartilage integration  
Chondrogenic pre-conditioning of tissue-engineered cartilage constructs prior to 
implantation has been demonstrated in a number of studies to have beneficial effects in 
withstanding the immediate load-bearing at the time of implantation (Lee et al., 2003; 
Chen et al., 2009b). These studies have also demonstrated that pre-conditioning of 
cartilage constructs through in vitro culture can improve the in vivo cartilage repair (Lee 
et al., 2003; Chen et al., 2009b). In the study by Chen et al., 2009b, chondrocyte-
mediated cartilage constructs cultured for 3 weeks in bioreactors induced better in vivo 
cartilage repair than those cultured for shorter durations. However, there have also been 
concerns that prolonged (> 4 weeks) cultivation of the tissue-engineered cartilage 
constructs tend to result in poor integration between the cartilage graft and the host 
cartilage (Obradovic et al., 2001; Schaefer et al., 2002). In our study, chondrogenic 
differentiation of the HCCEC constructs in the presence of BMP7/TGFβ1 growth factor 
conditions resulted in formation of hyaline-like ECM-enriched cartilaginous construct by 
the end of 4-week differentiation. Upon HCCEC implantation, two-thirds of the cases 
demonstrated complete integration in cartilage repair at the end of 12 weeks. Consistent 
with other studies (Chen et al., 2009b, Cui et al., 2009), chondrogenic pre-differentiation 
induces some extent of ECM synthesis, which in turn probably improves the ability of the 
cartilage implant to withstand load-bearing at the time of implantation, and helps in 
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subsequent integration with the host cartilage for a better repair. Due to limitations of the 
small animal model, mechanical testing was not carried out in this study. Nevertheless, 
reparative ability of HCCEC in cartilage repair can still be inferred based on the 
histological evidence. 
 
Secure fixation of tissue-engineered cartilage constructs in defects is another critical issue 
for success in cartilage integration and overall regeneration as it ensured close interaction 
between the engineered cartilage and the host cartilage and subchondral bone. Based on 
our findings, it can be inferred that a press-fit biomaterial-assisted strategy of implanting 
HCCEC can facilitate the integration process and improve the overall cartilage repair.  
 
5.4.2.4 Orderly remodeling of HCCEC in cartilage regeneration 
Following press-fit implantation into osteochondral defects in adult rats, HCCEC 
demonstrated remodeling over a 12-week period into an osteochondral tissue with 
characteristic features including a hyaline-like neocartilage layer with complete 
integration with the adjacent host cartilage and underlying subchondral bone. It is likely 
that press-fit implantation enables secure fixation of HCCEC in the osteochondral defect, 
supports close interaction between the implant and the host cartilage, better integration 
with the host cartilage and improves the eventual cartilage regeneration. These findings 
are in agreement with our in vitro findings which highlight the pivotal role of 
biomaterials, in this case HA hydrogel, in both lineage-specific differentiation in vitro as 
well as cartilage regeneration in vivo.   
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On the other hand, no obvious repair or only fibrous tissue was observed in defects left 
empty or treated with HA hydrogel alone at all time-points examined. Of note, residual 
HA was evident in the HA-treated defects at 2 weeks but was completely resorbed by 6 
weeks, probably by cellular matrix metalloproteinases in vivo. HA-based biomaterials, 
besides being the essential component of cartilage ECM, also have the advantage of 
suitable degradation rate which matches the kinetics of new cartilage formation in vivo. 
The early degradation of HA might render a positive effect on chondrogenesis and 
remodeling by allowing more spaces for replacement with cells and cell-secreted ECM 
which in turn may facilitate more cell-to-cell and cell-to-matrix interactions. Taken 
together, these findings suggest the HA hydrogel that was used as a cell carrier for 
construction of HCCEC is highly-biocompatible and biodegradable (Liu et al., 2006).     
 
Defects repaired with HCCEC demonstrated a progressive development from a 
prechondrogenic state with synthesis of collagen types I and II to a hypertrophic state 
with synthesis of collagen types II and X. These findings support the hypothesis that 
HCCEC can provide a functional template capable of orchestrating orderly remodeling 
during the repair of critical-sized osteochondral defects in adult rats. Remodeling process 
which is important for the preservation of the cartilage layer and the regeneration of the 
subchondral bone can be attributed to the local microenvironment and the chemical and 
physical factors at the defect site (Caplan et al., 1997). It is important to note that 
functional restoration and survival of the cartilage layer is also largely dependent on the 
underlying subchondral bone regeneration (Amin et al., 2009; Ho et al., 2009). In this 
model, an orderly remodeling process was observed, where HCCEC induced a hyaline-
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like cartilage layer at the articular surface, with good structural integration with the host 
cartilage at the lateral boundaries. Within the deep zone of the vascularized subchondral 
bone, HCCEC induced a progressive endochondral process of ossification repair. This 
supports an ordered spatial-temporal remodeling of the osteochondral repair being 
induced by the transplanted HCCEC.  
 
5.4.2.5 Fate of hESC-derived chondrogenic cells in cartilage regeneration  
To our knowledge, the fate of implanted cells, especially hESC-derived cells in cartilage 
defect site has not been reported. Further examination in this study revealed good 
survival of human chondrogenic cells at 6 weeks, followed by gradual decline up to 12 
weeks post-transplantation. By 12 weeks when the remodeling process is almost 
completed, human cells account only for 4% of all cells in the regenerated cartilage layer, 
while none could be detected in the regenerated subchondral bone. Remodeling process 
seemed to be most active in the centre of the defect with relatively lower human cell 
chimerism than in the periphery. This overall decline in human cell chimerism and 
survivability is in line with the endochondral ossification process, where cells in the 
vascularized microenvironment of the subchondral bone underwent hypertrophy 
maturation, apoptosis and eventual replacement by bone cells. Another explanation may 
have been graft cellular apoptosis described in many cellular transplantation paradigms 
even after immune suppression (Carr et al., 2009; Lee et al., 2009b; Zhang et al., 2010). 
This is often associated with infiltration of host macrophages to the injury site during 
repair. In this instance, rapid decline in human cell chimerism might have been due to 
non-specific immune reactions between species as well as the remodeling process during 
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osteochondral regeneration, which host macrophages are likely to be implicated in these 
processes, as reported in several other transplantation paradigms (Carr et al., 2009; Zhang 
et al., 2010). Our findings highlight a key aspect of cellular transplantation not fully 
addressed in many studies of cell transplantation for cartilage regeneration: the host 
inflammatory/immune response to the xenograft and its role in remodeling process during 
cartilage and bone repair, which can only be addressed through clinical trials.  
 
Importantly, we showed that hESC-derived chondrogenic cells played a direct pivotal 
role in cartilage regeneration by forming a preliminary neocartilaginous tissue at the early 
stage that undergoes continuous remodeling to bring about regeneration of a neocartilage 
layer. This regeneration process was mainly mediated by the implanted human cells since 
the scaffold alone resulted only in fibrous tissue repair. Although hESC-derived 
chondrogenic cells showed direct reparative ability in cartilage regeneration, we do not 
exclude the possibility of hESC-derived chondrogenic cells inducing host cartilage 
regeneration via paracrine activity that have been reported in a number of other cell 
transplantation paradigms (Gelse et al., 2009; Laurila et al., 2009; Chen et al., 2009a). 
Indeed, hESC-derived cells have been reported to secret a broad spectrum of growth 
factors including BMPs, TGFs, FGFs that are likely to play important roles in recruitment 
and differentiation of host progenitors, and overall tissue regeneration (Sze et al., 2007; 
Chen et al., 2009a; Laurila et al., 2009).   
 
To date, there is only one study that has applied hESC-derived cells in cartilage repair to 
an orthotropic model (Hwang et al., 2008b). In the study, co-cultured human EB-derived 
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MSCs were pellet-cultured in chondrogenic medium for 3 days before implanted as cell 
pellets into the osteochondral defects in nude rats. Cartilage tissue formation could be 
observed, which remodeled over 8 weeks to repair the osteochondral defects. Although 
there was no teratoma formation, it was not clear if the regenerated tissue was hyaline 
cartilage. Furthermore, the fate of transplanted cells remained elusive. Evaluation of the 
repair was only assessed at a single time-point and histological scoring of the cartilage 
repair was not performed in the study (Hwang et al., 2008b). In contrast, our study has 
clearly demonstrated the reparative ability and fate of hESC-derived chondrogenic cells 
in cartilage regeneration. Both the cells and biomaterial played important roles in the 
success of a tissue engineering strategy for cartilage repair.  
 
In conclusion, our studies have described a stepwise approach of generating non-
tumorigenic, lineage-restricted chondrogenic cells from hESCs under defined conditions, 
applying tissue engineering techniques of creating engineered cartilage constructs and 
demonstrating the orderly remodeling process that the engineered cartilage based on 
hESC-derived chondrogenic cells undergoes during the repair of critical-sized 
osteochondral defects, and resulted in complete osteochondral regeneration, with a 
hyaline-like cartilage composition. In addition, our study also provided strong evidence 
of hESC-derived chondrogenic cells and their role in cartilage regeneration.  
 
5.4.2.6 Phenotypic stability of hESC-derived chondrogenic cells 
Endochondral ossification of HCCEC observed in an osteochondral defect environment 
was further recapitulated in a subcutaneous ectopic environment, which confirmed the 
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impeding phenotypic instability of cartilage formation by hESC-derived chondrogenic 
cells following vascular invasion. Indeed, after ectopic implantation in SCID mice for 12 
weeks, HCCEC displayed signs of phenotypic instability with maturation, calcification, 
and subsequent replacement by bone tissue. Hallmarks of hypertropic cartilage, bone-
aligned cartilage and new bone formation are evident in all the tissues examined. 
Approximately 50% of the engineered cartilage developed to become bone after 12 
weeks of implantation, with the rest of the tissue being cartilaginous and fibrous tissues. 
In line with findings from the orthotopic model, hESC-derived chondrogenic cells 
implanted in the subchondral bone, due to vascularization and host cell interference, has 
potential to mature and enter the process of endochondral ossification, following the 
route of embryonic cartilage development (Mackie et al., 2008). This is in agreement 
with the current understanding that stem cell-derived cartilage has a tendency to mature 
and enter the process of endochondral ossification in vivo (Pelttari et al., 2006; Jukes et 
al., 2008b; Yamashita et al., 2009). In a study by Yamashita et al., 2009, high-density 
micromass cultures of mESCs, cultured under ITS medium supplemented with TGFβ1 
and BMP2, yielded chondrogenic cells that developed into cartilage formation, following 
4 weeks of ectopic implantation into the muscles of SCID mice. This was coupled with 
endochondral ossification, which observed vascularization and bone formation. Similarly, 
Jukes et al., 2008b demonstrated that chondrogenically-differentiated mESCs underwent 
hypertrophy, calcification and eventual replacement by bone tissue after subcutaneous 
implantation for 3 weeks in immunodeficient mice. In the study, mESCs that were 
differentiated under TGFβ3-chondrogenic condition for 3 and 7 days failed to initiate 
bone formation, suggesting that the cartilaginous template that resulted from 
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chondrogenic induction of mESCs for more than 14 days was critical for endochondral 
ossification and subsequent bone formation in vivo.  
 
No study to date has reported on endochondral ossification of hESCs. Findings from this 
study suggested an alternative strategy using hESC-derived chondrogenic cells, based on 
the process of endochondral ossification, for other orthopaedic applications including 
tendon-bone healing in anterior cruciate ligament (ACL) reconstruction and bone tissue 
engineering. Future work should investigate the exact mechanism of endochondral 
ossification and the factors involved.  
 
In summary, we have further demonstrated that engineered cartilage based on hESC-
derived chondrogenic cells is able to induce cartilage regeneration in osteochondral 
defect model and exhibited potential for further maturation and endochondral ossification 
in a vascularized environment for bone regeneration.  
 
5.4.2.7 Tumorigenicity of hESC-derived chondrogenic cells 
In this study, no teratoma was found throughout the course of implantation of up to 12 
weeks in the rat osteochondral defects, and even up to 12 weeks after subcutaneous 
ectopic implantation in the SCID mouse model, consistent with the earlier findings from 
the flank teratoma assay (Toh et al., 2009). Based on these findings, it can be concluded 
that chondrogenic cells generated from hESCs in this study were non-tumorigenic and 
this property was independent of the transplantation site, which the osteochondral defect 
site has been reported to be chondroinductive and prevents tumor formation by mouse 
 148 
ESCs (Wakitani et al., 2004; Nakajima et al., 2008). Our strategy of utilizing lineage-
restricted chondrogenic cells from hESCs is similar to several studies where lineage-
restricted cells are differentiated and isolated from hESCs before transplantation to avoid 







In summary, this study established human embryonic stem cells (hESCs) as a model 
system to study chondrogenesis, and in the process, potentially clinically-compliant 
chondrogenic cell lines were derived for application in cartilage tissue engineering and 
regeneration.   
 
In Phase I of this study, a 3D high-density micromass system was established, and in 
using this system, the potential of hESCs to undergo well-defined full span 
chondrogenesis was demonstrated.  
 
Based on the established high-density micromass model system, effects of growth factors 
BMP2 and/or TGFβ1 on chondrogenesis of hESCs were examined in Phase II of this 
study. TGFβ1 was identified as the pivotal growth factor for chondrogenic differentiation 
of hESCs, and was shown to induce the highest level of cartilage gene expression and 
matrix synthesis.  
 
In Phase III of this study, highly-expandable, homogenous and unipotent chondrogenic 
cell populations were derived. Like primary chondrocytes, hESC-derived chondrogenic 
cells (named TC1) rapidly dedifferentiated upon isolation and monolayer expansion but 
retain the chondrogenic differentiation potential and responded to TGFβ1 for 
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cartilaginous tissue formation in vitro. In addition, the hESC-derived chondrogenic cells 
displayed normal somatic cell cycle kinetics, a normal karyotype and did not produce 
teratoma in vivo.  
 
In the last phase (Phase IV) of this study, the potential of hESC-derived chondrogenic 
cells for cartilage tissue engineering and regeneration was addressed. The engineered 
cartilage construct, exhibited superior neocartilage morphology, tissue homogeneity and 
appeared hyaline-like in nature. Following press-fit implantation into osteochondral 
defects in adult rats, hESC-derived chondrogenic cell-engineered cartilage (HCCEC) 
demonstrated orderly remodeling over a 12-week period into an osteochondral tissue with 
characteristic features including a hyaline-like cartilage at the articular surface, a 
tidemark at an appropriate depth, a new subchondral bone, and a complete integration 
with the adjacent host cartilage. 
 
This study demonstrates a progressive advancement from the basic science of 
establishing hESCs as a model system of chondrogenesis, understanding the role of 
signaling growth factors in chondrogenesis to translational applications of deriving 
potentially clinically compliant chondrogenic cell lines for cartilage tissue engineering 
and repair in animal models. This study has satisfied all its stated objectives and fulfilled 
the goal of devising a safe, highly-efficient and practical strategy of applying hESCs for 
cartilage regeneration, which may assist in future strategies to treat cartilage-related 




7. LIMITATIONS AND FUTURE WORK 
 
This study has established a safe, highly-efficient and practical strategy for the utilization 
of hESCs for applications in cartilage tissue engineering and regeneration. However, 
there is still a need for improvements in the cell source, the tissue engineering strategy, 
the choice of biomaterial and the validation of the functional repair before clinical 
application can be safely achieved.  
 
The recent ability to generate embryonic-like stem cells, also known as induced 
pluripotent stem cells (iPSCs), from a patient’s own skin or blood cells may serve as an 
autologous stem cell source for transplantation (Takahashi et al., 2007; Loh et al., 2009). 
It would be useful in future studies seek to apply our established differentiation protocol 
and tissue engineering techniques on iPSCs to validate their efficacy in cartilage repair. 
Comparison would be made with autologous chondrocytes and adult MSCs to better 
establish the treatment efficacy. In addition, the safety for clinical use would have to be 
established.   
 
Based on the HA-based biomaterial used in this study, further studies should explore 
other biomaterials (collagen, s-GAG, etc) and evaluate in vitro and in vivo the 
biocompatibility, cross-linking and degradation kinetics of these biomaterials, and their 
effects on the remodeling of the reparative tissue.  
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Pre-conditioning of the cartilage construct prior to implantation is an important variable. 
It is unclear how different growth factors and culture duration influence cell 
differentiation and matrix synthesis both in vitro and in vivo. Further work should 
determine the optimal growth factor and culture conditions prior to implantation of the 
constructs.  
 
Further work should also characterize the maturation and endochondral ossification of 
hESCs, so as to devise better strategies for controlling cartilage and bone formation. A 
limitation in the ectopic implantation experiment of this study was that only one time 
point was evaluated. The exact mechanism of endochondral ossification and the factors 
involved remains to be elucidated. By explanting the constructs at different time points 
after implantation, insights into the fate of the implanted cells and the cartilage and bone 
tissue formed can be obtained. It would be meaningful to explore in future research the 
potential of hESC-derived chondrogenic cells for other orthopaedic applications 
including tendon-bone healing in ACL reconstruction and bone tissue engineering.   
 
Another related limitation to this study is the animal model. The current rat model, by far, 
is the largest established xenograft model, considering hESC-derived cells may be 
immunogenic. This model was useful for this study as a proof-of-concept. Further work 
needs to be done in larger animal models such as pigs, together with the evaluation of the 
functional (mechanical) properties of the cartilage repair tissue, in addition to histological 
evaluation. Another limitation related to the animal model is the type of cartilage defect. 
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Hypertrophy maturation and endochondral ossification of the implant are likely to occur 
as a result of vascular invasion and host cell interference in the subchondral bone in the 
osteochondral defect. The phenotypic stability and reparative ability of hESC-derived 
chondrogenic cells certainly warrant further investigation for chondral defect repair in a 
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